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Abstract 
Background 
There is growing interest in preoperative chemotherapy for patients with 
colorectal liver metastases (CRLM) but personalising treatments to maximise 
response and minimise toxicity remains a challenge. Transcatheter hepatic 
therapy with irinotecan-eluting beads (DEBIRI) allows targeted delivery of 
irinotecan direct to CRLM. However, the safety and efficacy of DEBIRI in a 
preoperative setting has not yet been defined. In addition, very little is 
understood about why response to DEBIRI varies between patients.  
Aims 
This thesis had 2 key aims: (1) To assess the safety and efficacy of neoadjuvant 
DEBIRI (2) To investigate inter-patient variations in treatment response. 
Methods 
Patients with resectable CRLM received a single treatment with DEBIRI 1 month 
prior to surgery (maximal dose 200mg). The primary end-point of the study was 
R0 tumour resectability. Hepatic parenchyma and CRLM were sampled at the 
time of resection. Hepatic expression of key metabolising enzymes was 
assessed using mass spectrometry based proteomics. Hepatic irinotecan 
metabolism was characterised and correlated with tumour response. 
Results 
DEBIRI was successfully administered in 40 patients. 1 patient (3%) developed 
post-DEBIRI pancreatitis. All 40 proceeded to surgery, with 38 undergoing 
resection. 30 day operative mortality was 5%, morbidity 27.5% (Clavien-Dindo 
1-4). 63 discreet lesions were targeted, with 74% R0 resection rate. 
Histopathological examination found no residual tumour in 17% of lesions, 
<50% residual tumour in 59% and >50% tumour in 24%. 91% of treated lesions 
demonstrated stable disease by RECIST, with 9% demonstrating disease 
progression. RECIST was a poor predictor of pathological response or long-term 
outcome. At a median follow up of 293 days, fourteen patients (36%) had 
disease recurrence. On multivariate analysis, only tumour KRAS status was 
predictive of long-term outcome (p=0.02). There was a strong correlation 
between hepatic CES-2 expression and irinotecan activation (p < 0.001). 
Patients with a UGT1A1*28 6/7 SNP showed no difference in drug metabolism 
or pathological response. Hepatic CES-2 mediated activation of irinotecan 
clearly correlated with tumour replacement by fibrosis (p = 0.01). 
Conclusions 
This study demonstrates the safety and efficacy of neoadjuvant DEBIRI for 
CRLM, with impressive pathological response rates. Systemic exposure to 
irinotecan was low. The ability of hepatic tissue to activate irinotecan into SN-38 
clearly correlated with tumour replacement by fibrotic tissue, suggesting that 
hepatic CES-2 activation is the key step in the effectiveness of DEBIRI. These 
preliminary data provide a pharmacological rationale for whole lobe embolisation 
and suggests a potential predictive biomarker of treatment efficacy for future 
validation. 
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RECIST Response Evaluation Criteria in Solid Tumours 
SD Radiological stable disease 
SDS Sodium dodecyl sulfate 
TACE Trans arterial chemoembolisation 
TEAB Triethylammonium bicarbonate 
TFA Trifluoroacetic acid 
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Tmax Time to maximum concentration 
Tris 2-Amino-2-hydroxymethyl-propane-1,3-diol 
TWEEN Polyoxyethylene (20) sorbitan monolaurate 
UDPGA Uridine 5'-diphospho-glucuronic acid 
UGT1A1 UDP-glucuronosyltransferase 1-1 
UICC Union for International Cancer Control 
XELOX! Capecitabine/Oxaliplatin 
µg Microgramme 
µl Microlitre 
µM Micromole 
µm Micrometre 
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1 Introduction !  
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1.1 Epidemiology of colorectal cancer !
Colorectal cancer is the fourth commonest cancer in the UK, with 40 000 new cases 
diagnosed every year. It is the third highest cause of cancer related death in the UK, 
with 16, 259 people dying from the disease in 2012. Prognosis is improving, with 
survival rates climbing dramatically. For those diagnosed between 1971-75, 5-year 
survival was 25% for men and 28% for women compared to 50% and 51% for those 
diagnosed between 2001-2006 (Cancer Research UK, 2012).! Population level 
studies have highlighted the increasing prevalence of colorectal cancer, possibly 
because of an aging population. Incidence is directly associated with increasing 
age; 71% of new cases occur in patients over 65 years, and 42% occur in those 
older than 75 years (Eheman 2012). According to US Surveillance, Epidemiology 
and End Results (SEER) and Census Bureau data, an estimated increase in CRC 
incidence of 52% is projected over the next 20 years (Smith et al., 2009). 
Stage specific survival varies, with over 93% of patients diagnosed with Dukes A 
colorectal cancer surviving 5 years, compared to less than 5% for those with 
metastatic disease. There is also a survival difference between social groups within 
the UK, with the most affluent having a 5-9% increased 5-year survival compared to 
the least well off (Coleman et al., 2004).!Perhaps unsurprisingly, the incidence of 
colorectal cancer is not uniform across the UK with the highest incidence in 
deprived urban areas (Dunlop, 1992)!$ a trend reflected across Europe (Bray et al., 
2002).!
!
!
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1.2 Risk factors for colorectal cancer !
1.2.1 Dietary factors 
Several studies have suggested a link between a diet low in fruit and vegetables 
and colorectal cancer (Terry et al., 2001; Reedy et al., 2008) although hypotheses 
vary as to whether it is the fibre, antioxidant or flavone content of these foodstuffs 
that exerts this protective effect. The evidence for fibre exerting a protective effect is 
reinforced by several large observational studies showing an inverse correlation 
between fibre intake and colorectal adenomas and carcinomas (Negri et al., 1998; 
Peters et al., 2003; Bingham et al., 2003). However, a 2002 Cochrane Review 
suggested there was insufficient evidence to support increasing fibre intake to 
reduce the incidence of colorectal adenoma (Asano et al., 2002). It has also been 
suggested that red meat and, indirectly, high saturated fat intake may be related to 
the incidence of colorectal cancer (Sandhu et al., 2001).!An association between 
excess alcohol intake and colorectal cancer has been supported by meta-analysis 
(Longnecker et al., 1990) and it has been suggested that this may be related to 
reduced folate intake and absorption (Harnack et al., 2002).!
 
1.2.2 Lifestyle factors 
Observational studies have suggested that low levels of exercise are associated 
with increased risk of developing colorectal cancer. However, this effect may be 
confounded by higher levels of obesity, metabolic syndrome and diabetes amongst 
patients with low levels of activity (Mao et al., 2003). Smoking is also associated 
with an increased risk of colorectal cancer (Colangelo et al., 2004).!
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1.2.3 Inflammatory bowel disease 
Patients with inflammatory bowel disease such as Ulcerative Colitis and Crohn’s 
disease are at significantly increased risk for colorectal cancer, presumably as 
inflammatory changes trigger dysplasia (Choi et al., 1994). In patients with 
Ulcerative Colitis, risk seems to be highest in those with pancolitis and appears to 
rise markedly after 10 years of symptoms (Gyde et al., 1988) with a cumulative 
incidence of 5-10% after 20 years, 12-20% at 30 years and 30% at 40 years 
(Ekbom et al., 1990). There is growing evidence that the risk of colorectal cancer in 
longstanding Crohn’s disease is similar to that of Ulcerative Colitis (Ekbom et al., 
1990). As might be expected, the mean age of incidence for inflammatory bowel 
disease-related colorectal cancer is lower than for sporadic cases (45 vs. 60 years) 
(Choi et al., 1994).!
 
1.3 Aetiology of colorectal cancer !
1.3.1 The adenoma-carcinoma sequence 
Localized lesions within the colon that project above the mucosa are commonly 
termed polyps. Most colorectal polyps, particularly those smaller than 5 mm in size, 
are hyperplastic (a large number of normal appearing cells) and are not thought to 
develop into cancer. Adenomas arise from glandular epithelium within the lining of 
the large bowel and have distorted morphology, with altered appearance of the 
epithelial cells, and premalignant potential (Jass, 2007).  Around 50% of patients 
aged 70 will have at least one adenoma (Rex et al., 1993). Polypectomy reduces 
the risk of colorectal cancer, and patients who have their polyps removed at 
endoscopy have a lower incidence of malignant disease (Winawer et al., 1993). 
Adenocarcinoma can often be detected in adenomatous polyps, and regions of 
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adenomatous epithelium are often observed in resected colorectal cancer 
specimens (Fearon, 2011).! It is thought that only a small proportion of adenomas 
progress to cancer; adenomas approximately 1 cm in size have a 10% to 15% 
chance of progressing to carcinoma over a 10-year period (Stryker et al., 1987).!
These findings have led to the development of the adenoma-carcinoma concept, 
first hypothesized by Fearon and Vogelstein (Fearon et al., 1990). This hypothesis 
was developed following a number of observations. The incidence of adenomatous 
polyps is highest in the distal colon, where there is also the highest incidence of 
colorectal cancer. Clark et al demonstrated that geographical locations with high 
incidence of colorectal cancer were the same regions with high incidence of 
adenomatous polyps (Clark et al., 1985). Age-distribution curves for adenomas and 
carcinomas also show an increase with age, although incidence of adenomas peaks 
5 years before that of carcinomas (Muto et al., 1975).!
!
1.4 Molecular biology of colorectal cancer !
Most patients with colorectal cancer have no identifiable hereditary risk factors. 
However, around 20% occur on a background of an immediate family member 
having a primary colorectal malignancy, implying some degree of inherited 
predisposition (Lynch et al., 2003). A smaller proportion (approximately 10%) occurs 
in patients with recognized genetic syndromes that predispose towards 
gastrointestinal malignancy, such as hereditary non-polyposis colorectal cancer 
(HNPCC) (see section 1.4.7.1) or familial adenomatous polyposis (FAP). The 
remaining 80% of colorectal cancers are considered sporadic in nature, with the 
cancer developing from multi-potent stem cells located within intestinal crypts. 
Extensive work on the molecular pathogenesis of colorectal cancer suggests that 
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the majority of genetic alterations in colonic epithelial cells are harmless, triggering 
no functional change in phenotype. However, a number of key genomic and 
epigenomic changes have been identified which give rise to functional change and 
are positively selected for during carcinogenesis (Wood et al., 2007). These 
mutations tend to be intrinsically involved in DNA stability and repair, migration, cell 
adhesion and proliferation and lead to the development of adenomas and 
carcinomas. 
!
1.4.1 APC deactivation 
In FAP, multiple colonic adenomas occur throughout the length of the colon in the 
late teens and early twenties. The large number and early incidence of adenomas 
results in the formation of carcinomas in most patients by age 50 (Lynch et al., 
2003). The number of polyps makes surveillance endoscopy impossible, and most 
patients undergo prophylactic subtotal colectomy with surveillance of the rectal 
stump. The condition is caused by mutation of the adenomatous polyposis coli 
(APC) gene, with truncating germ-line mutations the cause of classical APC (Lynch 
et al., 2003). The APC tumour suppressor gene encodes a 300-kDa protein that 
integrally regulates cell-to-cell adhesion, migration, chromosomal segregation, and 
apoptosis (Fearon et al., 1990).!
As well as being integrally involved in the development of FAP, APC is also 
fundamental to the development of sporadic colorectal cancer; around 75% of 
sporadic tumours have somatic mutations that inactivate APC. There is good 
evidence that somatic APC mutations are an early and potentially rate-limiting step 
in the development of the adenoma-carcinoma sequence.  APC mutations occur 
with the same frequency in very small adenomas, advanced adenomas and 
carcinomas (Fearon et al., 1990) and APC mutations are found in all adenomas, 
even microscopic adenomas with only a small number of dysplastic glands (Kinzler 
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et al., 1996). The most established role for APC in the development of cancer is as 
a major binding partner and regulator of the β-catenin/WNT signaling pathway. 
 
1.4.2 WNT- β catenin dysregulation 
Mutations in the APC/WNT-β-catenin signaling pathway have been reported in 98% 
of colorectal cancers (Cancer Genome Atlas Network, 2012). APC down regulates 
WNT signaling by targeting β-catenin for degradation. Inactivation of APC leads to 
nuclear β-catenin accumulation, increased WNT signaling and cellular proliferation. 
Despite the clear role of WNT-signal dysregulation in the development of colorectal 
cancer, targeted agents tackling this mutation have yet to move beyond preclinical 
testing (Pritchard et al., 2011).!
 
1.4.3 TGF- β dysregulation 
TGF-β signaling is dysregulated in the majority of colorectal cancers, and mutations 
have been identified in genes coding for extracellular receptors (TGFBR1, 
TGFBR2), postreceptor signaling genes (SMAD2, SMAD4) and superfamily genes 
(ACVR2) (Pritchard et al., 2011). 
Mutations in TGFRB2 are detected in around 30% of colorectal cancers, and have 
been associated with malignant transformation in late adenomas (Grady et al., 
1999). SMAD4 is located on 18q, a region commonly deleted in colorectal cancer. 
Loss of this gene is associated with progression through the adenoma-carcinoma 
sequence in mouse models, supporting its role as a tumour suppressor gene 
(Taketo et al., 2000). Furthermore, loss of SMAD4 has been suggested as predictor 
of a more aggressive cancer phenotype and is associated with local invasion and 
lymph node metastases (Tanaka et al., 2008).!
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1.4.4 KRAS/BRAF dysregulation 
KRAS is a proto-oncogene, and is arguably the most clinically important oncogene 
in the development of colorectal cancer. KRAS is a downstream effector of 
endothelial growth factor receptor (EGFR), with binding of the ligand to the receptor 
triggering downstream signaling via the PI3K/AKT/MTOR and RAF/MEK/ERK 
proliferation pathways (Figure 1) (Fearon, 2011). Mutations in codon 12, 13 and less 
frequently codon 61 of KRAS have been reported in approximately 40% of 
colorectal tumours (Downward, 2003) with almost perfect concordance between 
primary and metastatic tumour (Artale et al., 2008; Vakiani et al., 2012). This 
concordance is exploited clinically as decisions on the appropriateness of treatment 
with targeted EGFR antibodies in a metastatic setting are based on primary tumour 
KRAS status. Patients with KRAS mutant tumours have previously been shown to 
derive no benefit from the administration of the targeted antibodies Cetuximab and 
Panitumumab (see section 1.9). However, this treatment algorithm is now being 
questioned with growing evidence that patients with KRAS G13-D mutant tumours 
may benefit from Cetuximab alongside cytotoxic chemotherapy (Tejpar et al., 2012).!
To date, KRAS remains the only clinically utilized predictive biomarker to guide 
therapeutic choice. 
 
 
28 
 
Figure 1 Downstream mediators of epidermal growth factor (EGFR) signaling. 
EGFR stimulation leads to activation of the KRAS/BRAF/MAPK pathway and 
indirectly the PI3K/AKT pathway, triggering cell growth, differentiation, 
survival and invasion. Monoclonal antibodies such as Cetuximab and 
Panitumumab act by blocking EGFR receptor stimulation. Downstream 
mutations in RAS/RAF/MAPK (leading to constitutive activation of 
KRAS/BRAF) pathways can render these agents ineffective. Adapted from 
Pritchard et al., 2011."
 
The BRAF gene codes for a protein kinase downstream of KRAS in the 
RAS/RAF/MEK/ERK pathway. The overwhelming majority of BRAF mutations are 
single base changes resulting in the substitution of glutamic acid for valine at codon 
600 (V600E) (Siena et al., 2009). BRAF and KRAS mutations appear to be mutually 
exclusive, supporting the hypothesis that only one mutation in this pathway is 
required to trigger upregulation of MAPK signaling (Rajagopalan et al., 2002). 
Interestingly, BRAF mutation in colorectal cancer has been associated with global 
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DNA hypermethylation (CIMP-high, see section 1.4.7) (Ogino et al., 2008). High 
levels of DNA methylation are associated with increased sensitivity to Camptothecin 
(Orta et al., 2009) and it has been hypothesized that hypermethylated BRAF-
mutated tumours may be more sensitive to irinotecan. This was supported by the 
retrospective analysis of BRAF status in patients treated as part of the large CALGB 
89803 RCT comparing 5-FU/LV vs. 5-FU/LV/irinotecan in patients with stage III 
CRC which demonstrated a non-significant trend towards improved OS for BRAF-
mutant patients treated in the irinotecan-containing arm (HR 0.52, 95% CI 0.25-
1.10) (Ogino et al., 2012). By contrast, the UK MRC FOCUS trial performed a 
retrospective analysis on 711 patients with stage IV CRC treated with a combination 
of non-targeted therapies (5-FU+/-Oxaliplatin/irinotecan). Mutation in KRAS (Codon 
12, 13, 61) or BRAF (V600E) was associated with a poor overall survival (HR, 1.40; 
95% CI, 1.20 to 1.65; P < .0001) but had minimal impact on progression-free 
survival (HR, 1.16; 95% CI, 1.00 to 1.36; P = .05) irrespective of treatment 
(Richman et al., 2009).  
1.4.5 PI3K pathway dysregulation 
The PI3K pathway is most commonly mutated in the p110α subunit of PI3KCα and 
is thought to promote the transition from adenoma to carcinoma (Figure 2) 
(Samuels et al., 2004). The PI3K pathway is modulated in part by KRAS, and it has 
been postulated that both PI3K and KRAS status may predict outcome after anti-
EGFR treatment (Razis et al., 2008) although this has yet to be validated in a 
clinical setting. 
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Figure 2 Proposed genetic model of adenoma-carcinoma sequence (a) 
Sporadic mutations accumulate, leading to development of malignant 
phenotype. The order in which mutations are accumulated is 
unimportant, although it has been suggested that certain mutations 
(e.g. APC, KRAS) are associated with early adenoma formation.  (b) In 
some cancers, MMR function is inactivated either by somatic 
mutations (HNPCC) or by epigenetic inactivation (CIMP), leading to 
high-frequency microsatellite instability (MSI-H). These epigenetic 
changes then lead to tumour-suppressor inactivation via microsatellite 
instability or promoter hypermethylation. Adapted from Fearon, 2011."
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1.4.6 p53 dysregulation 
p53 protein is a key transcriptional regulator for numerous cell-cycle checkpoints, 
promotes apoptosis in damaged cells and restricts angiogenesis (Vousden et al., 
2009). The high prevalence of p53 mutations in colorectal cancer suggests that 
stresses on tumour cells (the frequent need to activate cell-cycle arrest, apoptosis 
etc.) may apply a selective pressure in favour of a clonal subtype with p53 
deficiency, leading to continued growth and the acquisition of invasive properties. 
Baker et al  (Baker et al., 1990) assessed p53 status in 58 resected colorectal 
tumours. Isolated p53 mutations were rarely seen in carcinomas that contained both 
copies of chromosome 17p (17%). However, in 70% of tumours that contained 17p 
allelic deletions (the location of the p53 gene) the remaining p53 gene was mutated 
over 80% of the time. The authors concluded that a single point mutation is the rate 
limiting step and once a single mutated allele has developed, p53 deactivation 
rapidly follows.  
 
1.4.7 Genomic and epigenomic colorectal cancer subtypes 
As well as interest in the full DNA coding sequence of colorectal cancer (genomics), 
there is a growing recognition that modifications to DNA molecules that do not 
directly affect the DNA coding sequence can regulate gene activity (epigenomics). 
Epigenomics can explain whether genes are activated, and can influence protein 
function within cells. Importantly, epigenomic changes can be passed from 
generation to generation, and can also be affected by a lifestyle factors – for 
example, diet and exposure to pollutants. A number of distinct genomic and 
epigenomic colorectal cancer phenotypes have been recognized. 
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1.4.7.1 HNPCC 
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant 
inherited condition that leads to a high risk of cancer, especially colorectal cancer 
(25-70% lifetime risk) (Vasen et al., 2013). This increased risk is due to patients 
inheriting germ-line mutations in mismatch repair (MMR) genes which repair DNA 
replication errors. Classically, multiple generations of a family are affected with a 
much earlier mean age of incidence than sporadic cases. Over 70% of these 
lesions are right sided, and are found proximal to the splenic flexure. Unsurprisingly, 
these patients have a higher than average number of synchronous lesions (Lynch et 
al., 1999). Patients with HNPCC undergo enhanced carcinogenesis, with 
progression from adenoma to carcinoma within 2-3 years, as opposed to 8-10 years 
in general population (Lynch et al., 1999). Sufferers of HNPCC are also at risk of 
developing other primary tumours, including stomach, small bowel, pancreas and 
hepatobiliary malignancies (Aarnio et al., 1999).!As understanding of the molecular 
biology of colorectal cancer grew, investigators sought to identify the specific loss of 
function mutation in these affected individuals. These studies failed to identify a 
relevant sequence, but found the microsatellite DNA sequences used for the 
analysis showed marked variations in length compared to normal tissue from the 
same patient (Aaltonen et al., 1993). The phenotype was ultimately termed the 
microsatellite instability (MSI) phenotype (See section 1.4.7.2)!
!
1.4.7.2 Microsatellite instability (MSI) tumours 
Microsatellite instability is a condition of genetic hypermutability that results from 
impaired mismatch repair mechanisms, and is detected in approximately 15% of 
colorectal cancers. Tumours are defined as high-MSI or low-MSI based on the 
proportion of unstable loci in a panel of 5-10 points (> or < 30%) (Boland et al., 
1998). Patients with MSI tumour types have been shown to have a favourable 
 
 
33 
prognosis compared to patients with chromosomal instability tumours (CIN) (Popat 
et al., 2005), and it has been suggested that these tumour types may respond 
differently to chemotherapeutic agents (Jo et al., 2006). MSI is thought to be due to 
inactivation of genes integral to DNA repair - the DNA mismatch repair (MMR) 
family, which includes MLH1, MSH2, MSH6 and PMS2 (Grady et al., 2008).!During 
cancer development, cells with impaired DNA repair manifest a mutator phenotype 
and accumulate mutations in a much more rapid fashion than cells with functioning 
DNA repair function (Aaltonen et al., 1993).!
 
1.4.7.3 CpG island methylator phenotype (CIMP) and global DNA hypomethylation 
Epigenetic instability in colorectal cancer is associated with both global DNA 
hypomethylation, as well as hypermethylation of CpG islands. CIMP is defined as 
methylation of at least 3 loci from a panel of 5 gene-associated CpG islands, 
although this panel has not been standardised leading to discrepancies between 
studies (Carragher et al., 2010). CpG islands are associated with the start of a gene, 
and aberrant methylation may lead to gene silencing by promoter repression. It has 
been suggested that CIMP may be a novel predictive and prognostic marker for 
colorectal cancer (Shen et al., 2007). Global DNA methylation (hypomethylation) is 
reduced in many colorectal cancers, and work is ongoing to assess the importance 
of this finding (Rodriguez et al., 2006).!
!
1.4.7.4 Chromosomal instability (CIN) tumours 
Chromosomal instability is found in 85% of colorectal cancers (Grady et al., 2008), 
with a large meta-analysis demonstrating that CIN is associated with poor prognosis 
(Walther et al., 2008). Although felt to be important in the progression from 
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adenoma to carcinoma, the precise mechanisms which cause this instability remain 
poorly understood. 
1.5 Staging of colorectal cancer !
The first attempt at uniform staging of rectal cancer was made by the English 
pathologist Dr. Cuthbert Dukes in 1932 (Dukes, 1932) who classified tumour 
according to degree of spread. Dukes defined a tumour as stage A if it was confined 
to the intestinal wall, B if it invaded through the wall or C if there was local lymph 
node involvement. Metastatic disease was not included in the original grading, as it 
was considered a terminal diagnosis of limited clinical interest. In a later paper, 
Duke added stage D to represent distant metastatic spread. However, this was to 
confirm the dismal prognosis associated with metastatic disease rather than offer 
improved management (Dukes, 1949). Duke’s demonstration that the stage of the 
cancer correlated with prognosis led to its adoption for the description of all 
colorectal tumours.  
Improving preoperative radiological imaging and post-operative pathological 
assessment have led to the development of improved assessment of local invasion 
and degree of local lymph node spread and the development of more advanced 
staging systems. The current gold standard staging system is the unified 
International Union against Cancer/American Joint Committee for Cancer TNM 
classification. 
The TNM classification records the degree of local invasion and spread of a tumour. 
T records the extent of primary tumour, N records the absence, presence and 
extent of local lymph node invasion, and M considers evidence of distant metastatic 
spread (Table 1).   
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TNM Stage Description 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in-situ. Cancer has not breached the muscularis mucosa 
T1 Cancer extending into the submucosa 
T2 Cancer extending into the muscularis propria 
T3 Tumour invading through muscularis propria, into non-peritonealised 
pericolic/rectal structures 
T4a Tumour perforating visceral peritoneum 
T4b Tumour attached to or invading adjacent organs 
Nx Nodal spread cannot be assessed 
N0 No regional lymph node metastasis 
N1a Metastasis to 1 regional lymph node 
N1b Metastasis to 2-3 regional lymph nodes 
N1c Metastasis to perilymphatic fat, but no true lymphatic spread identifies 
N2a Metastasis to 4-6 regional lymph nodes 
N2b Metastasis to 7 or more lymph nodes 
Mx Distant metastasis cannot be assessed 
M0 No evidence of distant metastasis 
M1a Metastatic spread to 1 distant organ or set of lymph nodes 
M1b Metastatic spread to more than 1 distant organ or set of lymph nodes 
 
Table 1 UICC TNM Staging of Colorectal Cancer (Edition 7); (Stewart, 2010) 
this staging system assesses degree of local invasion, local and distant 
metastatic spread of colorectal disease. 
  
The large number of potential TNM combinations has resulted in the creation of a 
stage grouping system (Table 2), which groups TNM stages into I-IV with the 
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proposed benefit that decisions on treatment strategy can be made based on this 
classification (Carrato, 2008). 
Stage grouping TNM Staging 
0 Tis, N0, M0 
I T1-2, M0, N0 
IIa T3, N0, M0 
IIb T4a, N0, M0 
IIc T4b, N0, M0 
IIIa T1-T2, N1, M0 / T1, N2a, M0 
IIIb T3-T4a, N1, M0 / T2-T3, N2a, M0 / T1-T2, N2b, M0 
IIIc T4a, N2a, M0 / T3-T4a, N2b, M0 / T4b, N1-N2, M0 
Iva Any T, Any N, M1a 
IVb Any T, Any N, M1b 
 
Table 2 UICC/AJCC Stage grouping of TNM staging. The TNM system presents 
a large number of potential cancer stages. Stage grouping allows grouping of 
TNM stages, upon which treatment decisions can be made.  
!
1.6 Diagnosis of colorectal liver metastases !
Because of its unique location at the head of the portal venous system, the liver is 
the primary site of metastasis for colorectal cancer.  It is thought that 
haematogenous spread of metastatic disease occurs in a step-wise fashion along 
the portal tract (Simmonds et al., 2006) and the liver may be the only site of spread 
in 30-40% of patients with advanced cancer (Hugh et al., 1997). Around 50% of 
patients with colorectal cancer will develop liver metastases during the course of 
their disease (Lochan et al., 2007) and around 25% will have liver metastases at the 
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time of presentation of their bowel pathology (Bengmark et al., 1969). A further 25% 
of patients who have undergone curative resection of their bowel primary will go on 
to develop liver metastases at a later date; so called metachronous disease. These 
patients often have liver metastases detected as part of a routine follow-up program 
following bowel resection. This is clinically relevant, as it is progression of liver 
disease rather than progression of primary bowel pathology which determines 
overall life expectancy (Wood et al., 1976).!
 
1.7 Imaging of colorectal liver metastases !
Imaging plays an important role in the detection and management of CRLM. The 
ability to correctly stage disease in order to guide treatment as well as assess 
resectability and response to therapy is vital.  
Transabdominal ultrasound imaging allows rapid non-ionising assessment of the 
liver in patients suspected of having CRLM. However, ultrasound scanning is 
operator-dependent, with a sensitivity of only 66% (Soyer et al., 1992). 
Transabdominal ultrasound is also limited by fatty infiltration of liver parenchyma; a 
common finding in post-chemotherapy patients (Pawlik et al., 2007). The 
development of contrast agents for use with ultrasound has reinvigorated this 
technique, with studies suggesting 97% of CT detectable lesions are identifiable on 
contrast enhanced ultrasound (Bernatik et al., 2001). 
Intraoperative ultrasound (IOUS) is currently the most sensitive way of detecting 
lesions, with a sensitivity of between 95-99% in the hands of specialist hepatic 
surgeons, with the added advantage of being able to detect lesions as small as 
2mm (Schmidt et al., 2000; Zacherl et al., 2002). IOUS is now considered the 
standard of care, and has achieved almost universal usage. Indeed, IOUS has been 
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shown to change the operative plan in up to 59% of resections where it is employed 
(Jarnagin et al., 2001). 
Modern helical CT techniques have improved pre-operative detection of CRLM with 
a sensitivity of 60-90% (Ong et al., 2007). Vascular reconstructions of CT scans 
allow appropriate surgical planning of resections (Sahani et al., 2004), and whole 
body preoperative scanning allows single session analysis of potential extrahepatic 
metastatic disease. Multi-detector helical scanning can acquire information about 
the entire chest and abdomen during a single breath-hold, reducing the risk of 
breathing artifact (Ong et al., 2007). Rapid introduction of iodine based contrast 
agents coupled with high-speed scanning allows the entire liver to be visualized in a 
number of different vascular phases and may improve characterization of 
hypovascular colorectal liver metastases (Scott et al., 2001). 
Indeterminate lesions on CT are further visualized using MRI scanning, which is 
now considered the most effective imaging modality for detecting and characterizing 
liver lesions (Kamel et al., 2003). Reported sensitivities for CRLM detected by MRI 
range between 66-83% (Vidiri et al., 2004)!with detection and characterization of 
liver lesions improved by the addition of liver-specific contrast (Schima et al., 2005). 
18-fluorodeoxyglucose positron emission topography (FDG-PET) is a functional 
imaging technique that exploits the altered glucose metabolism of tumour cells to 
accumulate a contrast agent (Arulampalam et al., 2004). It is based on the 
hypothesis that metabolic abnormalities precede anatomical changes in metastatic 
spread of disease, suggesting PET may allow earlier detection of disease. Recent 
studies have suggested a sensitivity of between 94-100% (Arulampalam et al., 
2004). FDG-PET has the advantage of assessing the entire body, and may detect 
early recurrent primary disease, as well as low volume peritoneal and lymphatic 
disease that is not identifiable on CT (Zealley et al., 2001). A study by Huebner et al 
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suggested that in 29% of cases, patients with CRLM had their management plan 
altered by further information elucidated through FDG-PET (Huebner et al., 2000). 
FDG-PET is limited by its inability to accurately provide precise anatomical 
information. This problem has been addressed by the development of PET-CT, 
which combines high quality CT images with FDG-PET data, improving tumour 
detection and lesion localization. Cohade et al reported an improvement in staging 
and restaging accuracy from 78 to 89% when CT was combined with PET (Cohade 
et al., 2003). A prospective study by Ruers et al randomized patients to staging by 
CT-PET or standard CT alone. The number of resections which failed to achieve R0 
resection, or patients in whom recurrence was detected within 6 months, was 
significantly lower in the PET-CT group (28% vs. 45%, P=0.04) (Ruers et al., 2009). 
 
1.8 Surgical management of colorectal liver metastases !
Only 10-20% of patients with colorectal liver metastases will be candidates for 
curative surgery (Adam et al., 2004), but 5 year survival for those who do undergo 
liver resection is around 50% (Choti et al., 2002; Nordlinger et al., 1994; Yamada et 
al., 2001; Crowe et al., 2001; Mala et al., 2002; Figueras et al., 2001; Ambiru et al., 
1999; Wang et al., 1996; Rees et al., 1997; Wanebo et al., 1996; Schlag et al., 
1990; Scheele et al., 1991; Bakalakos et al., 1999) with a recent meta-analysis 
reporting 10 year survival between 9 - 69% (Taylor et al., 2012). However, 65% who 
survive for 5 years will experience disease recurrence (Mayo et al., 2009; Jones et 
al., 2012). 
Previously patients with synchronous disease, rectal primary, multiple diffuse 
metastases, metastases larger than 5cm, disease-free interval of less than 1 year 
from the diagnosis of primary disease or a high serum CEA were considered to 
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have a poor prognosis and suitable only for palliative treatment (Poston, 2008). 
Improved surgical techniques and evolution of neoadjuvant and adjuvant treatments 
has led to a paradigm shift in selecting patients for surgical resection. 
Contraindications to resection can now be grouped into two main categories; 
technical contraindications and oncological contraindications. 
 
1.8.1  Technical resectability  
Technical definitions of resectability have evolved. Current consensus in Europe 
and the US is that disease is resectable if it possible to leave sufficient future liver 
volume (FLV) to maintain adequate hepatic function, whilst removing all 
macroscopic disease with negative margins and preserving vascular inflow and 
outflow (Garden et al., 2006; NCCN 2012) . 
Deciding what constitutes sufficient liver volume varies depending on the underlying 
quality of remaining liver parenchyma (known as future liver remnant, or FLR). 
Twenty-five percent volume (approximately two Couinaud segments) is generally 
considered adequate. Patients with impaired hepatic function, including those with 
cirrhosis, steatosis and chemotherapy-associated parenchymal changes, require a 
larger FLR with significant parenchymal disease considered a barrier to surgery; 
patients with Childs class B and C liver failure rarely undergo resection. The 
regenerative nature of liver parenchyma means that significant regrowth takes place 
after resection and this unique feature means that two stage procedures are 
feasible with parenchymal regeneration between operations ensuring adequate FLR 
(Narita et al., 2011). This regenerative capacity is manipulated further using pre-
operative portal vein embolisation (PVE) to cause reactive hypertrophy in the 
proposed FLR (Oussoultzoglou et al., 2006). 
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Removal of all macroscopic disease traditionally refers to resectability with a 
negative margin >1mm (R0 resection)  (Pawlik et al., 2005). This still remains the 
gold standard, but there is growing evidence that patients undergoing resection with 
microscopically positive margins (R1 resection) (de Haas et al., 2008) have better 
survival than those with macroscopically positive margins (R2 resection). This is 
thought to be due to hepatic transection devices destroying tissue either side of the 
transection plane, resulting in obliteration of microscopic residual tumour from the 
margin. 
Anatomical location of metastases may make lesions technically irresectable, as 
disease cannot be safely removed without sacrificing nearby vessels and drainage 
structures. The structure itself may be vital (vena cava), or sacrificing the structure 
may result in the loss of significant parenchyma leaving an insufficient FLV. 
Development of novel surgical techniques means that a subset of patients with 
involvement of the vena cava may be candidates for surgery, using total vascular 
exclusion and ex vivo resection techniques (Garcea et al., 2008). However, 
expertise in these techniques is limited and so the number of patients who may 
benefit is small.  
 
1.8.2 Oncological resectability 
Although numerous factors are associated with poorer long-term outcome (See 
section 1.10.2), current oncological contraindications to resection mainly focus on 
extrahepatic malignancy. However, this is no longer seen as an absolute barrier to 
surgery with some centres now demonstrating good long-term outcomes in selected 
groups of patients with resected extrahepatic disease. Survival after partial 
pneumonectomy for colorectal metastases is similar to that seen after liver 
resection, with most series quoting a five-year survival in the order of 40-50%, with 
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low operative morbidity and mortality (Yedibela et al., 2006; Shiono et al., 2005; 
Pfannschmidt et al., 2003; Saito et al., 2002). Repeat resection of pulmonary 
metastases may also confer survival benefit, with 5-year survival of 42% reported 
after repeat resection (Kanzaki et al., 2011). Limited peritoneal and hepatic pedicle 
nodal disease is also potentially curable, with 5-year survival around 25% following 
resection (Adam et al., 2011).  
Progression on neoadjuvant chemotherapy is a relative contraindication to surgery. 
A retrospective series of 131 patients who underwent resection for CRLM found that 
patients whose lesions continued to progress on chemotherapy had a poorer long 
term prognosis (8% vs. 37% 5-year survival) (Adam et al., 2004). Interestingly, 
further analysis of data from the same registry suggested patients who underwent 
liver resection despite progression on chemotherapy in the absence of other high-
risk features (synchronous presentation, bilobar disease, multiple [>3] metastases, 
large [>5cm] metastases, high [>100] preoperative CEA levels) had a 5-year 
survival of 53.3%. By contrast, resection of progressive disease with high-risk 
features was associated with a 3-year survival of less than 10%, suggesting 
progression on chemotherapy alone should not be considered an absolute 
contraindication to resection (Viganò et al., 2012).  
NICE guidance in the UK now recommends that surgery for colorectal liver 
metastases should be considered if a patient is fit enough, and complete resection 
can be achieved leaving adequate future liver remnant (Poston et al., 2011). The 
guidance gave no absolute oncological contraindications to surgery, but suggested 
that liver resection should not be carried out in the presence of:  
• Non-treatable primary tumour 
• Widespread pulmonary disease 
• Locoregional recurrence 
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• Uncontrollable peritoneal disease 
• Extensive nodal disease, such as retroperitoneal or mediastinal lymph nodes 
• Bone or CNS metastases 
1.8.3 Techniques of surgical resection !
1.8.3.1 Transection techniques 
Technological innovations in liver surgery have mainly focused on minimising blood 
loss during transection of the hepatic parenchyma, as blood transfusion is 
associated with increased postoperative morbidity and mortality as well as reduced 
long-term survival (Kooby et al., 2003). Inflow occlusion (Pringle manoeuvre) and 
low central venous pressure (CVP) anaesthesia minimises blood loss but may 
cause liver damage by ischaemia and reperfusion injury. Consequently, there has 
been an interest in devices that facilitate a more bloodless liver transection, 
obviating the need for inflow occlusion associated with the traditional clamp-
crushing technique. 
The most popular of these techniques include the ultrasonic aspirating dissector 
(CUSA) using ultrasonic energy, the Hydrojet using a pressurised jet of water and 
the dissecting sealer (TissueLink) using radiofrequency energy. These techniques 
were compared in a randomised controlled trial (Lesurtel et al., 2005) and in a 
subsequent Cochrane review (Gurusamy et al., 2009). There was little difference 
demonstrated between the four techniques, though the clamp-crushing technique 
was found to be associated with faster tissue transection, and lower transfusion 
requirements. The Cochrane review also found an association with fewer infective 
complications. Both studies highlighted the significantly reduced cost associated 
with the clamp crushing technique, and therefore could not advocate the use of 
newer techniques in standard practice. A further randomised control trial of 
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radiofrequency-assisted versus clamp-crushing transection in 50 patients showed a 
higher rate of postoperative complications in the radiofrequency group (20%), 
compared to none in the clamp-crushing group (Lupo et al., 2007).!
 
1.8.3.2 Ablation for colorectal liver metastases 
Ablative therapy takes numerous forms. Cryotherapy, laser hyperthermia and 
ethanol injection are decreasing in popularity due to high complication rates or lack 
of efficacy. Radiofrequency ablation (RFA) and microwave ablation (MWA) offer 
significant advantages over older ablative techniques and are increasingly used. 
However, there remains a lack of clarity surrounding the precise role of ablation 
compared to surgery. Recent American Society of Clinical Oncology (ASCO) 
guidelines highlighted the wide variation in overall survival and local recurrence 
rates after ablation, and suggested that in the absence of adequate data resection 
should remain the gold standard treatment for resectable disease (Wong et al., 
2010). Despite these concerns, ablation still has a role as an adjunct to resection.  
Patients with small volume resectable metastases who are not sufficiently fit to 
undergo liver resection should be considered for ablation as should those with 
limited liver metastases who have insufficient liver volume to undergo resection 
(Oshowo et al., 2003; Jansen et al., 2005).! 
There is growing interest in the use of ablation alongside systemic chemotherapy 
for irresectable liver disease. EORTC 40004 compared systemic chemotherapy vs. 
systemic chemotherapy plus ablation for patients with technically unresectable liver 
limited disease. 3-year DFS was improved in the combined ablate and 
chemotherapy arm (27.6% vs. 10%, p=0.03) with a trend towards improved OS 
(median 45.3 months vs. 40.5, p=0.2) (Ruers et al., 2012). In the French ARF2003 
single arm phase II study, 52 patients with unresectable liver limited disease were 
 
 
45 
treated with a combined ablate and resect strategy using RFA (Evrard et al., 2012). 
One year local DFS was 46% (95% CI 32-59) whilst 5 year OS was 43% (21-64), 
demonstrating that ablation and resection can lead to good long-term survival. The 
evidence now points towards managing stage IV colorectal cancer as a chronic 
disease condition, where surgery or ablation is performed in the expectation of 
potentially treatable disease recurrence rather than a single entity which can only be 
surgically treated once with curative intent or not. Patients who experience 
recurrence after liver resection can now often be treated with further interventions 
including surgery or ablation (Jones et al., 2012). Parenchymal sparing techniques 
(including ablation) preserve functional liver volume, so maximising the opportunity 
for further liver directed interventions in the future.  
 
1.8.3.3 Laparoscopic liver surgery 
Laparoscopic surgery for hepatic neoplasms aims to provide curative resection 
while minimising complications. There are no randomized controlled trials 
comparing laparoscopic and open hepatectomy, and so the evidence is based on 
retrospective series.  A meta-analysis of series published between 1998 and 2005 
(Simillis et al., 2007) included eight non-randomised studies, reporting on 409 
resections of hepatic neoplasms, of which 165 (40.3%) were laparoscopic and 244 
(59.7%) were open. Operative blood loss and duration of hospital stay were 
reduced significantly after laparoscopic surgery. These findings remained consistent 
when considering studies matched for the presence of malignancy and segment 
resection. There was no difference in postoperative adverse events and extent of 
oncological clearance. This paper concluded that laparoscopic liver resection has 
the potential to reduce operative blood loss and allow earlier recovery with 
oncological clearance comparable with open surgery.  
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The largest single-centre experience of laparoscopic resection of CRLM included 83 
resections within a series of 133 liver resections (Abu Hilal et al., 2012). The authors 
reported a median operating time of 210 minutes (30-480 minutes), median blood 
loss of 300ml (10-3000ml) and a median postoperative stay of 4 days (1-15 days). 
Severe postoperative bleeding occurred in 5 patients (3.7%) requiring intensive care 
management or reoperation, and overall serious complications occurred in 16 
patients (13%). Microscopically negative margins (R0/R1) were achieved in 96% of 
patients with CRLM. In 2008 a group of 45 experts in hepatobiliary surgery 
participated in a consensus conference and concluded that the laparoscopic 
approach to liver resection is a safe and effective technique for appropriately trained 
surgeons (Buell et al., 2009).  
 
1.9 Chemotherapeutic management of colorectal liver metastases !
In the last 10 years, overall survival (OS) in patients with metastatic CRC has 
improved substantially (Kopetz et al., 2009) reflecting improved chemotherapeutic 
manipulation of disease. Before 2000, 5-flourouracil (5-FU) was the only available 
treatment. With the development of the cytotoxic agents Oxaliplatin and irinotecan, 
doublet regimens are now considered standard therapy (5-FU/leucovorin/Oxaliplatin 
as FOLFOX or 5-FU/leucovorin/irinotecan as FOLFIRI).  
In the last 5 years, major advances in the management of advanced colorectal 
cancer have been made by harnessing targeted monoclonal antibodies against 
extracellular receptors. Epidermal growth factor receptor (EGFR) is a 
transmembrane glycoprotein that utilises tyrosine kinase activity for signal 
transduction with downstream signaling intrinsically involved in multiple biological 
processes essential for tumour survival (See section 1.4). Cetuximab is a 
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recombinant human/mouse chimeric antibody that binds specifically to the 
extracellular domain of the human EGFR, inhibiting this pathway. Panitumumab is a 
fully human monoclonal antibody with a similar method of action. It is now 
recognized that patients who have a mutation in the downstream KRAS proto-
oncogene are resistant to Cetuximab and Panitumumab therapy, and so KRAS 
testing is routinely performed prior to commencing treatment (Van Cutsem et al., 
2009). Concordance between primary and metastatic tumour is high (>98% for 
KRAS), allowing analysis of previously resected primary tumour to guide therapy 
(Vakiani et al., 2012). Improved understanding of the KRAS signaling pathway has 
identified other common mutations in downstream effectors (including BRAF, NRAS 
and PIK3CA) which may also confer resistance to anti-EGFR treatments (Roock et 
al., 2010). 
Vascular endothelial growth factor (VEGF) is one of the most important regulators of 
the dynamic balance between pro and antiangiogenic factors that are crucial for 
tumour growth and metastasis, with signaling leading to angiogenic proliferation and 
increased microvascular permeability. Bevacizumab is a humanized monoclonal 
antibody directed against VEGF receptors. Proposed mechanism of action includes 
inhibition of vessel development, regression of aberrant tumour vasculature and 
normalization of tumour perfusion (Ellis, 2006). 
 
1.9.1 Chemotherapy for resectable colorectal liver metastases 
Relapse after resection is common, with around two thirds of patients experiencing 
hepatic recurrence within 2 years (Jones et al., 2012). Chemotherapy aims to 
maximise the number of long term survivors following such surgery by treating 
occult disease (Chong et al., 2005; Ellis et al., 2005) and systemic adjuvant 
chemotherapy has been shown to improve survival after resection of high risk stage 
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II and all stage III colorectal cancer (Poston et al., 2011). It therefore seems logical 
that adjuvant therapy after resection of any stage IV disease should also improve 
long-term outcome.  However, the evidence supporting this approach is less than 
clear.  
 
1.9.1.1 Adjuvant therapy for resectable colorectal liver metastases 
In the FFCD AURC 9002 trial (Portier et al., 2006) 171 patients were randomized to 
liver resection alone or resection followed by adjuvant 5-FU/leucovorin (FU-LV). 
Due to poor accrual, the trial failed to demonstrate its primary endpoint of improved 
5-year overall survival (26.7 vs. 33.5%, ns). The EORTC 0923 trial (Mitry et al., 
2008) followed a similar model of resection vs. resection with adjuvant FU-LV and 
again failed due to poor accrual to demonstrate a significant overall survival (OS) 
benefit to the combined therapy arm (Median OS 53 vs. 43 months, ns). Both 
studies were underpowered, and a subsequent pooled analysis demonstrated a 
median OS of 62.2 months in the chemotherapy arm compared with 47.3 months in 
the surgery alone arm (HR 1.32, 95% CI 0.95-1.82, p=0.095), with multivariate 
analysis demonstrating a benefit to adjuvant 5-FU based chemotherapy in terms of 
both improved disease free survival (DFS) and OS (Mitry et al., 2008). Of note, only 
66.7% of patients received all 6 cycles of chemotherapy.  
The improved response rates seen after systemic doublet-agent chemotherapy 
compared to FU-LV suggests that patients might gain a greater benefit from more 
effective regimens such as FOLFOX/FOLFIRI, but results in stage II and III disease 
have been mixed. The MOSAIC study demonstrated a clear improvement in long 
term DFS and OS for stage III patients treated with FU-LV with the addition of 
Oxaliplatin over FU-LV alone (HR = 0.80; 95% CI, 0.65 to 0.97; P = .023) but this 
benefit did not translate to patients with stage II disease (André et al., 2009), whilst 
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the pan-European Trials in Alimentary Cancer (PETACC-3) study failed to 
demonstrate any improvement in DFS or OS with the addition of irinotecan to 
adjuvant FU-LV acid in patients with stage III disease (Van Cutsem et al., 2009). 
For patients with resectable stage IV disease, the evidence is equally limited. A 
phase III study comparing adjuvant FU-LV versus FOLFIRI following R0 resection of 
CRLM reported a 2-year disease free survival of 51% and 46% respectively (HR 
0.89, 0.66-1.19, p=0.43) (Ychou et al., 2009) similar to that reported in series of 
resection alone (Morris et al., 2010). The evidence for adjuvant systemic 
chemotherapy after liver resection may therefore appear marginal.  However, 
variable delivery of any adjuvant regimen may limit any therapeutic advantage, with 
toxicity, physician or patient preference meaning that many patients do not receive 
a full treatment course. In the FFCD trial, only 66.7% received complete adjuvant 
treatment (defined as 85% of the planned dose) whilst the only 53% of patients in 
the EORTC 0923 trial completed the proposed 6 cycles of adjuvant treatment.  
 
1.9.1.2 Neoadjuvant therapy for resectable colorectal liver metastases 
Preoperative treatment offers several potential advantages over adjuvant therapy. It 
allows the monitoring of chemo-responsiveness in measurable disease, aiding 
selection of appropriate adjuvant therapy, as well as reducing tumour volume 
allowing more parenchymal sparing surgery. It also identifies patients with 
aggressive tumour biology in whom resection may not be appropriate.  
A number of early studies suggested that neoadjuvant therapy is safe and well 
tolerated. A non-randomized phase II study of 20 patients treated with neoadjuvant 
high-dose 5-FU (2600 mg m-2), folinic acid and bi-weekly Oxaliplatin demonstrated 
successful delivery of 99% of scheduled FU-FA, and 99% of scheduled Oxaliplatin, 
with a 50% post-operative morbidity and 0% operative mortality (Wein et al., 2003). 
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Another phase II non-randomized study of neoadjuvant FOLFOX followed by 6 
cycles of adjuvant FOLFIRI found no difference in patient compliance between 
neoadjuvant and adjuvant therapy, with 97% of planned cycles successfully 
delivered, and no operative mortality (Taïeb et al., 2005). A single-arm study of 6-
cycles of neoadjuvant CAPOX (Capecitabine and Oxaliplatin) plus Bevacizumab 
was able to deliver the planned 6 cycles to 85% of patients, although only 45% 
received the full schedule. Postoperative morbidity was 21%, with no post-operative 
deaths, data consistent with matched historical chemonaïve controls (Gruenberger 
et al., 2008). 
Data assessing the efficacy of neoadjuvant therapy on long-term outcome are more 
limited. A retrospective study of 1471 patients, each with a solitary metachronous 
resectable colorectal metastasis, compared patients who received at least 3-cycles 
of FOLFOX/XELOX/CAPOX/FOLFIRI (n=1302) with a group treated with surgery 
alone (n=169) (Adam et al., 2010). The rate of postoperative complications was 
significantly higher in the chemotherapy group (37.2% vs. 24%, P = 0.006). At 
univariate analysis, preoperative chemotherapy did not improve OS (60% at 5 years 
in both groups); however, postoperative chemotherapy was associated with better 
OS (65% vs. 55% at 5 years, P < 0.01). Despite the theoretical benefits, the role of 
perioperative chemotherapy in resectable stage IV colorectal cancer therefore 
remains unclear.  
The multicentre EORTC 40983 study attempted to definitively address this question 
by randomising 364 patients with resectable liver only CRLM to 12 cycles of 
perioperative FOLFOX (6 before surgery, 6 after) or surgery alone (Nordlinger et al., 
2008). The primary endpoint of the study was 3-year progression free survival (PFS, 
defined as time from treatment to detection of disease progression), with secondary 
endpoints including response rate, safety, and OS. In the combined therapy arm 
only 94% of patients received any preoperative chemotherapy, and only 78.6% 
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received the full 6 cycles. 152 patients from each arm underwent resection. In the 
chemotherapy arm, 5% randomised to combined therapy did not undergo surgery; 4 
patients were found to have new previously unidentified lesions, whilst 4 (2%) failed 
resection because of progression of known lesions. Progression on chemotherapy 
was therefore a rare cause of failed resection. Within the chemotherapy arm, only 
115 (63.2%) patients proceeded to post-operative chemotherapy and only 43.9% 
received the full 6 cycles. For those patients who underwent hepatectomy, the 
primary endpoint of 3 year PFS was 36.2% in the perioperative chemotherapy arm 
compared to 28.1% in the surgery alone group (HR 0.77, 06-1.00, p=0.041) (Figure 
3). This positive result was taken by many as a definitive answer to the benefit of 
perioperative chemotherapy, and since then it has become the standard of care in 
many units for patients with resectable CRLM (Nordlinger et al., 2010; Nordlinger et 
al., 2009). At a median follow up of 8.5 years, nearly half the patients in both arms 
had died from cancer related causes. However, the addition of perioperative 
chemotherapy to surgery produced no demonstrable improvement in long term OS 
(HR 0.87, 0.66-1.14, p=0.303), although there was a non-significant trend towards 
improved 5-year survival and median overall survival (63.7 months vs. 55 months) 
in the chemotherapy arm (Nordlinger et al., 2012). 
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Figure 3 Kaplan-Meier survival curves from EORTC 40983 trial comparing 
perioperative chemotherapy vs. resection alone for patients with initially 
resectable CRLM (Nordlinger et al., 2008). The trial showed improved 3-year 
PFS (primary endpoint). At 8.5-year follow-up, this improvement in PFS did 
not translate to overall survival benefit (Nordlinger et al., 2012). 
 
1.9.2 Chemotherapy for irresectable disease 
A major development in the chemotherapeutic management of advanced disease 
over the last ten years has been the recognition that there is a subgroup of patients 
who may not be resectable at presentation but become resectable after 
chemotherapy.  
Resectability rates after chemotherapy for initially irresectable disease vary widely 
from around 6-60%, the wide variety reflecting patient selection, local approach to 
resection as well as chemotherapeutic regimen (Poston, 2008). Attempting to 
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convert irresectable disease into resectable is a worthwhile aim, with 5 year survival 
around 35-50%, similar to those patients who underwent resection at presentation 
(Figure 4) (Adam et al., 2001). Radiological response to chemotherapy is known to 
correlate with resection rate (Folprecht et al., 2005), with studies with defined 
criteria for resectability reporting higher rates of secondary resection (Figure 5) 
(Jones et al., 2014).  It therefore seems sensible that patients with borderline 
resectable disease should be treated with the most aggressive regimen possible to 
provide the best possibility of reaching resection (Nordlinger et al., 2007).  
 
 
 
Figure 4 Kaplan-Meier survival curves showing survival following 
hepatectomy for CRLM comparing those who were initially resectable at 
presentation to those patients who were considered initially unresectable but 
were brought to resection using systemic chemotherapy (Adam et al., 2001). 
This clearly demonstrates long term outcomes superior to systemic 
chemotherapy for those patients brought to resection. 
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Study Type Regimen No of ptnts. 
Overall 
response 
rate 
 
p 
Patients 
resected 
 
p 
OPUS 
Phase II 
RCT 
FOLFOX+ 
Cetuximab 169 61% (WT) 
 
0.01 
9.8% 
 
0.03 
FOLFOX 168 37% (WT) 4.1% 
CRYSTAL 
Phase 
III 
RCT 
FOLFIRI + 
Cetuximab 599 59.3% (WT) 
 
0.03 
7% 
 
0.002 
FOLFIRI 599 43.2% (WT) 3.7% 
CELIM 
Phase II  
RCT 
FOLFOX + 
Cetuximab 
56 68%  
0.23 
40%  
0.4 
FOLFIRI + 
Cetuximab 
55 57% 43% 
POCHER 
Single 
arm 
phase II 
FOLFOXIRI + 
Cetuximab 43 79% 
 
60.5% 
 
BEAT 
Phase 
IV 
prospect
ive 
study 
First line 
cytotoxic + 
Bevacizumab 
704 
liver 
only 
 
 
15.2% 
 
GONO 
Group 
Single 
arm 
phase II 
FOLFOXIRI + 
Bevacizumab 
57 76% 
 
40% (liver 
only) 
 
Table 3 Table showing response rate and resection rate for key trials of 
cytotoxic agents with the addition of targeted biological agents in patients 
with initially irresectable metastatic colorectal cancer. WT=KRAS wild type 
 
 
 
 
 
55 
 
Figure 5 Rates of secondary liver resection following systemic chemotherapy. 
The size of each data point reflects the number of patients included in each 
study. Blue squares are series that had clearly defined criteria of irresectable 
disease, and show a highly significant correlation between response rate and 
secondary resection rate (R2=0.62, p=0.003). Red triangles represent series 
without clearly defined criteria for irresectability, and also show a significant 
correlation between response and secondary resection (R2=0.71, p=0.004). For 
studies with clearly defined criteria for resectability, rates of secondary 
resection were much higher for similar rates of radiological response 
(p=0.006).  (Jones et al, 2014)."
!
The UK National Institute for Clinical Excellence (NICE) currently recommend the 
use of 5-FU, leucovorin and Oxaliplatin based regimens (FOLFOX) with or without 
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Cetuximab as first line therapy for all patients with non-resectable liver-limited 
disease, with irinotecan based regimens (FOLFIRI) for second line therapy after 
failure of first line treatment, although efficacy of FOLFIRI is comparable to that of 
FOLFOX in the setting of metastatic disease (Tournigand et al., 2004; Colucci et al., 
2005) with no differences in response rate, PFS or overall survival. The rationale for 
choosing FOLFOX over FOLFIRI is the perceived increased toxicities associated 
with systemic irinotecan including early and delayed diarrhoea and severe 
neutropenia (Innocenti et al., 2004).! 
Intensive triplet chemotherapy with FOLFOXIRI has been compared with FOLFIRI 
alone in a phase III randomised controlled trial (Falcone et al., 2007). Response 
rates were higher after FOLFOXIRI, with a secondary resection rate of 36% in 
patients with liver-limited disease compared to 12% for those treated with standard 
FOLFIRI (p=0.017). However, off-target toxicity (mainly severe diarrhoea) was high 
and so double agent cytotoxic therapy remains the first line  
The large phase III CRYSTAL trial randomized 1198 patients to FOLFIRI +/- 
Cetuximab as first line treatment (Van Cutsem et al., 2009). Retrospective analysis 
of KRAS status was performed on 1063 patients (Van Cutsem et al., 2011) and 
found response rates of 57.3% vs. 39.7% for FOLFIRI and Cetuximab compared to 
FOLFIRI alone in KRAS wild-type patients. By contrast, Cetuximab offered no 
survival advantage to the KRAS mutant group. Resectability rates for the entire 
group (irrespective of KRAS status) were 7% in the FOLFIRI + Cetuximab arm, 
compared to 3.7% in the FOLFIRI arm, with R0 rate of 4.8% vs. 1.7% (p=0.002) 
The randomized phase II OPUS trial compared the alternative regimen of FOLFOX 
+/- Cetuximab in 337 patients with metastatic colorectal cancer, with response rates 
of 46% vs. 36% respectively (p=0.06) (Bokemeyer et al., 2009). However, subgroup 
analysis of 315 patients assessed KRAS status demonstrating overall response rate 
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of 61% in wild type patients compared to 37% in KRAS mutants (p=0.01) 
(Bokemeyer et al., 2011). 
The 2010 phase II CELIM study of neoadjuvant FOLFOX and Cetuximab, or 
FOLFIRI and Cetuximab, for a more selected group of patients with irresectable 
metastatic liver only disease found response rates of 85% and 66% respectively. 
40% of the FOLFOX and Cetuximab arm underwent resection, compared to 43% of 
FOLFIRI and Cetuximab.  These impressive results suggested that the addition of a 
targeted biological agent increased the possibility of bringing irresectable liver only 
disease to resection. In a combined retrospective analysis of both arms, 67 patients 
with KRAS wild-type tumours achieved a response rate of 79%, (Folprecht et al., 
2010). The 2010 phase II POCHER study assessed a chemotherapeutic backbone 
(irinotecan, Leucovorin, 5-Fluorouracil and Oxaliplatin) alongside Cetuximab in 43 
patients with irresectable liver only metastases (Garufi et al., 2010). Despite therapy 
not being allocated on the basis of KRAS status (the effect of KRAS status on 
response was unknown at the time of study design), the authors reported a 60% 
R0/R1 resection rate after a median of 6 cycles, with an objective response rate of 
79.1%. Two-year survival was 80.6% in resected patients, compared to 47.1% in 
those who did not undergo resection (p=0.01). These impressive results highlight 
the importance of optimal chemotherapeutic manipulation in patients with liver only 
metastatic disease. 
The largest experience of Bevacizumab to date remains the BEAT trial (Van 
Cutsem et al., 2009). This large phase IV uncontrolled trial assessed the addition of 
Bevacizumab to first line chemotherapy for patients with irresectable hepatic and 
extrahepatic metastatic colorectal cancer. 1914 patients were included, with a 
median PFS of 10.8 months (95% CI 10.4-11.3) and median OS of 22.7 months 
(95% CI 21.7-23.8). In this unselected group, curative resection was performed in 
7.6%. In 704 patients with metastatic disease limited to the liver, resection was 
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achieved in 15.2%. Two-year survival was 89% in those undergoing resection, 
compared to 54% in those who did not. This study confirmed a similar efficacy of 
Bevacizumab in routine clinical practice compared to that observed in a trial setting. 
The impressive results reported by the GONO group following systemic FOLFOXIRI 
led to them performing a single arm phase III trial of FOLFOXIRI with the addition of 
Bevacizumab (Masi et al., 2010). Treatment was given as first line to 57 patients, 
with a 74% PFS at 10 months (95% CI 62-85). Curative resection was performed in 
40% of those patients recruited with irresectable liver only disease, and this group 
has now developed a phase III randomised study comparing FOLFOXIRI plus 
Bevacizumab with FOLFIRI plus Bevacizumab. Preliminary results were presented 
at ASCO GI 2013, and demonstrated a significantly improved progression free 
survival (9.5 vs. 11.9 months) and response rate (53% vs. 64%) for the 
Bevacizumab/FOLFOXIRI arm  (Loupakis, 2013). 
Interestingly, the addition of Bevacizumab to irinotecan containing regimens 
appears to improve response rate compared to Oxaliplatin based regimens, and so 
when conversion to resectability is the primary aim of therapy this combination may 
become first-line therapy in KRAS mutant patients (Fuchs et al., 2007; Hurwitz et 
al., 2004). A summary of these response and secondary resection rates is outlined 
in table 3. 
 
1.9.3 Chemotherapy-induced liver injury 
Growing evidence suggests that preoperative chemotherapy is associated with 
agent-specific patterns of chemotherapy associated liver injury (CALI, Figure 6) 
including steatosis (5-FU/irinotecan), (Parikh et al., 2003) steatohepatitis (5-
FU/irinotecan) (Fernandez et al., 2005) and sinusoidal obstructive syndrome 
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(Oxaliplatin) (Rubbia-Brandt et al., 2004). In addition, there has been concern about 
the perioperative impact of this hepatotoxicity.  
 
Figure 6 Representative photomicrographs of chemotherapy associated liver 
injury (A) Sinusoidal obstructive syndrome (SOS) produced by administration 
of systemic Oxaliplatin, showing dilated sinusoids suggestive of vascular 
congestion. (B) Steatohepatitis and steatosis induced by systemic irinotecan, 
with characteristic micro and macrosteatosis, inflammatory cell congregation 
and hyaline bodies (black arrows). (Both x30 magnification) (Figure adapted 
from Poston 2014)"
EORTC 40983 reported a moderate increase in reversible morbidity in the 
chemotherapy arm (25% vs. 16%, p=0.04), but 30-day mortality for both groups 
remained 1%. Conflicting results have been published since then (Parc et al., 2000; 
Ryan et al., 2010) with Vauthey et al (Vauthey et al., 2006) reporting a clear 
association between the administration of systemic irinotecan and steatohepatitis 
(20.2% vs. 4.4% in chemonaïve patients, p<0.01, OR 5.4 [95% CI 2.2-13.5]), which 
translated into a significant increase in 90-day post-operative mortality (14.7 vs. 
1.6%, p=0.001, OR 10.5 (95% CI 2.0-36.4)). There is a clear correlation between 
number of cycles of chemotherapy, degree of liver damage and perioperative risk 
 A B 
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(Karoui et al., 2006). However, this risk appears to be mitigated by allowing an 
appropriate interval (usually 6 weeks) between the final cycle of systemic therapy 
and surgery (Welsh et al., 2007). Interestingly, a high quality systematic review and 
meta-analysis suggested that the use of Bevacizumab alongside FOLFOX may 
offer a protective benefit, significantly reduced the risk of sinusoidal injury (relative 
risk 0.34; 95 % CI 0.15-0.75) (Robinson et al., 2012). However, the precise 
mechanism behind this remains unclear. 
As well as concerns about the perioperative impact, there is growing interest in the 
long-term oncological implications of chemotherapy associated liver injury with 
Tamandl et al (Tamandl et al., 2011) reporting shorter DFS (HR 2.05; 95% CI 1.23-
3.39, P = .005) and OS (HR 2.90; 95% CI 1.61-6.19, P < .001) in patients with 
sinusoidal obstructive syndrome caused by preoperative Oxaliplatin. 
 
1.9.4 Radiological assessment of chemotherapeutic response 
Imaging plays a key role in the assessment of response to treatment. A major 
international collaboration led to the definition of the Response Evaluation Criteria in 
Solid Tumours (RECIST) criteria to standardize reporting of response rates to 
therapy (Therasse et al., 2000).! All radiologically measurable lesions (longest 
diameter >10mm on spiral CT) up to a maximum of 5 per organ and 10 in total are 
identified and recorded as target lesions. A sum of baseline longest dimensions 
(LD) is then calculated (baseline LD). Response of target lesions is assessed as 
complete response (CR, disappearance of all lesions), partial response (PR, at least 
a 30% reduction in the sum of LD of target lesions compared to baseline LD), 
progressive disease (PD, at least 20% increase in the sum of LD compared to best 
LD since treatment began) and stable disease (SD, neither sufficient shrinkage or 
progression to classify as PR or PD). 
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In 2009, these criteria evolved into modified RECIST version 1.1 which reduced the 
maximum number of target lesions from ten to five, with a maximum of two per 
organ. Progressive disease (PD) of target lesions now required not only a > or = 
20% increase in the sum of the longest diameter (SLD) from the nadir but also a >  
= 5 mm absolute increase in the SLD. PD of non-target lesions could now only be 
applied if the increase in non-target lesions represented a change in overall tumour 
burden. 
Attempts to correlate pathological response with radiological response have proved 
difficult (Grothey et al., 2008) with over 80% of lesions demonstrating complete 
radiological response containing viable tumour on histological examination (Benoist 
et al., 2006). It has now been recognized that that change in tumour size may not 
accurately reflect the efficacy of therapy, shifting the focus toward new methods of 
evaluation including the assessment of tumor morphology, vascularity and cellular 
integrity defined by the degree of extracellular contrast enhancement. The 
European Association for the Study of the Liver (EASL) officially recommended the 
use of lesion enhancement on contrast-enhanced CT as the standard modality to 
determine treatment response of HCC after locoregional therapy (Bruix et al., 2001) 
and new guidelines are being developed to describe the different response of 
metastatic colorectal lesions to modern biologic therapies such as Bevacizumab 
(Chun et al., 2009).  
The role of PET imaging in the assessment of chemotherapeutic response and 
immediate post-chemotherapy period remains unclear. Glazer et al (Glazer et al., 
2010) found that PET scan within 4 weeks of finishing neoadjuvant chemotherapy is 
associated with a negative predictive value of 13.3% and a positive predictive value 
of 94.3%. Sensitivity was 89.9% and specificity was 22.2%, with an accuracy of 
85.5%.  A further study assessed correlation between complete response to 
neoadjuvant therapy on PET-CT and pathological response after resection. 
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Complete pathologic response was found in only 15% of treated lesions. Of seven 
lesions showing complete metabolic response of PET-CT, six still contained viable 
tumor. It therefore seems that complete metabolic response on FDG-PET after 
neoadjuvant chemotherapy is an unreliable indicator of complete pathologic 
response (Tan et al., 2007). 
!
1.9.5 Pathological assessment of chemotherapeutic response 
It is well recognised that patients who exhibit a good pathological response to 
chemotherapy have better overall survival (Rubbia-Brandt et al., 2007). A study by 
Blazer et al found complete pathological response to chemotherapy was associated 
with a 5-year survival of 75% (Figure 7) (Blazer et al., 2008). Complete response 
occurred in a small minority of patients (9%) but survival was significantly better 
than those with less response (75% 5-year survival, compared to 56% for those with 
a major response and 33% for those with a minor response, p=0.037).  
This finding was supported by Adam et al, who found patients exhibiting complete 
pathological response had a 5 year survival of 76%, compared to 45% for those 
without (Adam et al., 2008). Interestingly, there is now growing evidence that 
chemotherapy-associated change seems to be represented by fibrotic involution 
rather than necrosis (Poultsides et al., 2012).  
Complete pathological response is an impressive example of the effectiveness of 
modern chemotherapeutic regimes. Although oncologically desirable, it creates 
surgical difficulties. The correlation between complete radiological and pathological 
response is not clear, with many lesions showing complete radiological response 
containing viable tumour. Trying to locate a lesion that has disappeared is difficult, 
and results in patients undergoing blind resection on the basis of the last known 
location of that lesion. The difficulties associated with disappearing lesions 
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highlights the importance of combined surgical and oncological planning to optimise 
the chemotherapeutic manipulation of disease, as well as the timing of any 
intervention. Improved pre-operative assessment of pathological response by 
imaging will become increasingly important in deciding which patients can be 
managed with a “watch and wait” policy.  
 
 
Figure 7 Kaplan-Meier survival curves of patients treated with systemic 
neoadjuvant chemotherapy stratified by pathological response grade. 
Pathological response is stratified as minor, moderate or complete depending 
on degree of residual tumour (Adapted from Blazer et al., 2008).!
!!!!
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1.10 Prognostic and predictive markers for colorectal liver metastases !
1.10.1  Clinicopathological staging as a predictor of outcome  
 
Figure 8" Kaplan–Meier survival curves from a population of 110 000 UK 
patients diagnosed with primary colorectal cancer between 1998 and 2003 
with 5-year follow up stratified by disease stage. Patients with non-resected 
stage IV disease had a dismal prognosis, compared to those with resected 
stage IV disease who had long-term survival comparable to those who 
present with stage III disease. (Adapted from Morris et al., 2010)."
The wide patterns of colorectal disease, coupled with varied tumour biology and 
evolving management, help explain the wide variations in survival between disease 
subgroups. However, these varying outcomes are not currently reflected in the 
existing staging system for metastatic colorectal cancer. A recent UK study 
reviewing 110,000 patients with CRC found a 5-year survival for stage III disease of 
approximately 45% whilst patients with stage IV disease who underwent curative 
liver resection had a 5-year survival of over 50% (Figure 8) (Morris et al., 2010). 
That is, patients with curatively resected stage IV disease had better overall survival 
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than patients with stage III disease. The current staging system has no way of 
reflecting this. 
 
1.10.2  Prognostic scoring systems as a predictor of outcome 
It is clear that the boundaries of what is technically resectable continue to evolve, 
and the number of patients who initially present with irresectable disease and are 
converted into resectable disease by chemotherapy continues to grow. What 
remains unclear is how to identify patients in whom resection, whilst technically and 
oncologically reasonable, is not appropriate. Improved understanding of tumour 
biology is leading to increased interest in novel biomarkers to predict disease 
progression and survival (Ohtani, 2007; Tejpar et al., 2010). In the future, detailed 
analysis of individual tumour behaviour may offer a better predictor of outcome and 
response to therapy than traditional clinicopathological factors. High-throughput 
genomic and proteomic technologies suggest this would be technically and 
economically viable. However, large-scale validation of potential markers is required 
before they can be adopted for clinical practice. 
Currently, a number of scoring systems are used that attempt to classify patients by 
clinical prognosis based on existing preoperatively identifiable factors.   The most 
popular of these were produced by Fong (Fong et al., 1999),  Nordlinger (Nordlinger 
et al., 1996) and Rees. (Rees et al., 2008) The Fong classification (Clinical Risk 
Score) demonstrated a poor prognosis associated with synchronous presentation, 
rectal primary, multiple diffuse metastases, metastases larger than 5cm, disease-
free interval of less than 1 year from the diagnosis of primary disease or a high 
serum CEA, and this score is the most widely used owing to its ease of use.  
Nordlinger’s classification ranges from 0-7 with 1 point being awarded for each of 
the following adverse risk factors 
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• Extension into serosa of primary tumour 
• Lymphatic spread of the primary tumour 
• Delay from primary tumour to resection <24 months 
• Number of liver metastasis in preoperative imaging 
• Largest size of liver metastasis in preoperative imaging ≥ 5.0 cm 
• Preoperatively estimated clearance of normal parenchyma resected with 
liver metastasis <1cm. 
• Age ≥60 
 
These two scoring systems have been compared (Table 4) (Zakaria et al., 2007; 
Merkel et al., 2009), with the Clinical Risk Score proving to be more appropriate for 
use in clinical practice and better at differentiating between groups. Both scoring 
systems exclude patients with extrahepatic disease, and fail to take into account 
many other known adverse risk factors meaning that their clinical utility may 
become increasingly limited (Taylor et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
67 
Nordlinger Prognostic Index Fong Clinical Risk Score 
Extension into serosa of primary tumour Nodal status of primary 
Lymphatic spread of the primary tumor Disease free interval from primary to metastases <12 months 
Delay from primary tumour to resection <24 months Number of tumours >1 
Number of liver metastasis in preoperative imaging CEA >200 ng/ml 
Largest size of liver metastasis in preoperative imaging ≥ 
5.0 cm Size of largest tumour >5cm 
Preoperatively estimated clearance of normal parenchyma 
resected with liver metastasis <1cm. 
 
Age ≥60 
 Table 4 Comparison of Nordlinger Prognostic Index and Fong Clinical Risk 
Score. 
Rees (Rees et al., 2008) proposed a scoring system that could be used in either the 
preoperative or postoperative setting. In this risk prediction model, points were 
allocated up to a maximum of 30 based on primary lymph node status, primary 
tumour differentiation, CEA, number and size of lesions and resection margin (Table 
5). Patients with a score of 0, 10, 20 and 30 on preoperative scoring had 5-year 
survival rates of 66%, 35%, 12% and 2% respectively (Figure 9).  This compared 
very well with the scores determined postoperatively.   However, the complexity of 
this scoring system has limited its uptake as a clinical tool. 
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Figure 9 Kaplan-Meier plot showing survival after primary liver resection for 
CRLM stratified by Basingstoke Prognostic Index  (Rees et al., 2008). 
 
Despite the differences between these 3 prognostic indices, there is significant 
agreement and overlap between the key independent predictors of poor long-term 
outcome. 
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Basingstoke Predictive Index 
Risk Factor Preoperative Postoperative 
Primary Tumour Lymph node Status 
  Negative 0 0 
Positive 2 2 
Primary Tumour differentiation 
  Well 0 0 
Moderate 3 2 
Poor 5 4 
CEA at hepatectomy 
  <6 ng/mL 0 0 
6-60 ng/mL 2 1 
>60 ng/mL 3 3 
Number of hepatic metastasis 
  1-3 0 n/a 
>3 4 n/a 
Largest Tumour diameter 
  <5cm 0 0 
5-10cm 2 2 
>10cm 8 7 
Hepatic resection Margin 
  Negative n/a 0 
Positive n/a 11 
Extrahepatic disease 
  No 0 0 
Yes 7 4 
Table 5 The Basingstoke Prognostic Index. This scoring system can be used 
in either the preoperative or postoperative setting. Points are allocated (up to 
30) based on clinicopathological factors, with a higher score associated with 
worse long-term outcome (Figure 9)."
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1.10.3  Biomarkers for colorectal cancer 
Despite improved treatments for colorectal cancer, many patients receive toxic 
chemotherapies from which they derive no benefit. This has led to a drive to 
develop novel biomarkers for cancer that allow both the clarification of disease 
prognosis and prediction of patient response to therapy. A biomarker is a measured 
characteristic which can be used as an indicator of a biological state or condition. 
Putative oncological biomarkers include mRNA, DNA, protein, circulating tumor cells 
(CTC) or tumor-derived nucleic acids that can be used to stratify patients for 
treatment benefit within clinical trials, prognosticate patient outcome, or predict 
and/or monitor response to therapy (Sikorski et al., 2010).  These biomarkers may 
be measured in easily obtainable body fluids such as blood, bile or urine, or through 
more invasive techniques requiring tumour tissue. A prognostic biomarker provides 
insight into a patients overall cancer outcome, regardless of any therapy. Detection 
of a prognostic marker may guide decision making when it comes to recommending 
a certain treatment e.g. adjuvant treatment after surgery, but does not predict 
treatment response. A biomarker with predictive value gives information on the 
effectiveness of a therapeutic intervention in a patient.  
1.10.3.1 Existing predictive and prognostic biomarkers 
Multiple meta-analyses have assessed the value of genetic and epigenetic factors 
as prognostic markers of outcome, as well as predictive markers to help guide drug 
selection. This is of particular value in selecting expensive and potentially toxic 
treatments for heterogeneous disease. A summary of current prognostic and 
predictive molecular biomarkers is outlined in table 6 and 7. Although offering great 
potential, very few markers are validated and used in clinical practice. However, this 
seems likely to change as targeted agents and clinical trials with biomarker 
validation as a key endpoint become more common. 
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Biomarker Mutation Frequency Prognosis Evidence Status 
Microsatellite instability 
(MSI) 15% Favourable Strong 
Testing 
available but 
not widely 
used 
Chromosomal instability 
(CIN) 70% Unfavourable Strong 
No readily 
available test 
18qLOH/SMAD4 loss 50% Unfavourable Moderate No readily available test 
BRAF V600E 10% Unfavourable Moderate 
Test 
available, but 
insufficient 
evidence to 
justify clinical 
use 
KRAS Codon 12/13 40% Unfavourable in advanced disease Limited 
Testing 
available, but 
prognostic 
value unclear 
PIK3CA 20% Possibly unfavourable Limited 
Testing not 
readily 
available 
Table 6 Prognostic biomarkers in colorectal cancer (Adapted from Pritchard et 
al., 2011). 
 !!!!!!!!!!!
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!
Biomarker Mutation 
Frequency 
Drug selection Evidence Status 
KRAS codon 12/13 40% Predicts 
resistance to 
anti-EGFR 
therapy 
Strong Validated, in 
clinical use 
BRAF V600E 10% Probably 
predicts 
resistance to 
anti-EGFR 
Moderate In clinical 
use, not fully 
validated 
PIK3CA mutations 20% May predict 
resistance to 
anti-EGFR 
Limited No readily 
available 
test, not in 
clinical use 
PTEN loss 30% May predict 
resistance to 
anti-EGFR 
Limited No readily 
available 
test, not in 
clinical use 
Microsatellite instability 
(MSI) 
15% May predict 
adverse 
outcome with 5-
FU and 
improved 
outcome with 
irinotecan 
Moderate No routine 
clinical use 
18qLOH/SMAD4 loss 50% May predict 
resistance to 5-
FU 
Moderate Not in routine 
clinical use 
Topo1 Low 50% May predict 
resistance to 
irinotecan 
Limited Not in routine 
clinical use 
Table 7 Predictive biomarkers in colorectal cancer (Adapted from Pritchard et 
al., 2011). 
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1.11 Locoregional management of colorectal liver metastases !
1.11.1 Hepatic arterial infusion 
The unique blood supply of the liver, with portal flow supplying healthy hepatic 
parenchyma and arterial flow supplying metastatic disease, has led to the concept 
of delivering liver-only chemotherapy in an effort to increase metastatic exposure to 
the agent whilst reducing systemic dose and off-target side-effects. Most cytotoxic 
drugs have a steep dose response curve and therefore a higher cytotoxic effect is 
obtained by high local concentrations (Widder et al., 1979). Initial interest focused 
on hepatic arterial infusion (HAI) as a replacement for systemic adjuvant 
chemotherapy. A catheter is inserted at laparotomy into the umbilical vein remnant, 
through which a portable pump delivers an infusion of chemotherapeutic agent. Kerr 
et al randomized 290 patients with liver limited irresectable metastatic colorectal 
cancer to receive fluorouracil and folinic acid either as continuous intravenous 
infusion or delivered by HAI. 37% of patients allocated to HAI did not commence 
treatment because of catheter related complications, with a further 29% stopping 
before completing 6 cycles of therapy because of subsequent catheter failure. For 
those completing 6 cycles, overall survival was comparable between intravenous 
and HAI infusion (14.7 vs. 14.8 months, p=0.79) (Kerr et al., 2003). These findings 
were supported by a high quality meta-analysis by Mocellin et al (Mocellin et al., 
2007)! which found no benefit of HAI compared to systemic chemotherapy. 
However, interest continues in its use as an adjunct to first line systemic therapy. 
A phase III randomised trial considering FUDR (an analogue of 5-FU) HAI as 
adjuvant treatment alongside systemic 5-FU after resection of CRLM showed a 
significant improvement in 2-year recurrence free survival of 90%, compared to 60% 
for those receiving systemic chemotherapy alone (Kemeny et al., 1999). At a 
median follow up of 10.3 years, 10 year survival rates were 41.1 percent and 27.2 
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percent respectively (Kemeny et al., 2005). A further phase Ib study assessed 
pharmacokinetics of irinotecan in heavily pretreated patients with liver metastases 
and demonstrated higher activation of the prodrug into its active metabolite after 
intra-arterial infusion compared to intravenous infusion (van Riel et al., 2002).! 
However, this did not translate into a clinical benefit  in follow-on phase II studies. 
These impressive results stimulated interest in whether the high response rates to 
HAI could be harnessed to bring more patients to resection, with a systematic 
review of neoadjuvant hepatic arterial infusion alongside systemic chemotherapy in 
irresectable CRLM reporting secondary resection rates between 6-47% in 
unselected series (Pwint et al., 2010). Kemeny et al (Kemeny et al., 2009) published 
data of an early phase Ib trial of 49 patients treated with systemic FOLFOX with 
FUDR HAI in irresectable liver-only disease. Again, HAI was used as an adjunct to 
systemic chemotherapy. They reported an 8% complete radiological response rate, 
an 84% partial response and a 47% conversion to resectability, which increased to 
57% in chemonaïve patients (Shitara et al., 2006; Gallagher et al., 2007). 
Although these results are promising, technical and toxic complications (Kulaylat et 
al., 2010) including chemical hepatitis, biliary sclerosis, arterial and venous 
thrombosis and catheter displacement have restricted its role to preliminary 
research work.  The Memorial Sloan Kettering group reported their experience of 
544 consecutive insertions of HAI pump, and found a 16% failure rate within 2 years 
of insertion (Allen et al., 2005). 
 
1.11.2  Trans-arterial chemoembolisation (TACE) 
Attempts to minimise the technical aspects of liver-only treatment has led to the 
development of novel drug delivery methods. Although primarily developed for use 
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in irresectable hepatocellular carcinoma (Llovet et al., 2003) interest is growing in 
TACE as a tool for the management of CRLM. 
Conventional TACE (cTACE) involves the injection of chemotherapeutic agent into 
blood vessels supplying tumour, followed by embolic material in an effort to occlude 
the feeding blood vessels. This approach offers advantages. The ischaemic effect 
of the embolisation will lead to tumour infarct resulting in cell death, although this 
alone is unlikely to destroy all the tumour as tumour phenotypes tend towards 
hypoxia-resistant systems (Huerta et al., 2009). Hypoxic damage will however 
increase vascular permeability, encouraging diffusion of chemotherapeutic agents 
from the vascular compartment into tumour (Wallace et al., 1990). Reduced 
perfusion after embolisation reduces chemotherapeutic washout, increasing local 
concentrations of the drug and increasing total tumour exposure.  
Kato et al (Kato et al., 1981) first described the use of cTACE in the management of 
metastatic colorectal disease in 1981. Since then, a variety of embolic devices 
loaded with different drugs have been trialed (Fujimoto et al., 1985; Sasaki et al., 
1990; Meakem et al., 1992; Maeda et al., 1993; Voigt et al., 2002; Salman et al., 
2002).!The heterogeneous nature of these studies as well as the extensive time-
period makes direct comparison difficult, but a critical review by Vogl et al reported 
morphological response (complete/partial response on RECIST) of CRLM to cTACE 
of 14 – 76 % (Vogl et al., 2007). 
Vogl et al also performed a large prospective study investigating the role of repeat 
cTACE for the palliative treatment of patients with CRLM (Vogl et al., 2009). 463 
patients with liver limited metastatic colorectal cancer failing second-line systemic 
chemotherapy were treated with 4-weekly cTACE. Embolisation was performed 
using lipidiol or starch microspheres, with a combination of mytomycin C, 
gemcitabine and irinotecan depending on previous chemotherapeutic regimen and 
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response. 14.7% of patients exhibited partial response, 48.2% had stable disease 
and 37.1% had progressive disease. 1- and 2-year survival after 
chemoembolisation was 62% and 28% respectively, with median survival from 
diagnosis of 38 months, compared to 7-8 months for palliative treatment. They 
concluded that cTACE offered an effective and minimally invasive therapy for the 
palliative management of CRLM. 
Tsuchiya et al (Tsuchiya et al., 2007) reported 27 cases of irresectable CRLM 
treated with cTACE using irinotecan and degradable starch microspheres. cTACE 
was performed 47 times, with 9 patients (33%) being downstaged to surgery. 
Response rate was 59%, with a 3-year survival of 20%.  
Ceelen et al (Ceelen et al., 1996) assessed 23 patients in a treat and resect 
experimental study, 14 of whom were treated preoperatively with cisplatin/iodized 
oil/gelfoam chemoembolisation. cTACE had no effect on operating time, transfusion 
requirements or post-operative complications. Although this was a small study, a 
significantly lower rate of recurrence was seen in those patients treated pre-
operatively with embolisation (8% vs. 67%), suggesting preoperative cTACE might 
improve survival post-resection. 
 
1.11.3  Drug eluting beads for TACE (DEB-TACE) 
Drug eluting beads (DEB, marketed as DC Bead in Europe) are compressible 
beads produced from polyvinyl alcohol (PVA) hydrogel that can be loaded with 
irinotecan, and offer a theoretical advantage over hepatic arterial infusion and 
conventional TACE because of simplified delivery (embolisation and chemotherapy 
are combined, with no need for a pump) and offers the potential to add locoregional 
irinotecan to systemic FOLFOX with the aim of achieving comparable response 
rates to that seen after FOLFOXIRI whilst minimising morbidity. DC Bead loaded 
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with irinotecan is CE Marked in Europe for the treatment of metastatic colorectal 
cancer. DC Bead does not yet have market approval in the US to be used in 
combination with irinotecan but is used in FDA approved investigational clinical 
trials, and has previously shown impressive results in both chemo-naïve and heavily 
pre-treated irresectable patients (Martin et al., 2010; Martin et al., 2012). 
DC beads are compressible embolic microspheres produced from polyvinyl alcohol 
(PVA) hydrogel and are available in 3 sizes (100-300 µm, 300-500 µm and 500-700 
µm). Bead size is selected by the administering radiologist based on the size of the 
targeted vessels. The variation in diameter within each size allows the bead to be 
carried to the point where the size of the microsphere determines the point of 
blockage, as opposed to the more proximal embolisation caused by particle 
aggregation when using other embolic materials.  
 
The beads are supplied in a glass vial. Loading is performed immediately prior to 
delivery by adding an irinotecan solution to the vial. The beads contain multiple 
negatively charged sulfonate groups which form ionic bonds with positively charged 
drugs, allowing for rapid loading (Lewis, 2009).  Liquid chromatographic analysis 
has shown that loaded beads are stable for up to seven days after loading. All of the 
drug can be recovered from the bead i.e. no irreversible chemical reaction occurs 
between the drug and the bead (Lewis et al., 2006). Bead loading with irinotecan is 
affected by the existence of two forms of the drug; the active lactone and inactive 
carboxylate form, with the ratio between the two dependent on local pH. The 
lactone form carries more of an overall positive charge, and so is preferentially 
bound to the bead. As the lactone form binds to the bead, more carboxylate form is 
converted to lactone to maintain the equilibrium. When the drug disassociates from 
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the bead within tissue, it is the active lactone form which is released (Tang et al., 
2008). 
Drug-bead interaction modeling has shown that the loading time is both bead-size 
and drug-dose dependent, ranging between 1 and 12 minutes, with a maximum 
irinotecan loading of 50-60 mg ml-1 for beads for all sizes (Tang et al., 2006). 
Loading beads with drug has no effect on handling or compressibility, making them 
appropriate for selective embolisation using narrow gauge radiological catheters 
(Lewis et al., 2006).!
 
1.11.3.1 Animal and preclinical assessment of DEBIRI-TACE in metastatic liver 
disease 
Tang et al performed preliminary animal modeling using porcine hepatic arterial 
embolisation in four groups of animals using 100-300 µm control beads, 100-300 
µm irinotecan loaded beads, 700-900 µm irinotecan loaded beads and intra-arterial 
injection of irinotecan alone. Irinotecan loaded beads were loaded at a 
concentration of 50 mg ml-1. Plasma samples were taken over 90 days, and 
histopathology was performed after animal sacrifice at 30 and 90 days. Maximum 
plasma levels of irinotecan were 70-75% lower for irinotecan bead embolisation 
compared with arterial administration, with both bland and irinotecan embolisation 
showing necrotizing vasculopathy in keeping with ischaemia. Interestingly, Cmax was 
1791+/-521 ng ml-1 for the 100-300 µm beads compared to 1479+/-703 ng ml-1 for 
the 700-900 µm beads, suggesting bead size does not affect drug release. (Tang et 
al., 2006). Preclinical animal modeling using a WAG/Rij rat model with implanted 
metastases from a CC531 colorectal cancer cell line directly compared bland 
embolisation, irinotecan loaded bead embolisation and doxorubicin embolisation. 
Dose delivery was calculated by body weight, and so embolisation was not 
performed to stasis. Bland embolisation demonstrated no reduction in tumour 
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burden, compared to irinotecan loaded DC beads which demonstrated a 42% 
reduction in tumour burden (Eyol et al., 2008). 
Preliminary human safety and pharmacokinetic data on irinotecan bead therapy was 
produced by Professor Thomas Vogl at the Universität Frankfurt am Main (See 
appendix 2). Ten heavily pretreated patients with irresectable CRLM were treated 
with intra-arterial administration of irinotecan loaded beads at a median dose of 85 
mg (range 36-143 mg). The mean peak plasma dose of irinotecan was 194 ng ml-1 
(SD 124), whilst the mean peak level of SN-38 was significantly lower at             
17.2 ng ml-1  (SD 11.3).  The mean Tmax of irinotecan was 2 hours, whilst the mean 
Tmax for SN-38 was 1 hours (Figure 10).  
 
Figure 10 Preclinical analysis of serum drug and metabolite concentrations 
after treatment with DEBIRI. Mean (± standard deviation) plasma 
concentrations of irinotecan and its metabolite SN-38 in patients treated with 
irinotecan-loaded DC bead microspheres at a nominal dose level of 400 mg 
irinotecan from preliminary pharmacokinetic study by Prof Thomas Vogl (See 
appendix 2). Concentrations of irinotecan and SN-38 are significantly lower 
than those seen after IV infusion at comparable doses (See section 1.12.4). 
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However, accuracy is limited by the lack of sampling between 1 and 2 hours. Inter-
individual variability in peak drug concentrations was greater than 50% for 
irinotecan (co-efficient of variation 63.8%) and SN-38 (co-efficient of variation 
67.8%). 
1.11.3.2 Clinical assessment of DEBIRI-TACE in irresectable CRLM 
A pilot study assessed the safety and feasibility of DEBIRI-TACE in patients with 
heavily pretreated unresectable CRLM (Eichler et al., 2012). Eleven patients with 
progressive disease after second-line systemic Oxaliplatin or irinotecan based 
chemotherapy received up to 4 cycles of DEBIRI-TACE at 3-weekly intervals 
(median total dose 293mg). Only minor adverse events were noted, with 63% of 
patients developing abdominal pain, nausea and vomiting. No irinotecan-related 
toxicities were observed. DEBIRI-TACE was technically feasible in all cases, with a 
64% disease response rate after 9 weeks. Median time to progression was 154 
days from first treatment. 
An Italian group published preliminary results from a small phase II safety and 
efficacy study on ten patients with irresectable CRLM treated with irinotecan loaded 
beads (Aliberti et al., 2006) with a demonstrable radiological response in 70% of 
treated lesions. All patients experienced right upper quadrant and shoulder tip pain 
requiring analgesia. Final results of this study published in 2007 (Fiorentini et al., 
2007) included 20 patients treated with DEBIRI-TACE.  All patients had failed 
previous treatment with FOLFOX+/-FOLFIRI. Six patients received one DEBIRI-
TACE, 8 patients received two DEBIRI-TACE and 6 received three DEBIRI-TACE at 
3-weekly intervals each at a nominal dose of 100mg. Fifteen patients were alive at 
the time of study reporting, with a median follow-up of 200 days. All patients 
experienced pyrexia, right upper quadrant pain and nausea after embolisation. 
None of the patients demonstrated systemic toxicity to irinotecan. 
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The same group progressed to a larger single arm phase II study assessing tumour 
response and survival in heavily pre-treated patients with CRLM (Aliberti et al., 
2011). Eighty-two patients who had failed first line systemic therapy were treated 
with 185 DEBIRI-TACE (median 2.2 per patient) at 3 weekly intervals. Post-
embolisation syndrome was frequently observed, characterized by right upper 
quadrant pain, fever, nausea and transient increase in transaminases and reported 
after the majority of embolisations. There was a 78% 3-month lesional response 
rate, with a median duration of response of 6 (range 3-10) months. Median survival 
was 25 (range 6-34) months with progression free survival at 8 (range 4-16) 
months, comparable with first line systemic therapies. 
These impressive results led the same group to develop a phase III randomized 
control study comparing DEBIRI-TACE versus systemic FOLFIRI as first-line 
treatment for liver limited metastatic colorectal cancer (Fiorentini et al., 2012). 
However, patients were eligible for inclusion if they had received systemic therapy 
more than 3 months prior to enrollment in the study and in fact many of these 
patients had been heavily pretreated. Patients were randomized to FOLFIRI or 
DEBIRI based on percentage liver involvement, lines of previous therapy, weight 
loss, KRAS status and p53 expression. The systemic therapy arm received FOLFIRI 
for 4 months of treatment whilst the DEBIRI arm received drug eluting beads loaded 
with irinotecan twice a month for the same time period. Overall response rate after 
DEBIRI-TACE was 69%, compared to 20% after FOLFIRI with two-year survival of 
56% for the DEBIRI-TACE group, compared to 32% for the FOLFIRI group 
(p=0.03). All patients had extrahepatic disease progression at 2-year follow-up 
highlighting the poor biology of this cohort of patients. Surprisingly, a significant 
delay (4 months) in time to extrahepatic progression was noted in the DEBIRI-TACE 
arm that appears counterintuitive following liver-only therapy. Subgroup analysis by 
KRAS status found that wild-type patients had a median survival of 26 months after 
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DEBIRI-TACE, compared to 19 months for KRAS mutants. Comparison of toxicity 
between the two arms demonstrated grade 3 neutropenia in 4% and 44% 
(p<0.0001), diarrhoea in 6% and 18% (p=0.07) and mucositis in 1% and 20% 
(p=0.00002) of the DEBIRI and FOLFIRI groups respectively. This trial suggested 
that DEBIRI-TACE offers improved response rate, overall survival and reduced 
toxicity when compared to systemic FOLFIRI.  
A multi-institute registry of patients with irresectable CRLM treated with irinotecan 
DEBIRI-TACE considered 55 patients who underwent 99 embolisations for 
irresectable colorectal liver metastases (Martin et al., 2010). The treatment 
approach in this registry involved whole lobe embolisation, rather than selective 
embolisation adopted in the previous studies. A lobar approach aims to destroy 
previously unidentified occult disease, as well as targeted lesions. All patients had 
received a minimum of FOLFOX/FOLFIRI as first line treatment, with the majority 
having failed all second line treatments felt appropriate by a medical oncologist 
(including Cetuximab and Bevacizumab). A median of 2 embolisations (range 1-5) 
were performed for each patient with a median dosage of 100mg per embolisation 
(range 50-200mg) and a median total hepatic exposure of 185mg (range 150-
650mg). Adverse event rate after embolisation was 28%, with the majority of events 
consisting of grade 2 nausea, vomiting and transient liver dysfunction. One patient 
with large tumour burden (>55% volume replacement) died of MODS after 
developing delayed hepatic dysfunction 28-days post-embolisation, although it was 
unclear whether this was due to disease progression or treatment with DEBIRI-
TACE. Three-month response rate was 65% (12% complete response, 53% partial 
response), which reduced to 50% at 6 months and 40% at 12 months suggesting 
durable disease response. Median overall survival from time of first treatment was 
19 months, with an overall progression free survival of 11 months and a hepatic 
progression free survival of 15 months. These impressive results contrast 
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favourably with the median survival time for patients who have failed systemic 
chemotherapy. Eleven patients (20%) had their disease sufficiently downstaged to 
allow further treatment (Bower et al., 2010), with 4 undergoing resection and 2 
undergoing radiofrequency ablation. Evidence of chemotherapy-associated 
pathological change was not seen in this group. Adverse events were reported in 
28%, with an incidence of side-effects greater in those patients who received more 
than 100mg of the drug, although there was no significant difference in complication 
rates. 
A US led prospective phase I study by the same group is currently recruiting 
chemo-naïve patients with liver dominant irresectable metastatic colorectal cancer. 
Patients are treated with FOLFOX +/- DEBIRI-TACE in the off-week of FOLFOX 
therapy. At a median of 12 cycles of FOLFOX/2 cycles DEBIRI, 4 of 10 patients 
recruited so far (40%) had been converted to resectability with no evidence of drug 
induced liver injury in background parenchyma (Martin et al., 2012).!
 
1.11.3.3 Pharmacokinetics of irinotecan after DEBIRI-TACE 
Several studies have looked at systemic exposure to irinotecan following DEBIRI-
TACE. Eichler et al (Eichler et al., 2012) reported a median maximum irinotecan 
concentration of 194 ng ml-1 (standard deviation 124) with a maximal concentration 
achieved 2 hours after treatment. Exposure to SN-38, the active metabolite of 
irinotecan, was much lower with a maximal concentration of 16.7 ng ml-1 (standard 
deviation 11.3) achieved after 1 hour. 
Martin et al (Martin et al., 2012) reported a peak exposure to irinotecan and SN-38 
after 1 hour, with a median dose (range) of 281 (207-484) and 16.4 (11.4-27.8) ng 
ml-1 irinotecan and SN-38 respectively after first treatment with 100 mg DEBIRI-
TACE. 
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1.12 Irinotecan 
Irinotecan (7-ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-
11, Camptostar) is a camptothecin analogue used in the management of a number 
of solid tumours (Figure 11). A naturally occurring alkaloid derived from 
Camptotheca acuminata, its anticancer effects were known before its mechanism of 
action was discovered (Wall et al., 1996). Irinotecan is a prodrug that is converted 
into the biologically active metabolite SN-38 by cleavage of a dipiperidino side chain  
(Kawato et al., 1991).!SN-38 is 300-200,000 times more cytotoxic than irinotecan 
(Jansen et al., 1997; van Ark-Otte et al., 1998)  but is poorly soluble and highly 
cytotoxic and so cannot be administered systemically. Only 2-5% of intravenously 
administered irinotecan is converted to SN-38 (Senter et al., 2001). Animal modeling 
has suggested that there is no difference in anti-tumour efficacy between i.v. 
administration of SN-38 or irinotecan (Kawato et al., 1991) suggesting that local 
activation of irinotecan plays a key role in its anti-tumour effects. Both irinotecan 
and SN-38 are prone to interconversion between lactone and carboxylate form. The 
closed lactone configuration is the pharmacologically active form (Hertzberg et al., 
1989) with lower pH shifting the equilibrium towards the lactone form. Irinotecan and 
SN-38 are both inactivated; irinotecan is predominantly detoxified by CYP3A4 to the 
inactive metabolite APC, whilst SN-38 is conjugated to glucuronic acid by UDP-
glucuronyl transferase UGT1A1. 
Wide interpatient variability in the pharmacokinetics and handling of irinotecan have 
been shown  (Mathijssen et al., 2004; de Jong et al., 2004).  However, attempts to 
correlate this with toxicity and drug efficacy have so far failed. Dosing strategies 
based on body-surface area alone have proved unsuccessful at reducing side-
effects (Mathijssen et al., 2002), although a novel dosing algorithm based on 
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CYP3A4 phenotype improved predictability of the pharmacokinetic profiles between 
patients (van der Bol et al., 2010).  
1.12.1 Topoisomerase 1 
The therapeutic target of SN-38 is Topoisomerase 1 (Topo1). When DNA is placed 
under torsional strain Topo1 binds to and cleaves one strand, allows the intact 
strand to pass through the DNA-Topo1 complex then rejoins the cleaved DNA 
strand without damage. SN-38 stabilises the Topo1 DNA complex preventing repair 
of the single stranded break (Hsiang et al., 1985) resulting in S-phase cell cycle 
arrest (Hsiang et al., 1989). When a single strand break interacts with a DNA 
replication fork, the break is converted into a double strand break and cell division 
stalls. If this break remains unrepaired, the cell is diverted onto a FAS mediated 
apoptotic pathway (Creemers et al., 1994; Smith et al., 2006; Hsiang et al., 1989; 
Cao et al., 2010). The effect of Topo1 on cell cycle arrest is therefore more marked 
in rapidly replicating tumour cells.  
Topo1 is highly expressed in around half of colorectal cancers (Boonsong et al., 
2002) and it has been suggested that this varying expression may correlate with 
clinical response to irinotecan with cell modeling demonstrating a clear correlation 
between cellular levels of Topo1 and sensitivity to irinotecan (Jansen et al., 1997). 
This hypothesis was assessed in a clinical setting by the UK MRC FOCUS trial, 
which found that immunohistochemical analysis of CRC identified subpopulations 
that did or did not benefit from irinotecan containing regimens (Braun et al., 2008). 
Patients with low Topo1 were found not to benefit from the addition of irinotecan or 
Oxaliplatin to 5-FU. However, attempts to confirm this finding in an independent 
cohort (The Dutch Colorectal Cancer Group CAIRO study) failed (Koopman et al., 
2009). A large retrospective review by the Hellenic Cooperative Oncology Group 
(HeCOG) (Kostopoulos et al., 2009) of 498 patients treated with adjuvant therapy 
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after resection of primary CRC demonstrated that high Topo 1 expression was 
associated with a reduced risk of death (HR=0.61, 95% CI 0.42-0.88, p=0.01) and 
those with high Topo1 treated with irinotecan containing regimens had a better OS 
(HR=0.47, 95% CI 0.23-0.94, p=0.03). Despite these conflicting results, the follow 
on UK MRC FOCUS 3 trial will attempt to randomize patients with metastatic 
colorectal cancer based on tumour Topo1 expression and KRAS status. Low Topo1 
tumours will be treated with 5-FU, whilst those with high Topo1 will receive 5-FU+/-
irinotecan+/-Oxaliplatin with appropriate biologic therapy based on tumour KRAS 
status. The results of this ambitious study will be extremely informative from both 
the clinical and personalized treatment perspective. 
 
1.12.2  Metabolism of irinotecan 
A variety of different intracellular proteins involved in activation, transport and 
metabolism of irinotecan allow it to exert its therapeutic effect (Figure 11). Variations 
in these proteins are thought to contribute to variations in pharmacokinetic profile, 
and there is now growing interest in these differences as potential predictors of 
response and toxicity (de Jong et al., 2006).!
!
!
!
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Figure 11 Schematic diagram showing intracellular metabolism of irinotecan. 
The key pathways and enzymes are highlighted (key pathway = red arrow, key 
enzyme = yellow bubble). The water soluble prodrug irinotecan diffuses into 
cells, where it can be converted to the inactive metabolite APC by CYP3A4 or 
activated into SN-38 by CES-1 and CES-2. SN-38 acts on Topoisomerase-1, 
inhibiting DNA repair leading to apoptotic cell death. SN-38 is deactivated by 
glucuronidation through a UGT1A1 mediated pathway. CES-
1=carboxylesterase 1, CES-2=carboxylesterase 2, CYP3A4=Cytochrome p450 
3A4, UGT1A1=UDP-glucuronosyltransferase 1A1, ABC=ATP-binding cassette.  
 
1.12.2.1 Carboxylesterase mediated hydrolysis 
Mammalian carboxylesterases (CES) are a phase 1 drug metabolism enzyme 
located in the endoplasmic reticulum and bound by a preserved 4 amino acid C-
terminal retention sequence  (Morton et al., 1999; Holmes et al., 2010). The most 
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abundant and well-studied carboxylesterase subtypes in cancer are 
carboxylesterase (CES) 1 and 2, both of which belong to the β-carboxylesterase 
family and are involved in the detoxification of xenobiotics and the activation of ester 
and amide prodrugs.  rPCR analysis of 24 primary tumours by Sanghani et al 
showed that CES-2 was the most abundant carboxylesterase within colorectal 
cancer (CES-2 ≈ 6 times > CES-1). Interestingly, expression of CES-2 varied  ≈ 23 
fold between tumour (Sanghani et al., 2003). Tang et al (Tang et al., 2008) found 
that levels of CES-2 were lower in more advanced colorectal cancers, suggesting 
that down regulation of this enzyme may be part of a more aggressive phenotype. 
Using enzyme purifications, CES-2 has been directly demonstrated as the key 
carboxylesterase involved in the activation of irinotecan in humans (Senter et al., 
2001) with a 12.5 time higher affinity and 60-100 time more efficient hydrolysis of 
irinotecan into SN-38 than CES-1 (Humerickhouse et al., 2000; Sanghani et al., 
2003). Despite the relative inefficiency of CES-1 compared to CES-2, it has been 
suggested that the relative abundance of CES-1 within human liver may mean it is 
responsible for 50% of hepatic conversion of irinotecan to SN-38 (Hatfield et al., 
2011). In vitro attempts to increase tumour levels of CES-2 by recombinant cDNA 
transfection have shown promise, suggesting that in the future manipulation of 
tumour phenotype may be possible in order to increase the efficacy of 
chemotherapy (Matzow et al., 2007). 
As well as being expressed in a variety of solid tumours, CES-2 is also expressed in 
normal tissues (Xu et al., 2002) including small bowel, lung, testes, kidney and liver 
parenchyma (Guichard et al., 1999). Absolute levels of CES-2 appear highest in 
hepatic parenchyma, with colorectal primary tumour having levels two to three fold 
lower (Guichard et al., 1999). Expression of CES-2 within hepatic parenchyma 
varies widely, with 15 fold interpatient variations reported in some series (Xu et al., 
2002).!Despite the recognition of a number of single nucleotide polymorphisms in 
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the CES-2 gene, attempts to correlate a single nucleotide polymorphisms with RNA 
expression and protein function have failed to identify a clear correlation (Marsh et 
al., 2004; Bellott et al., 2008). 
Surrogate markers of CES activity have been explored. Guemei et al (Guemei et al., 
2001) found no association between plasma esterase activity and SN-38 AUC, 
whilst Shingyoji et al (Shingyoji et al., 2004) found no association between plasma 
activation of irinotecan and SN-38 AUC. An Italian study measured serum 
concentrations of irinotecan, SN-38 and SN-38G in 45 patients treated with 
FOLFIRI. They measured CES-2 mRNA in peripheral blood monocytes as a 
measure of global CES-2 expression and attempted to correlate this with irinotecan 
activation, response and toxicity. They identified a high level of variation in 
expression levels of CES-2 (around 28 fold), which was weakly associated with the 
irinotecan activation ratio (SN-38AUC+SN-38GAUC/irinotecanAUC). However, when 
patients were grouped based on median CES-2 expression, those above the 
median had a statistically significant higher activation ratio than those below with a 
weaker non-significant association with SN-38AUC (Cecchin et al., 2005).!
 
1.12.2.2 CYP3A metabolism 
Multiple plasma, urine, bile and faecal metabolites of irinotecan have been identified 
(Santos et al., 2000) the most abundant of which is APC, formed by oxidation of the 
terminal piperidine ring (Smith et al., 2006). NPC, the second most abundant 
metabolite, is formed from cleavage of the distal piperidine ring and is formed at 
much lower levels than APC (Santos et al., 2000). Formation of these products is 
via cytochrome P450 3A subfamily members CYP3A4 and CYP3A5, with the 
overwhelming majority produced by CYP3A4 (Haaz et al., 1998; Santos et al., 
2000). Neither of these metabolites are pharmacologically active (Mathijssen et al., 
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2004).!Expression of CYP3A4 is lower in colorectal tumour than matched colonic 
tissue, suggesting that reduced deactivation of irinotecan into APC/NPC may 
explain the chemo-susceptibility of these tumours (Massaad et al., 1992).  
CYP3A is most abundantly expressed in human hepatic parenchyma, where it 
shows ≈ 30 fold variation in protein and mRNA expression (Watanabe et al., 2004). 
It has been suggested that genetic polymorphisms in CYP3A may affect function 
(Marsh et al., 2010). Many polymorphisms in CYP3A coding genes have been 
identified, but no correlation has been found between genotype and irinotecan 
metabolism in vitro (Mathijssen et al., 2003; Mathijssen et al., 2004) possibly 
because these polymorphisms do not change functional enzyme activity in vivo (Xie 
et al., 2004). However, conflicting data was produced by the recent North American 
Gastrointestinal Intergroup Trial N9741 which found a clear correlation between the 
presence of CYP3A5*3C SNP and radiological response to IFL (irinotecan and 
bolus 5-FU) (29% v 60%; p=0.007) (McLeod et al., 2010).  
Concomitant exposure to other drugs and endogenous compounds may alter 
CYP3A expression levels and therefore change the rate of irinotecan deactivation. 
For example, Rifampicin and St. John’s Wort activates the pregnane X-receptor 
(hPXR) increasing expression of CYP3A4 mRNA (Meijerman et al., 2006). Raynal et 
al (Raynal et al., 2010)!found that increased  hPXR expression in CRC cells limited 
chemosensitivity by increasing CYP mediated metabolism. This was validated 
clinically in a phase I trial which found that patients taking St. John’s Wort treated 
with irinotecan had a 42% lower circulating dose of SN-38 (Mathijssen et al., 2002).  
Phenotypic profiling to guide irinotecan dosing has shown some promise. A 
randomized control trial gave patients irinotecan dose calculated by CYP3A4 
activity (characterized by pre-treatment midazolam clearance) or routine dosing 
based on body surface area, and demonstrated a reduction in interpatient variation 
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in irinotecan pharmacokinetics and reduced drug-related toxicity in the 
phenotypically profiled group (van der Bol et al., 2010).  
 
1.12.2.3 UDP-glucuronosyltransferase 
UDP-glucuronosyltransferases (UGTs) represent a key group of enzymes involved 
in phase II metabolism of irinotecan, converting the active metabolite SN-38 into the 
inactive glucoronidated form SN-38G. Inhibition of UDP-glucuronolsyltransferase by 
valproic acid prevents 99% of SN-38G formation in rat models whilst UGT induction 
with phenobarbitol caused a 72% increase in the area under curve (AUC) (Gupta et 
al., 1997). 
Bound to endoplasmic reticulum, UGTs are of major importance in the conjugation 
and subsequent elimination of potentially toxic xenobiotics and endogenous 
compounds. The liver represents the major site of glucuronidation, although UGT’s 
are also expressed in a variety of other tissues throughout the gastrointestinal tract 
(Smith et al., 2006). Considerable variation in the conversion of SN-38 into SN-38G 
in liver homogenate has been shown in vitro, with a study of microsomes from 25 
normal human livers showing 52 fold variation (0.5-26 pmol mg-1 min-1) in activity 
(Iyer et al., 1998). 
Many UGT polymorphisms have been identified, but only a few clinically relevant 
isoforms have been defined (Guillemette, 2003). UGT1A1, the isoform involved in 
the conjugation of bilirubin, has been most extensively investigated. UGT1A1*28, 
which results from a TA dinucleotide insertion into the TATA element of the 
promoter region, is associated with reduced enzyme production and SN-38 
metabolism (Iyer et al., 2002). UGT1A1*28 has an allelic frequency of 39% in 
Europeans, with a homozygous incidence of 10% (Beutler et al., 1998). This is the 
same mutation implicated in Gilbert’s syndrome, characterized by an inability to 
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conjugate bile. A study of 95 colorectal cancer patients treated with irinotecan 
showed a trend towards worse survival in patients with UGT1A1*28 SNP compared 
to wild type (p=0.07), and found significantly higher levels of severe diarrhoea in 
patients homo- or heterozygous for this allele compared to wild type. 
Haematological impairment followed a similar trend, but did not reach significance 
(Marcuello et al., 2004). The North American Gastrointestinal Intergroup Trial N9741 
(McLeod et al., 2010) performed a retrospective analysis on 520 patients treated 
with systemic chemotherapy, and found a strong correlation between patients with 
homozygous mutant UGT1A1*28 treated with irinotecan/Oxaliplatin and grade 4 
neutropenia (55% vs. 15%, p=<0.002). A meta-analysis by Hoskins et al (Hoskins et 
al., 2007) found that the risk of haematological toxicity for patients with UGT1A1*28 
SNP was dose-dependent, and suggested toxicity was only relevant at doses above 
125mg/m2. However, the large UK MRC FOCUS trial using high dose irinotecan 
(350 mg/m2) showed no correlation between UGT1A1*28 genotype and toxicity 
(Richman et al., 2009; Seymour et al., 2007). It therefore seems that heterozygosity 
is less clinically relevant than homozygosity, and UGT1A1*28 genotyping is now 
recommended by the US FDA prior to commencing irinotecan-based therapies to 
identify homozygotes (Innocenti et al., 2004). Impaired glucuronidation leading to 
accumulation of SN-38 may also be expected to increase efficacy of irinotecan 
therapy. However, a high quality systematic review and meta-analysis assessed 
whether radiological response to irinotecan based therapy for colorectal cancer was 
related to UGT1A1 SNPs found no evidence to support this hypothesis (Dias et al., 
2012).  
1.12.2.4 Adenosine-triphosphate binding cassette (ABC) transporters 
ABC transporters are a large family of transmembrane proteins that use ATP to 
transport molecules across cell membranes (Gottesman et al., 2002) and are 
classified into 7 distinct families based on the topology of their transmembrane 
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domains (ABC-A to ABC-G) (de Jong et al., 2006). Irinotecan, SN-38 and SN-38G 
are actively excreted from cells by these transporters. The biliary recovery of 
irinotecan was lower in ABCB1 knockout mice, whereas the excretion of SN-38 and 
SN-38G was unaffected (Iyer et al., 2002). Transfection of KB-3-1 human 
epidermoid carcinoma cells with ABCC1 cDNA resulted in decreased accumulation 
and increased resistance to irinotecan, whilst treatment with an ABCC1 inhibitor 
increased accumulation and restored sensitivity (Chen et al., 1999). Rat modelling 
with ABCC2 deficient animals also showed reduced irinotecan and SN-38 biliary 
excretion (Chu et al., 1997; Chu et al., 1997).   
ABCG2 SNPs have been studied extensively, with conflicting results. A group of 
Caucasian patients carrying one defective ABCG2 421A allele were found to have 
higher serum drug levels (Morisaki et al., 2005) although this hypothesis was 
rejected by a further larger study (de Jong et al., 2004). In addition, it has been 
shown that ABCG2 mRNA content of colorectal liver metastases is higher in 
patients who have been treated with irinotecan suggesting a role for ABCG2 
upregulation in acquired chemo-resistance (Candeil et al., 2004).  
Irinotecan and its metabolites are also effluxed from cells by other active transport 
mechanisms including P-glycoprotein multi-drug resistance protein (MDR1), and 
multi-drug resistance protein-2 (MRP2) although only MDR1 expression appears to 
correlate with cytotoxicity (Jansen et al., 1998).!
 
1.12.2.5 β-glucuronidase biotransformation 
As well as tumour specific-activation of irinotecan through CES, SN-38G 
reactivation within the tumour microenvironment may be important (Dodds et al., 
2002). β-glucuronidase is found in the extracellular matrix surrounding tumour tissue 
due to lysosomal release from inflammatory cells and necrotic tumour (Bosslet et 
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al., 1998) and an in vitro analysis of irinotecan metabolism found that at equal 
concentrations of irinotecan and SN-38G, the rate of β-glucuronidase mediated SN-
38 production was higher than that formed directly from irinotecan. However, at 
pharmacologically relevant levels the rate of production of SN-38 was comparable 
between the two pathways (Tobin et al., 2006). 
Adenovirus mediated transfection of a colorectal cell line to express plasma cell 
membrane β-glucuronidase increased sensitivity to SN-38G by 80 fold, with animal 
modeling showing tumours transfected with β-glucuronidase had markedly 
increased sensitivity to irinotecan. Interestingly, transfection of only 15% of cells led 
to increased sensitivity suggesting that bystander activation of SN-38G to SN-38 
can lead to cell death (Huang et al., 2011).!
1.12.3 Transport of irinotecan in blood 
In blood, 80% of irinotecan is bound to erythrocytes whereas SN-38 is almost 
completely bound to albumin and lymphocytes (Mathijssen et al., 2001). In plasma, 
around 60% of irinotecan is bound to albumin for doses up to 4000 ng/ml, whilst 
over 94% of SN-38 is bound at doses up to 200 ng/ml. Free irinotecan is 
metabolized in blood to the active metabolite SN-38 by butyrylcholinesterases, 
although relative conversion is low (Morton et al., 1999). Intestinal epithelial cells 
and colon carcinoma cells take up the lactone forms of irinotecan and SN-38 by 
passive diffusion. The carboxylate form is absorbed by an active pH dependent 
transport mechanism (Kobayashi et al., 1999).!Intracellular conversion of irinotecan 
into SN-38 within a target cell may not be necessary to achieve a therapeutic effect. 
Transfection of an A549 colorectal cancer cell line with a recombinant replication-
deficient adenovirus vector coding for human carboxylesterase cDNA suppressed 
cell growth in the presence of irinotecan by 7–17-fold. Diffusion of SN-38 from 
 
 
95 
neighbouring cells meant only 10% of the A549 cells need to be infected for a 
cytotoxic effect in 48% of the cells (Kojima et al., 1998).!
1.12.4  Pharmacokinetics after intravascular administration of irinotecan 
Systemic exposure after IV administration has been thoroughly investigated. Rivory 
et al demonstrated a maximum systemic concentration of irinotecan of 2.8µM  after 
infusion with 115mg m-2 of irinotecan, with a median peak concentration of 0.08 µM 
for SN-38 and 1.0 µM for APC (Rivory et al., 1997).  
De Jonge et al (de Jonge et al., 2000) reported a Cmax for after treatment with 175 
mg m-2 IV irinotecan of 1.98 (+/-0.84) µM, with Cmax of 0.075 µM (+/-0.046) for SN-
38, 0.46 µM (+/-0.21) for SN-38-G and 0.47 µM (+/-0.13) for APC. Tmax for these 
metabolites was 1.67 hours (+/-0.17), 2.03 hours (+/-0.03) and 2.25 hours (+/-0.25) 
respectively. 
A direct pharmacokinetic comparison of intraarterial and intravenous irinotecan in 
the same patient demonstrated a peak irinotecan concentration of 8.8 mM and 10.9 
mM respectively, with peak SN-38 of 273 nM and 190 nM. (Mambrini et al., 2008) 
Intriguingly, the AUC of irinotecan, SN-38 and SN-38G were 5462.2, 87.5 and 904.7 
after IA administration, compared to 6799.2, 60.9 and 460.8 for IV infusion, 
suggesting that intra-arterial administration leads to increased drug activation. 
In all of these reports, systemic exposure is significantly higher than that seen after 
DEBIRI-TACE (See section 1.12.4). 
 
1.12.5  Enterohepatic reactivation of irinotecan 
Irinotecan, SN-38 and SN-38G are actively excreted into bile and accumulate within 
small bowel lumen (Lokiec et al., 1995). Although minor (Atsumi et al., 1995), an 
additional pathway involves direct transport of irinotecan and its metabolites from 
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bowel to lumen across the intestinal epithelial cells. When SN-38G is excreted into 
the intestine, bacterial species including Escherichia coli, Bacteroides species and 
Clostridium perfringens cleave the glucuronide group from the drug converting it 
back to SN-38 via the enzyme β-glucuronidase (Takakura et al., 2012). Irinotecan, 
SN-38 and SN-38G are believed to be reabsorbed to a certain extent by intestinal 
cells and to enter the entero-hepatic circulation. Accumulation of reactivated SN-38 
within the lumen of the bowel is believed to be responsible for irinotecan-associated 
diarrhea (Kobayashi et al., 1999).!
 
1.12.6  Metabolism of irinotecan in patients with hepatic disease 
It has been shown that CYP3A4 inhibition in vivo decreases APC formation and 
increases the systemic dose of SN-38 (Kehrer et al., 2000) with several clinical 
series reporting increased toxicity in patients with liver disease (Wasserman et al., 
1997; Raymond et al., 2002; Schaaf et al., 2006). Caution has therefore been 
advised in the use of irinotecan in patients with hepatic toxicity. 
d’Esposito et al (d'Esposito et al., 2010) assessed irinotecan biotransformation in 
patients with normal liver and chronic liver disease. They found that patients with 
diseased parenchyma had down-regulated CYP3A4 expression and impaired 
CYP3A4-dependent oxidation of irinotecan into its inactive metabolite APC. They 
found a similar pattern with carboxylesterase, with impaired CES expression and 
reduced activation of irinotecan into SN-38. They found that in some cases this 
change in expression was not equal resulting in altered SN-38: APC ratio, and 
suggested this may explain reported clinical findings of increased irinotecan toxicity 
in patients with underlying parenchymal liver disease. 
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1.13 Aim of thesis 
This thesis had two key aims: 
• To assess the safety and efficacy of neoadjuvant DEBIRI for patients with 
CRLM  
• To investigate inter-patient variations in treatment response to neoadjuvant 
DEBIRI 
1.14 Plan of study 
The plan of study aimed to: 
• Assess the safety and efficacy of neoadjuvant DEBIRI through a phase II 
clinical trial with the following key outcome measures 
o Pathological tumour response (using Blazer score) 
o DEBIRI-related morbidity 
o Surgical morbidity and mortality 
o Radiological response rate (RECIST) 
o Overall and disease free survival 
• Develop and validate a novel LC-MS/MS assay in order to measure 
irinotecan and its key metabolites in  
o Serum 
o Hepatic parenchyma 
• Use this assay to measure hepatic drug metabolism using tissue from trial 
patients, and correlate drug metabolism with pathological tumour response  
• Use this assay to measure drug concentrations in serum taken around the 
time of treatment with DEBIRI, and correlate levels with pathological tumour 
response 
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• Perform a global and targeted proteomic analysis of hepatic parenchyma 
taken from patients treated with DEBIRI and identify proteins associated with 
individual hepatic activation of irinotecan and pathological tumour response 
• To identify potential predictive biomarkers of response to DEBIRI by 
correlating proteomic data, metabolic profile and pathological tumour 
response  
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2 PARAGON II trial of neoadjuvant DEBIRI for 
colorectal liver metastases 
!  
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2.1 Introduction 
For patients with irresectable liver metastases, standard of care remains first 
line systemic chemotherapy with the aim of shrinking tumour and bringing 
patients to resection. Resectability rates after chemotherapy vary widely, with 
modern regimens converting up to 60% of patients to resection (Folprecht et 
al., 2005). Patients who exhibit good pathological response to chemotherapy 
have better overall survival (Rubbia-Brandt et al., 2007) with tumour 
replacement by fibrosis associated with good long term outcome (Poultsides et 
al., 2012). Response to chemotherapy is also known to correlate with resection 
rate (Folprecht et al., 2005) and so it is vital that patients are treated with the 
most effective chemotherapeutic regimen possible. 
The benefit of perioperative therapy for initially resectable disease is less clear. 
A large multicentre study (EORTC 40983) compared long term outcomes 
following 12 cycles of perioperative FOLFOX (6 before surgery, 6 after) against 
surgery alone for initially resectable disease (Nordlinger et al., 2008). Three 
year PFS was 36.2% in the perioperative chemotherapy arm compared with 
28.1% in the surgery alone group but this produced no improvement in long 
term overall survival (Nordlinger et al., 2012). Growing evidence suggests that 
preoperative chemotherapy is associated with agent-specific patterns of 
chemotherapy-associated liver injury (CALI) (Parikh et al., 2003; Fernandez et 
al., 2005; Rubbia-Brandt et al., 2004), with Vauthey et al (Vauthey et al., 2006) 
reporting a clear association between CALI and 90-day post-operative 
mortality. The decision to treat resectable disease with neoadjuvant therapy is 
therefore a delicate balance between risk and benefit, with little way of 
predicting which patients are likely to benefit most.  
The liver dominant pattern of metastatic colorectal cancer has led to the 
development of liver-directed therapy in an effort to increase metastatic 
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exposure whilst reducing off-target side-effects. Drug eluting beads are 
compressible polyvinyl alcohol (PVA) microspheres loaded with irinotecan 
(DEBIRI), and have shown impressive long-term outcomes in heavily pre-
treated irresectable patients (Martin et al., 2010). However, there is no 
evidence that it is safe to perform hepatic surgery on patients who have been 
treated with DEBIRI-TACE. The demonstration of safety in this setting is vital 
before further trials assessing the use of DEBIRI-TACE in a 
downsizing/conversion or true neoadjuvant protocol. The primary objective of 
this study was therefore to evaluate resectability after neoadjuvant DEBIRI-
TACE for liver metastases from colorectal cancer. 
 
2.2 Methods 
2.2.1 Study Design  
This was a pan-European multicentre open label, single arm phase II study. 
The trial had full ethical approval (South West Regional Ethics Committee 
reference 08/H0206/51, see appendix 3) and was registered at clinicaltrials.gov 
(NCT00844233).  
  
2.2.2 Patient identification 
Patients were identified as eligible for recruitment at a regional specialist 
hepatobiliary MDT. The trial had a recruitment target of 40 patients successfully 
treated with DEBIRI-TACE. 
 
2.2.3 Inclusion criteria 
Patients were aged between 18-80 years, with an ECOG status ≤2 i.e. 
symptomatic but ambulatory >50% of waking hours or better functional status. 
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All patients had undergone, or were deemed suitable for, an R0 primary 
colorectal resection and had liver-dominant metastatic disease with a maximum 
of 4 potentially resectable colorectal liver metastases (initially only unilobar 
distribution was included, but this was later expanded to include bilobar 
disease). Resectability was defined by the local hepatobiliary MDT after full 
staging with triple-phase CT chest/abdomen/pelvis, MRI with liver-specific 
contrast and PET-CT. Previous systemic chemotherapy within 1 month of 
recruitment was not allowed, nor was any previous exposure to irinotecan. 
 
2.2.4 Exclusion criteria 
Exclusion criteria included peripheral neuropathy, uncontrolled cardiac failure or 
angina pectoris, hypertension or arrhythmia.  Patients with abnormal WCC, 
platelets or renal function were excluded, as were those with a contraindication 
to irinotecan treatment and concomitant use of CYP3A4 inducers e.g. St John's 
Wort. Contraindications to transarterial chemoembolisation included allergy to 
contrast media, porto-systemic shunt, hepatofugal blood flow and severe 
peripheral atherosclerosis. 
 
2.2.5 Study endpoints !
2.2.5.1 Primary endpoint 
2.2.5.1.1 Tumour resectability after neoadjuvant DEBIRI-TACE 
The trial had a primary endpoint of R0 tumour resectability after DEBIRI-TACE. 
R0 resection was defined as a negative margin of ≥2mm on histopathological 
assessment for lesions treated with DEBIRI. 
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2.2.5.2 Secondary endpoints 
2.2.5.2.1 Safety of DEBIRI-TACE 
All observed toxicities and side effects after delivery of DEBIRI-TACE were 
graded according to NCI Common Terminology Criteria for Adverse Events 
(NCI CTCAE v 3.0) (Trotti et al., 2003).  
 
2.2.5.2.2 Radiological assessment of tumour response 
Triple-phase contrast enhanced CT was performed within 4 weeks of trial 
recruitment as a baseline assessment, then repeated 4 weeks after DEBIRI 
treatment immediately prior to resection. Two independent reviewers performed 
assessment of radiological response. Response of treated lesions were 
assessed using RECIST criteria v 1.1 (Eisenhauer et al., 2009). In brief, 
complete disappearance of all lesions was considered complete response, 
>30% reduction in sum of longest diameter of target lesion was classified as 
partial response, >20% increase in the sum of the longest diameter of target 
tumour was considered progressive disease. Stable disease was defined as 
fulfilling neither of the criteria for partial response nor progressive disease. The 
appearance of new lesions was considered as progressive disease. 
Response was also evaluated using novel morphological criteria validated by 
the MD Anderson group (Chun et al., 2009). Briefly, each lesion was assigned 
to one of three groups. Group 1 was characterized by homogenous low 
attenuation with a thin, sharply defined tumour-liver border. Group 3 lesions 
were characterized by heterogeneous attenuation and a thick poorly defined 
liver tumour interface. Group 2 included tumours that were neither group 1 nor 
group 3. Morphological response were defined as optimal if the lesion changed 
from group 3 or 2 to 1, incomplete if 3 to 2, and none if the lesion did not 
change appearance. Where more than one lesion was present, morphological 
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response was defined as that seen in the majority of lesions. The appearance 
of new disease between imaging was defined as progressive disease for all 
criteria. 
After resection, follow-up CT scans of chest, abdomen and pelvis were was 
performed at 3, 6, 9 and 12 months.  
 
2.2.5.2.3 Pathological assessment of tumour  
Immediately after resection, tumour was placed in formalin and processed 
according to normal hospital protocol. Timing of specimen cut-up after 
placement in formalin was not recorded or controlled, but was consistently less 
than 48 hours after delivery. Gross pathological examination of the specimen 
was then performed. Histopathological samples were prepared by embedding 
tissue in paraffin according to standard hospital procedures. Confirmation of 
adenocarcinoma was made using morphological assessment. The sampling of 
the tumour for histopathological evaluation was extensive, and included the 
periphery of the tumour including adjacent normal liver, the tumour and 
resection margin, and sampling of the tumour with a map of the tissue blocks. 
The location of each tissue sample was identified as either centre of tumour, 
mid part of tumour, periphery of tumour, tumour and adjacent liver parenchyma, 
or tumour and resection margin (see Figure 12). Untreated lesions detected 
incidentally at the time of resection were not included in pathological analysis 
as part of the trial protocol. 
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Figure 12 Tumour sampling strategy. Paraffin embedded blocks were 
produced from tissue taken from the centre of the tumour (1), mid-part of 
the tumour (2), periphery of the tumour (3), the border between tumour 
periphery and surrounding hepatic parenchyma (4) and the tumour and 
resection margin (5).  
 
Assessment of these tissue blocks was by microscopic examination. 
Background hepatic parenchyma was assessed and degree of steatosis and 
fibrosis quantified using a validated method!  (Kleiner et al., 2005). In brief, the 
score was defined as the unweighted sum of the scores for steatosis (0-3), 
lobular inflammation (0-3), and ballooning (0-2) with a total score ranging from 
0 to 8 (See table 8). Patients with a score ≥5 were considered to have 
steatohepatitis. 
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Pathology Criteria Score 
Steatosis <5% 0 
 5%-33% 1 
 >33-66% 2 
 >66% 3 
Lobular inflammation No foci 0 
 <2 foci per x 200 field 1 
 2-4 foci per x 200 field 2 
 >4 foci per x 200 field 3 
Ballooning None 0 
 Few balloon cells 1 
 Many cells/prominent 2 
 
Table 8 Summary of Kleiner score (Kleiner et al., 2005) for steatohepatitis 
in human hepatic parenchyma. Points are given for type and degree of 
pathological change, with a cumulative total from 0-8. A score ≥5 is 
considered pathognomic of steatohepatitis.  
 
Tumour was assessed and degree of differentiation, involvement of tumour 
border, and vascular invasion (defined as cancer cells identified within an 
epithelial lined channel) was commented on. Microscopic examination of 
resection margin was also performed.  
Assessment of degree of pathological response was made using a minimum of 
4 blocks stained with haematoxylin-eosin by a specialised gastrointestinal 
pathologist. This was performed using a validated method described by Blazer 
et al (Blazer et al., 2008), whereby a estimation of proportion of lesion 
consisting of viable tumour cells, proportion consisting of fibrotic tissue and 
proportion consisting of necrosis within the whole tumour assessed across all 4 
blocks was made.  Complete pathological response was defined as no viable 
tumour cells, major response as 1%-49% of viable tumour cells and minor 
response as >50% viable tumour cells. Patients with no response (100% viable 
tumour) were included in the minor response group. 
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2.2.5.2.4 KRAS/BRAF genotyping 
All KRAS and BRAF testing was performed by ManGen (Central Manchester 
University Hospitals), a commercial UKNEQAS compliant facility. 
Ten 10µm thick sections of FFPE primary colorectal cancer were collected and 
placed in a 1.5mL Eppendorf tube. The tissue sample was selected to 
maximise tumour cell content, with a minimum of 50% tumour tissue. DNA was 
extracted using a QIAamp DNA FFPE Tissue Kit and quantified by 
spectrophotometry using a NanoDrop ND-100 (Thermo Fisher Scientific). 
KRAS mutations (p.G12A, p.G12V, p.G12R, p.G12C, p.G12D, p.G12S and 
p.G13D) were analysed with TaqMan probes (Applied Biosystems) using a 
validated PCR method. Samples testing negative for KRAS mutation were 
further characterised for BRAF p.V600E mutations using a similar approach. 
 
2.2.5.2.5 Recurrence following resection 
Recurrence was defined as the identification of any new disease compared to 
the clinical and radiological assessment performed immediately prior to 
surgery. Time to recurrence was defined as the time from surgery to 
radiological confirmation of recurrent disease (See section 2.2.6.4). 
 
2.2.6 Study schedule !
2.2.6.1 Baseline assessment 
After obtaining written informed consent to trial participation, patients 
underwent baseline assessment within 4 weeks of proposed 
chemoembolisation date. A triple-phase CT chest/abdomen/pelvis was required 
prior to embolisation to provide a baseline for assessing radiological response. 
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Portal vein patency was formally assessed using this CT. Pre- and post-
operative CEA levels were not routinely recorded. 
 
2.2.6.2 Neoadjuvant chemoembolisation 
Chemoembolisation with DEBIRI was performed within 4 weeks of baseline 
screening visit and 4 weeks prior to the planned resection. Treatment consisted 
of a nominal dose of 2ml of DC Bead of 100 to 300 µM diameter containing 200 
mg of irinotecan (PARAGON Bead®). The beads were hydrated with water for 
injection, and mixed with a non-ionic contrast media in the vial immediately 
prior to use according to the manufacturers instructions. 
Using a unilateral femoral approach, selective catheterisation of the hepatic 
artery was performed.  Vascular access was obtained via the common femoral 
artery and a guidewire advanced under fluoroscopic guidance. A 5 Fr. sheath 
was then inserted over the guidewire. The superior mesenteric artery was 
selected and an angiogram performed to identify any aberrant arterial anatomy 
and verify portal patency. The coeliac axis was selected and an angiogram 
completed. The catheter and guidewire were used to select the proper hepatic 
artery and a limited angiogram performed to identify the branches of the hepatic 
artery. Depending on the location of the lesions to be treated, the right or left 
hepatic artery was selected distal to the cystic artery (if visualised). Initially very 
selective embolisation was performed with bead delivery direct to the 
subsegment containing the tumour. As experience grew, a more proximal 
catheter placement into the right or left hepatic artery was used. 
Once catheter placement was confirmed, the embolic mixture was injected 
slowly into the artery supplying the area where the lesion was located until the 
blood flow became sluggish i.e. embolisation did not proceed to full stasis.  If 
lesions were located in more than one segment, embolic mixture was injected 
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into the arteries feeding the individual segments where the tumours were 
located. If the embolisation endpoint was achieved before the delivery of 2ml 
irinotecan Bead, the injection was stopped and the volume of beads 
administered was recorded 
In prior studies of chemoembolisation with DC Bead, patients reported 
moderate to severe post procedural pain (Fiorentini et al., 2008).  An 
aggressive medication strategy was adopted to manage this; 1g paracetamol, 
50mg Diclofenac and a 10mg IV bolus of morphine was given at the time of 
embolisation, followed by regular paracetamol and on-demand opiate analgesia 
(PCA pump).  Intra-arterial injection of 2-4ml of lidocaine (1%) prior to injection 
of DC Bead has previously been shown to reduce peri-procedural pain and was 
therefore used during this study (Fiorentini et al., 2008).   
Blood samples were taken pre-TACE, then at 1 and 6-hours post-TACE for 
drug and metabolite analysis (See section 4.2.2). 
 
2.2.6.3 Surgery 
Approximately four weeks after embolisation, patients underwent repeat CT 
chest/abdomen/pelvis to assess radiological response to DEBIRI followed by 
surgical resection. All patients underwent resection during open surgery by an 
experienced hepatobiliary surgeon. Laparotomy was performed and 
extrahepatic abdominal disease excluded by full inspection. Intraoperative 
ultrasound (IOUS) was routinely performed to guide surgical planning. If the 
size of metastases reduced significantly after chemoembolisation, the extent of 
liver resection was not modified and therefore still performed as initially 
planned. However, when previously undetected deposits were discovered 
(either during surgery or during peri-surgical imaging), resection was adapted to 
ensure the removal of all identifiable disease. Low volume anaesthesia was 
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used aiming for a central venous pressure (CVP) of or below 5 mm Hg. Liver 
parenchyma was transected with the Cavitron ultrasonic surgical aspirator 
(CUSA, Valleylab). Use of intermittent vascular inflow occlusion was at the 
discretion of the operating surgeon. A curative resection of the metastases with 
a clearance of ≥1 cm of normal parenchyma was the surgical aim. However, 
metastases were considered resectable with a clearance less than 1 cm 
provided complete macroscopic resection of disease was possible.  
As soon as the specimen was delivered from the patient, samples of normal 
hepatic parenchyma and tumour were taken and immediately snap frozen for 
further analysis. Blood samples were also taken for drug and metabolite 
analysis immediately before the start of surgery (See section 4.2.2). 
Patients were managed post-operatively in a critical care or ward environment 
based on qualitative anaesthetic assessment at the end of surgery. Post-
operative morbidity was routinely recorded using the Clavien-Dindo 
classification (Dindo et al., 2004). 
 
2.2.6.4 Follow-up visits  
Follow-up visits took place 4-6 weeks after surgery to assess wound healing 
and recovery, as is routine after major resections. There was further outpatient 
review at 3, 6, 9 and 12 months post-resection, followed by routine 6-monthly 
review. These follow-up visits included clinical examination, liver function tests 
and a triple-phase CT chest/abdomen/pelvis to detect disease recurrence.  
 
2.2.6.5 Statistical analysis 
Patients were stratified according to pathological response rates. For patients 
with more than one lesion, the mean response score for all targeted lesions 
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was used for stratification. This was calculated by the sum of % viable tumour 
in all lesions, divided by the number of resected lesions. Quantitative and 
qualitative variables were expressed as medians (with range) and frequencies. 
Comparisons between groups were analysed with the chi-square test or Fisher 
exact test for proportions and the Mann-Whitney U test for continuous 
variables.  
Overall and disease free survival were calculated from the date of liver 
resection to the date of last follow-up, recurrence or death using the Kaplan-
Meier method. Comparisons were made using log-rank test. 
To identify factors associated with OS and DFS in the entire cohort, the 
following variables were assessed using univariate analysis; sex (male vs. 
female), age (>65, <65 – median age of patient cohort), presentation 
(synchronous (<6 months) vs. metachronous), interval between primary 
colorectal resection and liver resection (<25 months, >25 months), size of 
lesion (<25, >25mm longest diameter), margin (R0 vs. R1), pathological 
response to chemotherapy (major vs. minor, complete vs. minor), number of 
lesions (1, >1) and KRAS status (Mutant vs. wild-type).  All variables associated 
with P<0.05 in the univariate proportional hazards model were entered into a 
cox proportional hazards multivariate model using a forward step wise 
procedure. P <0.05 was considered significant. All statistical analyses were 
performed using IBM SPSS Statistics (v.20). 
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2.3 Results !
2.3.1 Patient demographics 
Forty-nine patients were recruited to the study. Forty underwent DEBIRI-TACE. 
Reasons for not proceeding to TACE included consent withdrawal 
(n=2), bilobar disease (n=2, beginning of protocol when bilobar disease was 
considered an exclusion criteria), tumour involving gallbladder wall (n=1), 
suspected hepatocellular carcinoma (n=1), arterial access difficulty (n=2) and 
contrast medium allergy (n=1). 
KRAS/BRAF status was determined in 28 local patients where tissue was 
accessible. The 8 patients with KRAS mutant tumours had KRAS G12A (n=2), 
G12D (n=1), G12V (n=2), G12C (n=2) and Q61H (n=1) mutations. Three further 
patients did not have enough tumour left after treatment for tissue typing. 
Patient demographics are detailed in table 9. 
 Patients 
Median age, years (range) 65 (39-78) 
Sex M:F 25:15 
Median ECOG (range) 0 (0) 
Synchronous:metachronous 11:29 
Median interval between primary surgery 
and diagnosis of metastases, months 
(range) 
25 (10-93) 
Median number of lesions per patient 
(range) 
1 (1-4) 
Median maximal diameter of lesion, mm 
(range) 
21 (4-150) 
KRAS wild type (n=28) 20 (71%) 
BRAF wild type (n=28) 28 (100%) 
 
Table 9 Demographic details of patients undergoing treatment with 
DEBIRI-TACE. 
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2.3.2 DEBIRI-TACE 
All 40 patients underwent uneventful DEBIRI-TACE. Sixty-six discrete lesions 
were targeted. Patients received a median dose of 103 mg irinotecan (range 
64-175 mg). No patients required sedation, and all patients were discharged 
home within 24 hours, apart from one who remained in hospital for an extra 24 
hours because of social reasons. 
One patient developed post-DEBIRI pancreatitis (CTCAE grade 2, treated with 
supportive care) and was readmitted after 48 hours (2.5% morbidity). After an 
uneventful 3-day inpatient stay he was discharged home, and underwent liver 
resection 95 days after TACE. No patients developed any systemic toxicity to 
irinotecan. 
 
2.3.3 Surgery 
All forty patients proceeded to surgery. Median interval from DEBIRI-TACE to 
surgery was 30 days (range 22-95). At laparotomy, 2 patients were found to 
have unresectable disseminated peritoneal disease (one with omental 
seedings, one with multiple nodules on small bowel mesentery) neither of which 
were identified on preoperative CT or PET imaging. Thirty-eight patients 
therefore underwent liver resection (95% resection rate). Twelve patients (32%) 
underwent anatomical resection (7 left hemihepatectomy, 4 left lateral 
sectionectomy, 1 right hemihepatectomy), with the remainder undergoing non-
anatomical metastectomy. Vascular exclusion time was less than 30 minutes in 
all cases. 
Four previously undetected intrahepatic lesions were found in three patients 
(See section 2.3.4.3). Sixty-eight lesions were therefore resected. Fifty were R0 
(≥2mm) resections (R0 resection rate 74%) according to trial protocol (see 
section (See section 2.2.5.1), with the remaining 18 undergoing R1 resection 
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(R1 resection rate 26%). If R0 margin was defined as ≥1mm, 84% of lesions 
were resected with R0 margin. 
Two patients died within 30 days of surgery (30-day mortality 5%), neither of 
which was TACE related. One patient died on the day of surgery from 
haemopneumomediastinum following insertion of a central line on the critical 
care unit. The second patient died 8 days after surgery, having developed 
aspiration pneumonia followed by multi-organ dysfunction syndrome (MODS). 
Eleven patients (27.5%) developed complications (Dindo-Clavien grade 1-4), 
with 2 (5%) developing grade 3 or 4 complications i.e. requiring intervention 
(one small bile leak requiring percutaneous drainage, one post-operative 
wound infection requiring clip removal).  
 
2.3.4 Pathological response 
One patient was found to have hepatocellular carcinoma on histopathology and 
so was excluded from further pathological and long-term analysis. The 4 
untreated lesions were outside the trial protocol, and so were not included for 
analysis. The remaining 63 treated lesions were assessed for pathological 
response. Median tumour diameter was 21mm (4-150 mm). Median viable 
tumour was 20% (range 0-100), necrosis 50% (range 0-100) and fibrosis 17% 
(range 0 -70). Tumour response was defined as complete in 11 lesions (17%), 
major in 37 lesions (59%), minor in 14 lesions (22%) and no response in 1 
lesion (2%) (Figure 14). !
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Figure 13 Representative photomicrographs of pathological tumour 
response after treatment with DEBIRI. * = tumour, < = tissue fibrosis,  ♯ = 
normal hepatic parenchyma. The black arrow shows distorted tissue 
architecture with parenchymal replacement with fibrosis at the site of a 
previous lesion. Response was classified by global assessment of at 
least 4 tumour blocks, with an estimation made of proportion of viable 
tumour remaining.  (A) Minor response >50% tumour remaining, (B) Major 
response 1-49% tumour remaining, (C) Complete response 0% tumour 
remaining. All images x 10 magnification. 
 
Figure 14 Column chart showing pathological response grade of 
colorectal liver metastases treated with DEBIRI. Complete response = 0% 
viable tumour, major response = 1-49% viable tumour, minor response = 
>50% viable tumour.  
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2.3.4.1 Steatosis and steatohepatitis after DEBIRI-TACE 
There was little evidence of steatosis or steatohepatitis in any patients treated with 
DEBIRI-TACE. Median Kleiner score was 0 (range 0-5), with 76.3% having a score 
of 0. Only one patient (2.6%) had a score (5) diagnostic for steatohepatitis (Figure 
15). There was no quantifiable difference between tissue immediately adjacent to 
treated tumour and tissue away from the treatment zone in any patients. 
 
 
 
Figure 15 Column chart showing Kleiner score for steatosis, 
steatohepatitis and fibrosis in background hepatic parenchyma from 
patients treated with DEBIRI. Median Kleiner score was 0, with 76.3% of 
patients having a score of 0 (no evidence of steatosis or steatohepatitis). 
Only one patient (2.6%) had a score ≥5, diagnostic of steatohepatitis. 
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2.3.4.2 Comparison of patient characteristics by pathological response rate 
Thirty-seven patients who underwent resection for CRLM were grouped by 
pathological response. Baseline characteristics are described in table 10. All 3 
groups were similar, with a marginally but statistically non-significant increased 
number of lesions in the complete response group (p=0.07). The major response 
group had a significantly larger median tumour size than the minor (p=0.04) and 
complete (p=0.03) response groups.  
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 Characteristics of patients treated with DEBIRI-TACE by Pathological 
Response 
 Minor 
(n=8) 
Major 
(n=24) 
Complete 
(n=5) 
Pɫ 
 
Pӿ 
 
Male sex (%) 72 86 50 0.63 0.2 
Median age 
(range), yrs 
70 (47-71) 63 (39-78) 54(40-69) 0.97 0.31 
Age >65yrs (%) 29 29 25 0.50 0.67 
Synchronous 
presentation (%) 
57 17 25 0.19 0.56 
Interval from 
primary to 
secondary 
resection (range), 
months 
19 (12-93) 25 (13-80) 25 (4-30) 0.15 0.73 
Median number of 
lesions (range) 
1 (1-4) 1 (1-4) 2 (1-4) 0.89 0.07 
Multiple CRLM (%) 29 38 75 0.39 0.71 
Median size of 
lesions (range), 
mm 
18 (12-35) 40 (12-150) 19 (10-25) 0.04 0.03 
R0 surgical margin 
(%) 
88 75 60 0.41 0.34 
WT KRAS (%) 71 79 100 0.34 0.44 
WT BRAF (%) 100 100 100 - - 
 
Table 10 Characteristics of patients who underwent hepatectomy for CRLM after 
neoadjuvant DEBIRI stratified by pathological tumour response. All 3 groups were 
similar, although median lesion size was significantly higher in the major response 
group compared to the minor and complete response group (ɫ=Minor vs. major, 
ӿ=Major vs. complete) 
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2.3.4.3 Comparison of treated and untreated lesions in the same patient 
Three patients had intrahepatic disease that was not identified preoperatively 
and so was not treated with DEBIRI-TACE. This allowed the comparison of 
treated and untreated lesions from the same patient, enabling assessment of 
pathological response directly attributable to DEBIRI-TACE. 
 
2.3.4.3.1 Patient 1 
Pre-treatment imaging identified a lesion in segment VIII. Angiography at the 
time of embolisation confirmed a hypovascular lesion in segment VIII, and 
irinotecan bead was administered via the segment VIII segmental artery. At 
laparotomy, IOUS demonstrated the previously identified and treated lesion in 
segment VIII as well as a second untreated lesion in segment IV. The treated 
lesion in segment VIII had a longest diameter 25mm, and showed no residual 
tumour and 100% replacement with necrotic tissue. By contrast, the untreated 
lesion in segment IV (longest diameter 25mm) demonstrated 30% residual 
tumour, 40% necrosis, and 30% fibrosis (Figure 16).  
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Figure 16 Photomicrograph (x20) of (A) targeted and (B) non-targeted 
CRLM from the same patient treated with DEBIRI. The treated lesion 
shows an absence of viable tumour (*), with complete replacement with 
necrotic tissue (♯) surrounded by normal hepatic parenchyma (=). The 
irinotecan beads (arrow) are clearly visible within the vasculature. By 
contrast, the untreated lesion shows islands of viable cells with minimal 
necrosis and fibrosis. Magnification x 10. 
 
2.3.4.3.2 Patient 2 
The patient was found to have a single lesion supplied by segment VI artery, 
which was treated by superselective (subsegmental) embolisation. At 
laparotomy IOUS demonstrated the previously identified and treated lesion in 
segment VI as well as a second previously unidentified lesion in the same 
segment, both of which were easily resected. The pre-operatively identified 
lesion in segment VI had a longest diameter of 15mm, with no evidence of 
viable tumour, 60% necrosis and 40% fibrosis. By contrast, the untreated lesion 
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in segment VI (longest diameter 14 mm) demonstrated 60% residual tumour, 
30% necrosis, and 10% fibrosis.  
 
2.3.4.3.3 Patient 3 
This patient was found to have a lesion on the border of segment II and IVa 
with longest diameter of 17mm. The patient underwent embolisation in a lobar 
fashion via the left hepatic artery until partial occlusion of the left subsegmental 
arteries was achieved. Pre-operative CT demonstrated a reduction in diameter 
of the target lesion to 10mm (a 41.2% reduction, RECIST partial response). 
However, on this imaging a second tumour in segment II (within the lobar 
treatment zone) could now clearly be identified. Radiological assessment 
suggested this lesion was 100% necrotic. Retrospective review of the initial 
staging imaging showed no evidence of this lesion prior to treatment with 
irinotecan bead.  During surgery, IOUS detected two further lesions. One, in 
segment III, had been treated by lobar infusion. The second intraoperatively 
detected lesion was in segment VII and had not been exposed to irinotecan 
bead. Post-operative examination of all 4 resected tumours showed varying 
degrees of response. All three lesions in the left hemiliver that had been treated 
with irinotecan bead (including the original target lesion in segment II/IVa, the 
second inadvertently treated lesion in segment II only identified after treatment 
with irinotecan bead but before resection, and the intraoperatively identified and 
inadvertently treated lesion in segment III) demonstrated absence of viable 
tumour and 100% replacement with fibrotic or necrotic tissue. By contrast, the 
lesion in segment VII that was not in the treatment zone for irinotecan bead 
demonstrated 45% residual tumour, 50% necrosis and 5% fibrosis. 
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2.3.5 Radiological response 
Radiological response immediately prior to resection was evaluable in 22 
patients with 37 discrete lesions (Table 11). In the 10 patients with multiple 
metastases, response criteria were the same for all lesions. Inter-observer 
agreement on radiological response was high, with 100% agreement on 
RECIST criteria. Inter-observer agreement was also high for morphological 
response, with agreement in 84% of cases (κ=0.82). All disagreement was 
solved by consensus review. !
 No. patients (%) (n=22) 
Age (median, range yrs.) 64 (40-78) 
Male 16 (73) 
Female 6 (27) 
Colonic primary 11 (50) 
Solitary liver metastasis 12 (55) 
Multiple liver metastases 10 (45) 
Median tumour size (longest diameter 
mm, range) 24 (4-150) 
Interval from DEBIRI to resection 
(median, range days) 32 (27-95) 
Interval from DEBIRI to preoperative 
imaging (median, range days) 33 (16-98) 
Table 11 Demographics of patients assessed for radiological response !
2.3.5.1 Radiological response and pathological tumour response 
!
There was no correlation between radiological response rates and pathological 
tumour response. Twenty of 22 patients had stable disease by RECIST criteria, 
with the remaining 2 demonstrating progressive disease. Interestingly, both 
patients with progressive disease had a major pathological response with <10% 
viable tumour on post-resection analysis. 
Eleven patients demonstrated incomplete morphological response, with 11 
showing no response (Figure 17). Morphological response showed no 
association with degree of residual tumour: lesions showing no morphological 
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response had a median of 10% viable tumour (IQR 0-40), compared to 23% for 
partial response (IQR 10-30) (p=0.79). There was no association between 
morphological response and amount of tumour necrosis, with non-responders 
having a median of 40% necrosis (IQR 0.33-0.75), compared to 55% for partial 
responders (IQR 0.38-0.73) (p=0.55). Non-responsive lesions had a median 
10% fibrosis (IQR 10-40), compared to 13% (IQR 10-33) for partial responders 
(P=0.91) (Figure 18). 
When pathological response was stratified as major, minor or complete, 10 of 
17 (59%) patients with complete/major pathological response had an 
incomplete morphological response. 
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!
Figure 17 CT scan of patient [A] before and [B] 34 days after single 
treatment with DEBIRI. The lesion shows >20% increase in diameter 
(progressive disease using RECIST). This lesion had 10% viable tumour 
on post-resection histopathological analysis. CT scan of patient [C] 
before and [D] 29 days after treatment. Enhancement of the lesion 
became less heterogeneous with a more clearly defined tumour-liver 
interface. This was defined as an incomplete morphological response. 
This lesion had 20% viable tumour on post-resection histopathological 
analysis. !!
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Figure 18 Box and whisker plot showing correlation between morphological 
response and pathological tumour assessment. Morphological response did 
not correlate with amount of viable tumour (A), degree of fibrosis (B) or 
necrosis (C). The dark line inside the box represents the median value, whilst 
the end points of the whiskers represent minimum and maximum values. 
Lower and upper edges of boxes represent 25th and 75th percentiles. P-value 
by Mann Whitney U test. 
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!
2.3.6 Long-term outcome !
2.3.6.1 Overall survival 
Survival analysis was performed on 35 of 38 patients who underwent 
hepatectomy for CRLM (2 early post-operative deaths were excluded from 
analysis, as was one patient found to have hepatocellular carcinoma on 
histopathology). At a median follow-up of 313 days (range 63-565) one patient 
had died of cancer progression with widespread hepatic and pulmonary 
metastases 565 days after resection. Nominal 1-year overall survival was 
100%. 
 
2.3.6.2 Disease free survival 
There were 15 recurrences detected with a median DFS of 379 days (95% CI 
276-498) (Figure 19). Nominal 1-year DFS was 56%. Nine patients had 
intrahepatic recurrence, four had hepatic and pulmonary recurrence whilst two 
had only pulmonary recurrence.  
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Days 0 100 200 300 400 
Number 
at risk 
35 31 18 13 6 
 
Figure 19 Kaplan-Meier curve showing disease free survival after hepatic 
resection following neoadjuvant DEBIRI-TACE. Median DFS was 379 days. 
The table shows number at risk for each 100-day time interval. 
 
2.3.7 Predictors of long term outcome 
The results of univariate and multivariate analyses of factors associated with 
DFS are summarized in table 12. 
On univariate analysis, synchronous presentation (p=0.03) and KRAS status 
(p=0.04) were associated with a poor DFS (Figure 20). On multivariate 
analysis, only KRAS status was independently associated with DFS (HR=0.12, 
CI 0.02-0.73, p=0.02). 
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 Univariate analysis Multivariate Analysis 
 N=35 
(%) 
Median 
DFS 
(days) 
Number 
progressed 
P HR 95% CI P 
Sex Male 21 324 7 0.37    
Female 14 388 8     
Age <65 13 411 5 0.79    
>65 22 388 10     
Presentation Synchronous 9 286 2 0.03   NS 
Metachronous 26 388 13     
Interval from 
primary to 
secondary 
<25 months 13 213 9 0.41    
>25 months 12 411 4     
Days between 
TACE and 
resection 
<30 days 19 411 9 0.44    
>30 days 16 324 6     
Size, mm <25 17 388 3 0.24    
>25 18 286 6     
Margin R0 26 - 2 0.33    
R1 9 388 13     
Pathological 
response 
Minor 6 145 3     
Major 25 324 12 0.51    
Complete 4 - 0 0.24    
Vascular 
invasion 
Positive 11 287 8     
Negative 24 336 7 0.11    
KRAS status Mutant 8 210 3 0.03 0.12 0.02-
0.73 
0.02 
Wild-type 20 388 5     
Number of 
lesions 
1 20 286 9 0.07    
>1 15 411 6     
RECIST 
response @ 4 
weeks 
SD 20 13.6 7 0.79    
PD 2 9.5 6     
Morphological 
response @ 4 
weeks 
None 11 12.9 5 0.24    
Incomplete 11 - 5     !
Table 12 Univariate and multivariate analysis of clinicopathological variables associated 
with DFS in 36 patients who underwent hepatectomy following neoadjuvant DEBIRI. 
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Days 0 100 200 300 400 
KRAS 
WT 
20 18 12 8 2 
KRAS 
mutant 
8 6 4 1 1 
 
Figure 20 Kaplan-Meier curve showing the negative prognostic effect of 
KRAS mutation on disease free survival after neoadjuvant treatment with 
DEBIRI-TACE (log-rank p=0.03). The table shows number at risk for each 
100-day time interval. !!!!! !
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!
2.4 Discussion 
This study clear demonstrates the safety and efficacy of single treatment 
neoadjuvant DEBIRI-TACE prior to liver resection for colorectal liver metastases.  
One of the theoretical advantages of DEBIRI-TACE is its targeted nature and ease 
of administration, which may transfer to reduced treatment costs. Ninety-eight 
percent of patients in the current study were discharged within 24 hours of 
embolisation. Although not fulfilling the definition of a true “day case” intervention, 
DEBIRI-TACE was performed quickly and easily with short inpatient stay and low 
complication rates (2.5% adverse event rate). Previously, a US-based registry of 
patients with heavily pretreated liver dominant colorectal cancer reported a 28% 
adverse event rate, with a bead specific complication rate of 1% (Martin et al., 
2010), perhaps reflecting the pretreated nature of the patient cohort as well as 
higher tumour burden. In both series the bead specific complication rate compares 
favourably with the toxicity (Kemeny et al., 2009) and technical complication rates 
(Allen et al., 2005) reported after liver directed therapy delivered by hepatic arterial 
infusion pumps. 
Surgical safety was not compromised by neoadjuvant treatment with DEBIRI-TACE. 
Hepatic resection was performed in thirty-eight of forty cases (resectability rate 
95%), with two patients having widespread intraperitoneal carcinomatosis 
discovered at laparotomy. This pattern of disease is difficult to detect on 
preoperative imaging, and the delay of 4 weeks between DEBIRI-TACE and surgery 
is unlikely to be sufficient interval for the development of micrometastases. 74% of 
lesions treated with DEBIRI-TACE were resected with an R0 margin, with 100% 
R0/R1 resection. The R0 resection rate is slightly higher than other reported series, 
and likely reflects the easily resectable nature of patients recruited to the study. 
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The trial protocol defined an R0 resection as a margin of at least 2mm, whilst the 
International Union Against Cancer (UICC) defines R0 and R1 resections as the 
absence (tumor-free margin >=1 mm for all detected lesions) or presence (tumor-
free margin 0 mm) of microscopic tumor invasion of the resection margins 
(Wittekind et al., 2002).! Adopting the UICC definition increased the R0 lesional 
resection rate to 84%. Beyond 1mm (i.e. microscopically negative margin) width of 
resection margin does not appear to impact on long-term survival (Pawlik et al., 
2005). This study confirmed these findings, with patients undergoing R0/R1 
resection margin having equivalent disease free survival.  
Post-operative surgical mortality (5%) was higher than other contemporary series 
(Nordlinger et al., 2008; Adam et al., 2008; Vauthey et al., 2006), which report 30-
day mortality for hepatectomy after neoadjuvant chemotherapy consistently less 
than 2%. However, it seems unlikely that either of the deaths seen in this study 
were directly related to the neoadjuvant administration of DEBIRI-TACE. One 
patient died from anaesthetic misadventure, whilst a second patient died from a 
recognised postoperative complication. Post-operative morbidity was in keeping 
with other published series (Dunne et al., 2014).  
The pathological response rates demonstrated in the treated lesions are impressive, 
with 76% of lesions showing a major or complete pathological response. The 
intraoperative identification of untreated lesions in a treated patient gives an 
interesting control group. In patient 1, two distinct lesions were resected; one from 
within the treated segment, and one from an untreated segment. The difference in 
viable tumour (30% vs. 0%) was stark, and suggests that the lack of viable tumour 
seen within post-treatment specimen is directly attributable to DEBIRI-TACE. An 
indirect effect on the untreated segment cannot be completely ruled out, as the 
patient received 100mg of irinotecan with the beads. However, pharmacokinetic 
modelling has suggested systemic exposure after irinotecan eluting beads is low 
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and so this seems unlikely. A similar pattern was observed in patient 2, with 
targeted delivery leading to complete tumour destruction whilst the non-targeted 
lesion had a large proportion of viable tumour (0% vs. 60%). In both patients 1 and 
2, the treated and untreated lesions were of comparable size.  
In patient 3, the radiological appearance of a lesion after embolisation suggests an 
inherent change to the structure of that lesion. Post-resection analysis 
demonstrated that this lesion had 75% necrosis and 25% fibrosis. It therefore 
seems likely that the initial effect of irinotecan bead in this lesion was mediated 
predominantly by occlusion of the blood supply to the tumour rather than the effect 
of the irinotecan, as chemotherapy-associated change seems to be represented by 
fibrotic involution rather than necrosis! (Poultsides et al., 2012). Interestingly, all the 
lesions within the treated lobe showed 0% viable tumour. By contrast, the untreated 
lesion in segment VII demonstrated a large amount of viable tumour (45%) and a 
very low amount of fibrosis (5%), as would be expected in a chemo-naïve lesion. 
The large amount of viable tumour observed in lesions supplied by arterial flow 
proximal to the point of bead release and the absence of tumour in previously 
unidentified lesions targeted by lobar embolisation support the oncologic rationale 
for very proximal “whole lobe” embolisation.  
Another putative advantage of DEBIRI-TACE is the reduction in off-target effect with 
reduced systemic toxicity and CALI. Previous data have suggested that exposure to 
systemic irinotecan is associated with CALI irrespective of BMI (Robinson et al., 
2012), with the MD Anderson group identifying steatohepatitis (defined as Kleiner 
score >4) in 20.2% of patients treated with a median of 16 weeks of FOLFIRI 
(Vauthey et al., 2006). By contrast, only one patient in this series (2.6%) had 
evidence of steatohepatitis. As steatohepatitis is independently associated with 
postoperative mortality (Vauthey et al., 2006), the low reported rates after a single 
treatment with DEBIRI-TACE are encouraging. A potential role for DEBIRI-TACE is 
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in combination with systemic FOLFOX for liver-dominant disease in an effort to 
achieve the impressive response rates reported after the administration of 
FOLFOXIRI  (Falcone et al., 2007). If this is delivered with the intent of bringing 
irresectable disease to resection, CALI is a significant concern. The low incidence of 
steatohepatitis after single DEBIRI-TACE suggests this combination may not result 
in an increase in parenchymal liver damage. However, further work would be 
required to assess the combined effect of this regimen. 
Despite relatively short follow up after resection, median DFS was 379 days with a 
nominal 1-year DFS of 56%. Analysis of factors associated with worse DFS found 
synchronous presentation and KRAS status to be predictive on univariate analysis, 
although only KRAS status was significant on multivariate modelling. Interval 
between primary tumour and identification of metastases has previously been 
associated with a negative prognosis and incorporated into risk modelling systems 
by Fong and Nordlinger (See section 1.10.2).  
Importantly, radiological response assessed by both RECIST and morphological 
response criteria was not associated with disease free survival or with degree of 
tumour destruction. RECIST remains the current gold standard for assessing the 
response of solid tumors to anticancer drugs. However, there is growing evidence 
that RECIST criteria may not optimally reflect tumour response to therapy (Choi et 
al., 2007), (Chun et al., 2009). Radiological assessment of complete response is 
also poor, with 80% of lesions demonstrating complete response containing viable 
tumour (Benoist et al., 2006). Further work to improve radiological assessment of 
response to DEBIRI is therefore vital. As well as improving morphological and 
contrast-based criteria, functional imaging (such as PET) may offer better 
assessment of viable remnant tumour. 
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The findings of this study need to be viewed with some caution in light of a number 
of potential confounding factors. The beads used for embolisation varied in size 
from 100 – 300 µM, with the manufacturer reporting a normal distribution of bead 
sizes within this range (Taylor et al., 2007).  An identical bead slurry should 
therefore be delivered to every patient. However, differences in the diameter of 
feeding vessels may result in variations in embolisation distance from the tumour. 
This in turn may effect the degree of embolic effect, with more distant embolisation 
less likely to result in total tumour ischaemia. Although there is no in vivo data on 
drug concentration within tumour after embolisation, it seems plausible that more 
proximal embolisation would also lead to reduced drug concentration within a larger 
volume of tumour-containing tissue. 
Treatment consisted of a nominal dose of 2ml of bead containing 200 mg of 
irinotecan. However, actually volume delivered and therefore dose of drug 
administered varied as the radiological endpoint for delivery was near stasis of 
contrast. For patients with multiple metastases, this volume of bead slurry may not 
have been adequate to reach the endpoint for all lesions. This data was not 
captured by the trial data collection. Embolisation technique also evolved during the 
study period, from super-selective distal embolisation to lobar administration. 
Although the maximal volume of drug and radiological endpoint remained the same, 
it seems likely that the radiological endpoint would be achieved with a lower volume 
of bead slurry for selective delivery. This change may have led to significant 
differences in ischaemic effect and local drug concentration between patients. 
This single arm study was designed to assess safety of an existing medical product. 
Although the evidence supporting DEBIRI in the palliative setting is convincing, it 
remains unclear whether its effectiveness is due to vascular embolisation or the 
local delivery of chemotherapy. Evidence suggests that fibrotic involution results 
from chemotherapeutic effect, and necrosis from tissue ischaemia. The significant 
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degree of tumour necrosis seen within treated lesions suggest that the embolic 
effect is a significant factor. Direct comparison of bland vs. chemoembolisation with 
DC bead for CRLM is limited to preclinical animal modeling (Eyol et al., 2008), and 
tantalising evidence from hepatocellular carcinoma suggests that bland 
embolisation may be equally effective (Brown et al., 2013). However, these results 
must be interpreted with caution as hepatocellular carcinoma is a hypervascular 
disease compared to CRLM. A further randomised study comparing bland DC bead 
embolisation vs. DEBIRI chemoembolisation would provide a definitive answer to 
this question. 
Although tissue for analysis was sampled using the same protocol for each patient, 
inherent differences in the surgery patients received may have significantly altered 
the time from starting the procedure and tissue preservation in liquid nitrogen. A 
complex resection, involving a significant amount of intraoperative vascular 
exclusion, would result in the harvested tissue having a prolonged ischaemic time 
with a possible impact on tumour necrosis. By contrast, a straightforward 
metastectomy without vascular exclusion would result in much less tissue 
ischaemia. Operative data captured in the trial protocol did not record precise 
duration of vascular exclusion, and retrospective review of operative notes routinely 
reported vascular exclusion time as “less than n minutes”. Assessing the impact of 
intraoperative devascularisation on tumour response is therefore impossible. One 
potential approach for future studies would be to perform intraoperative biopsy of 
tissue and tumour prior to resection i.e. before any devascularisation has taken 
place. There are concerns about tumour seeding after biopsy, but this could be 
addressed by ensuring that the biopsy track was excised as part of the eventual 
resection. 
In conclusion, this trial has demonstrated the safety and efficacy of neoadjuvant 
DEBIRI-TACE is patients with easily resectable colorectal liver metastases. This 
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treatment can be delivered prior to surgery, with minimal morbidity. The impressive 
pathological response rates after a single treatment with DEBIRI-TACE are 
comparable with that seen after multiple cycles of systemic chemotherapy, with no 
evidence of damage to background hepatic parenchyma. Although follow-up data 
for this trial is immature and limited by relatively small numbers, KRAS status 
appears to be prognostic for disease free survival after treatment with DEBIRI-
TACE. 
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3 Development of LC-MS/MS bioassay for the 
measurement of irinotecan and its key metabolites 
!  
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3.1 Introduction 
Although DEBIRI-TACE has been investigated in preclinical and early clinical 
studies, the pharmacokinetics and hepatic metabolism of locally delivered irinotecan 
have not been well characterized. Various methods have been developed for the 
measurement of irinotecan and its major metabolites in a wide variety of biological 
matrices (plasma, urine, bile and faeces) from both animal models and humans. 
Most rely on sample separation by high performance liquid chromatography 
(HPLC), followed by ultraviolet or fluorescence detection of drug and metabolites 
(Humerickhouse et al., 2000; de Bruijn et al., 1997; Rivory et al., 1998). There is 
now growing interest in the coupling of mass spectrometers (MS) to HPLC systems. 
This technique offers several advantages, including high specificity and unequivocal 
quantification. To date, HPLC-MS based methods have relied on solid phase 
extraction techniques to remove sample protein prior to MS analysis (D'Esposito et 
al., 2008). However, this is both time-consuming and expensive. Although several 
methods for the LC-MS analysis of irinotecan and one or two metabolites have been 
reported, only two published LC-MS methods allow for the measurement of 
irinotecan and its three main metabolites (SN-38, APC and SN-38G) 
simultaneously. Neither of these methods has been fully validated in human 
samples (Corona et al., 2010; Chen et al., 2012). 
The aim of this study was therefore to develop and validate a novel, specific, rapid 
and simple LC-MS based assay for the accurate quantification of irinotecan, SN-38, 
APC and SN-38G in human biological matrices, which avoids the need for solid 
phase extraction. This validated assay was used to optimise microsomal incubation 
conditions, allowing further quantitative exploration of the hepatic metabolism of 
irinotecan. 
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3.2 Materials !
3.2.1 Hardware & reagents !
Applied Biosystems, Carlsbad, CA, USA!
TFA!
Fisher Scientific, Waltham, MA, USA!
Cryodorf vials, H2O, ACN!
Sigma Aldrich, St. Louis, MO, USA!
Irinotecan, Camptothecin, DMSO, Formic acid, NADPH, UDPGA, MgCl2, Sodium 
Acetate, β-glucuronidase, Chromacol autosampler glass vials, KH2PO4, Na2H3PO4!
Tocris Bioscience, Minneapolis, MN, USA!
SN-38!
Santa Cruz Biotechnology, Dallas, TX, USA!
APC!
Millipore, Billerica, MA, USA!
Multiscreen Solvinert 96 well filter plate!
Wheaton Glassware, Millville, NJ, USA!
LSL tube!
!
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3.2.2 Buffers 
Phosphate Buffer 
1.78 g KH2PO4 and 9.55 g Na2H3PO4 dissolved in 1 litre of ddH2O, pH titrated to 7 
with hydrochloric acid 
 
3.3 Methods !!
3.3.1 Biosamples !
3.3.1.1 Serum sampling 
Blood samples for assay validation were taken from a group of 10 control 
volunteers. Samples were placed on ice immediately after collection, then 
centrifuged at 640 g for 10 minutes at 4°C. Mixing 10 control sera in equal volume 
created a pooled reference sample. Serum was placed in a cryodorf vial and snap 
frozen in liquid nitrogen before storage at -80oC. Samples were thawed at room 
temperature when required. 
 
3.3.1.2 Hepatic parenchymal sampling 
Human microsomal samples for assay validation were generated from a chemo-
naïve control population of 10 patients undergoing liver resection for hepatic 
malignancy. Patients received a reverse L laparotomy. To reduce intraoperative 
blood loss, low venous pressure anaesthesia was used with CVP consistently 
maintained below 5 cm H2O. Parenchymal transection was performed using a 
Cavitron Ultrasonic Surgical Aspirator (CUSA)(Valleylab, Boulder, CO, USA). 
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Immediately after the specimen had been delivered from the patient, samples of 
normal hepatic parenchyma were placed in a Cryodorf vial then snap frozen in liquid 
nitrogen and stored at -80oC. Samples were thawed at room temperature when 
required. 
3.3.2 LC-MS/MS assay development 
"
3.3.2.1 Chemicals and reagents 
As purity of the reference standard can affect data quality, an authenticated and 
high purity reference sample of each analyte was purchased (Table 13). 
Analyte Source Externally validated purity Molecular mass 
Irinotecan Sigma Aldrich >97% 623.1 
SN-38 Tocris Bioscience >98% 392.4 
APC Santa Cruz Biotechnology >99% 618.7 
Camptothecin Sigma Aldrich >95% 348.4 
 
Table 13; Source, purity and molecular mass of reference analytes used for 
assay development. 
 
SN-38G could not be purchased as a standard, and so an alternative approach to 
quantification was developed (See section 3.3.4.5). Camptothecin was chosen as 
internal standard because of structural similarity to the analytes of interest. Formic 
acid (98%) and DMSO were from Sigma Aldrich. LC-MS grade H20 and acetonitrile 
were from Fisher Scientific. Peptide synthesis grade trifluroacetic acid (TFA) was 
from Applied Biosystems.!
3.3.2.2 Preparation of human liver microsomal fractions 
Approximately 1 gram of human hepatic parenchyma was placed in a fluted glass 
tube stored on ice, and 9 ml of iced phosphate buffer added. The parenchyma was 
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homogenised using a Kinematic Polytron homogeniser at 3 000 rpm for three 10 
second pulses. The homogenate was removed and centrifuged at 14 301 g for 25 
minutes at 4oC in a Beckman L-60 Ultracentrifuge. Following centrifugation, the 
supernatant was transferred to a fresh tube, diluted to 10ml final volume using 
phosphate buffer and centrifuged for a further 65 minutes at 125 812 g at 4oC. After 
centrifugation, the supernatant was discarded and the pellet resuspended in a final 
volume of 10ml of phosphate buffer. A final centrifugation of 65 minutes at 125 812 
g was carried out at 4oC and the pellet was transferred into a 2 ml Eppendorf tube 
and resuspended in 500 µl of phosphate buffer without KCl. Protein concentration 
was calculated using the method of Lowry (Lowry et al., 1951),! and microsomal 
extract from each of the 10 patients combined in equal proportion to give a final 
concentration of 50 mg ml-1. 
 
3.3.2.3 Sample preparation 
Biological samples (microsomal samples, serum samples) underwent protein 
precipitation by addition of an equal volume of ice cold 50% acetonitrile:50% 
methanol (v/v) with 0.005% TFA, containing 40 nM camptothecin as internal 
standard. The addition of TFA gave a final sample pH of 3, shifting SN-38 into the 
active lactone form. Samples were vortex mixed for 15 seconds, then centrifuged at 
20 130 g at 3oC for 20 minutes. 300µl of supernatant was filtered through a pre-
wetted Millipore Multiscreen Solvinert 96-well filter plate. Samples were collected in 
a clean 96 well plate, after which 100µl was transferred to a sealed 200µl 
Chromacol glass autosampler vial. 20 µl was injected onto the column.  
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3.3.2.4 Preparation of standard calibration curves 
Master stock solutions containing 1 mM of irinotecan, camptothecin and SN-38 
were generated. Irinotecan, APC and camptothecin were readily soluble in water 
with ultrasonification. SN-38 was initially dissolved in dimethylsulfoxide (DMSO) 
then diluted in water to produce a stock solution with a final concentration of DMSO 
< 0.03%. Serial dilutions were prepared from these stock solutions to generate 
calibration and quality control samples. Stock solutions were stored in aliquots at -
80oC, and only defrosted when required. 
Calibration standards were produced using a blank sample (only matrix), a zero 
sample (matrix containing only protein and internal standard) followed by 10 
samples dissolved in appropriate biological matrix containing a range of final 
concentrations (5 nM, 10 nM, 25 nM, 50 nM, 75 nM, 100 nM, 150 nM, 200 nM, 
300nM, 500 nM). Amount of analyte on column for each concentration is given in 
table 14. 
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Sample concentration Amount of analyte on column 
0 nM 0 nmol 
5 nM 50 fmol 
10 nM 100 fmol 
25 nM 250 fmol 
50 nM 500 fmol 
75 nM 750 fmol 
100 nM 1 pmol 
150 nM 1.5 pmol 
200 nM 2 pmol 
300 nM 3 pmol 
500 nM 5 pmol 
 
Table 14; Amount of analyte on column for each concentration of biosample 
 
3.3.2.5 HPLC conditions 
Chromatographic sample separation was performed on a Dionex HPLC stack, using 
an Ultimate 3000 pump, Ultimate 3000 autosampler and Ultimate 3000 column 
compartment.  An Alltima c18 (150 x 2.1mm, 5µm) column, protected by an Alltima 
c18 5µm guard column, was used for separation. Chromatographic conditions were 
optimised by experimentation to achieve good sensitivity and peak symmetry. 
Optimal separation was achieved with a dual-buffer technique consisting of an 
aqueous buffer A (LC-MS grade H20 with 0.25% formic acid) and an organic buffer 
B (LC-MS grade acetonitrile with 0.25% formic acid).  Formic acid was added as a 
proton donator and to improve peak resolution. A run time of 15 minutes was used, 
which included a prolonged rinsing period at the end of the run to eliminate analyte 
carryover. The buffer gradient (A:B) was 90:10 from 0-1.0 minutes, then switched to 
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10:90 between 1.0-5.0 minutes, then to 0:100 between 5.0-10.0 minutes, before 
reversing to 90:10 for 10.0-15.0 minutes (wash phase) (Figure 21). 
 
Figure 21 Solvent gradient used for HPLC separation of analytes.  
 
Analytes had nominal elution times of 4.95 minutes (SN-38G), 4.97 minutes (APC), 
5.05 minutes (irinotecan), 5.5 minutes (SN-38) and 5.61 minutes (camptothecin) 
(Figure 22). 
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Figure 22 Representative chromatogram of 1.5 pmol of on column analyte 
extracted from microsomal fraction, showing SN-38G eluting at 4.95 minutes 
(pink peak),  irinotecan eluting at 5.03 minutes (blue peak), SN-38 at 5.5 
minutes (red peak) and camptothecin at 5.7 minutes (green peak). APC elutes 
at 4.97 minutes (peak not visible). 
 
 
3.3.2.6 MS/MS conditions 
Analysis was performed on an Applied Biosystems QTRAP 4000 mass 
spectrometer operating in positive electrospray ionization (ESI) mode, controlled by 
Applied Biosystems Analyst software version 1.5.  Detection parameters were 
optimized by direct infusion of a 0.1µg ml-1 of analyte in buffer A onto the system 
with the MS operating in full scan mode. Ion spectra for irinotecan, SN-38, APC and 
Camptothecin gave protonated molecules ([M+H]+) of m/z 587.4, 393.2, 619.4 and 
349.2 respectively (Figure 23). The curtain gas was nitrogen at 35 psi. Ionspray 
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voltage was 4500 V and the source temperature 550oC. The declustering potential 
(DP), collision excitation potential (CEP) and collision energy (CX) were optimised 
for each compound (see table 15). The major precursor/product ion group produced 
was identified (irinotecan m/z 124.3, SN-38 m/z 349.2, APC m/z 227.2 and 
camptothecin m/z 305.2). Conditions for the detection of SN-38G were based on the 
method of Chen et al (Chen et al., 2012). A multiple reaction monitoring (MRM) 
method using these parameters was developed for further validation. 
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!
 Irinotecan SN-38 APC Camptothecin SN-38G 
Precursor ion (m/z) 587.4 393.2 619.4 349.2 569.1 
Product ion (m/z) 124.3 349.2 227.2 305.2 393.2 
Declustering potential (DP) 131.0 106.0 131.0 91.0 131.0 
Collision excitation 
potential (CEP) 8.0 19.0 12.0 13.0 12.0 
Collision energy (CX) 53.0 36.0 33.0 33.0 53.0 
Table 15 Ion source and analyte dependent MS parameters 
 
3.3.3 LC-MS/MS assay validation 
!
3.3.3.1 Calibration method 
Method validation was performed in line with US Department of Health & Human 
Services Food and Drug Administration guidelines, as outlined in Bioanalytical 
Method Validation; Guidance for Industry  (FDA, 2001). Full validation was 
performed using primary matrix (microsomal extract), with partial validation 
performed in human serum.  
 
3.3.3.2 Selectivity and ion suppression  
Selectivity was confirmed by measuring blank samples of different microsomal 
extracts and serum. Direct interference by endogenous substances was minimal, 
with no obvious peaks at the elution times of the metabolites of interest (Figure 24). 
Selectivity was also confirmed at the LLOQ (see section 3.3.3.4). Ion suppression 
was determined by the comparison of peak areas of pure analytes in mobile phase 
and peak areas of analyte added to microsomal fractions and blank serum. A small 
decrease in signal was observed for all analytes, but the decrease was 
proportionate for analytes and IS and so ion suppression was corrected. Ion 
suppression was less than 20% for both microsomal and serum samples. 
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Figure 24 Selectivity shown by representative chromatograms obtained from 
(a) blank microsomal fraction and (b) drug-free serum, demonstrating 
background signal but no discrete peaks that could be falsely identified as 
analyte.  
 
3.3.3.3 Linearity 
Concentration curves were constructed using at a blank sample (matrix sample 
without internal standard), a zero sample (matrix sample with internal standard) and 
ten further samples covering the expected metabolite concentration range, including 
the nominal LLOQ (5 nM, 10 nM, 25 nM, 50 nM, 75 nM, 100 nM, 150 nM, 200 nM, 
300nM, 500 nM).  The ratio of analyte: internal standard showed a linear 
relationship throughout the expected range of concentrations (0-500nM) (Figure 
25). Concentration curves were only accepted if values were within 15% of actual 
recordings, or 20% at LLOQ. 
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3.3.3.4 Lower limit of quantification 
The lower limit of quantification is defined as the concentration at which an analyte 
can be detected with adequate sensitivity and specificity, an accuracy and precision 
of >80% and a response at least 5 times greater than background signal. A nominal 
LLOQ was defined as 5nM (50 fmol on column) for all analytes, and validated in 
serum and microsomal extract (See table 16, Figure 26 & 27). 
 
 
 Analyte Detected (mean nM ±SD) Accuracy Precision 
Microsomal 
preparation 
Irinotecan 4.0±0.2 80.4% 96.0% 
SN-38 5.5±0.8 109.6% 98.6% 
APC 5.9±0.4 119.2% 93.8% 
Serum Irinotecan 4.3±0.1 85.7% 103.4% 
SN-38 4.7±0.1 93.6% 98.4% 
APC 5.5±0.7 109.1% 87.9% 
 
Table 16; Accuracy and precision analysis of human liver microsomes and 
serum spiked with 4 analytes at LLOQ (5nM). All values met FDA criteria for 
assay validation. 
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Figure 26 Representative chromatograph of analytes spiked and then 
extracted from microsomal matrix at LLOQ, showing peak response at least 5 
times greater than background noise. At this concentration, accuracy and 
precision was >80%. 
 
3.3.3.5 Interbatch accuracy and precision 
Accuracy is defined as the closeness of mean test results to expected values, 
determined by repeated measurements of samples containing known values. Three 
concentrations were used (LLOQ, mid-range, high-range), with each concentration 
measured 5 times. Mean value was accepted if it was within 15% of the actual 
value, except at the LLOQ where 20% was acceptable.  
The precision of an analytical method describes the closeness of individual 
measures of an analyte when the procedure is applied repeatedly to multiple 
aliquots of a single homogeneous volume of biological matrix. Precision was 
measured 5 times at the same 3 different concentrations. Precision met FDA assay 
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validation standards when values for the coefficient of variation were <15%, or 20% 
at LLOQ (Table 17 & 18). 
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3.3.3.6 Intrabatch accuracy and precision 
Once a method has been partially validated, accuracy and precision should be 
regularly monitored to ensure it continues to operate satisfactorily. Precision and 
accuracy can therefore be defined as intrabatch (repeat samples within the same 
run) and interbatch (repeat samples run on different days). Intrabatch accuracy and 
precision require the same thresholds as interbatch accuracy and precision. These 
results remained consistent, and within acceptable parameters (Tables 19 and 20).  
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3.3.3.7 Analyte recovery 
Recovery is defined as the detector response obtained from an amount of the 
analyte added to and extracted from a biological matrix, compared to the detector 
response obtained for the true concentration of the pure authentic standard in 
reconstitution solution. Although recovery does not need to be consistently 
approaching 100%, it is important recovery of both analyte and internal standard is 
consistent throughout the expected range of results to ensure validity. Recovery 
experiments were performed by comparing the amount of analyte detected in 
samples of microsomal extract and serum at three QC concentrations (low, mid and 
high-range) with unextracted standards dissolved in buffer A that represented 
presumed 100% recovery.!The overall recovery for irinotecan, SN-38 and APC was 
determined at 3 different QC concentrations (5, 100, 200 nM) (Table 21). 
 
 
nM 
Mean 
irinotecan 
% recovery 
Mean 
SN-38 
% recovery 
Mean 
APC 
% recovery 
Mean 
camptothecin 
% recovery 
Microsomal 
extract 
5 79.1% 76.9% 78.3% 84.1% 
100 72.8% 76.2% 74.9% 80.1% 
200 73.1% 78.1% 83.2% 78.6% 
Serum 
5 82.1% 84.2% 83.3% 77.3% 
100 76.3% 77.9% 75.4% 81.2% 
200 84.2% 78.7% 76.4% 88.6% 
Table 21 Analyte recovery from microsomal extract & serum 
 
3.3.3.8 Analyte stability 
A number of studies have already demonstrated the stability of irinotecan and its 
metabolites in biological matrices  (Sparreboom et al., 1998; de Bruijn et al., 1997). 
Stability of analytes within matrix was confirmed by sequential sampling of four 100 
 
 
159 
nM samples after storage at room temperature for 8 hours (the maximum period a 
sample was likely to remain on the autosampler). Freeze-thaw stability was 
assessed by subjecting four 100 nM samples to three freeze-thaw cycles (room 
temperature to -80oC).  
Samples re-analysed after 8 hours showed consistent levels of analyte in both 
protein precipitated serum and microsomal protein matrix. Samples subjected to 
freeze-thaw cycles showed consistent levels of analyte, indicating that drugs were 
not degraded by the freeze-thaw cycle (Tables 22 and 23). 
 
 Microsomal protein Serum 
Time 
(hours) 
Irinotecan 
nM SN-38 nM APC nM 
Irinotecan 
nM SN-38 nM APC nM 
0 101.0±2.7 109.2±5.7 102.9±2.1 102.2±4.8 110.3±5.4 97.1±1.7 
2 103.0±3.1 108.3±8.6 98.4±3.3 104.2±3.2 104.9±3.1 98.9±3.8 
4 99.6±0.9 109.4±5.9 101.06±2.7 98.2±0.9 106.2±2.9 105.4±2.2 
6 108.0±1.4 108.1±4.7 100.64±3.3 101.3±1.0 103.6±1.2 103.2±2.4 
8 112.9±10.4 102.0±3.2 109.45±8.8 107.2±4.1 99.1±6.8 101.2±4.6 
Table 22 Amount of analyte detected in 100nM standard protein-precipitated 
matrix stored at room temperature over time (mean ± standard deviation)  
  Irinotecan nM SN-38 nM APC nM Camptothecin nM 
Cycle 1 110.4±7.3 107.3±2.3 99.9±0.9 112.4±3.8 
Cycle 2 107.3±3.2 99.4±1.5 103.5±1.6 108.6±3.2 
Cycle 3 111.4±6.4 104.7±2.1 107.5±5.1 105.4±1.6 
Table 23 Amount of analyte detected in 100 nM standard after three freeze-
thaw cycles (mean ± standard deviation) 
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Figure 27 LC-MS/MS chromatograph of a representative biological sample 
(zoomed in to demonstrate sufficient peak shape for analysis and lack of 
baseline interference) in (a) microsomal extract and (b) serum. 
 
3.3.4 Microsomal incubation development 
Drug was suspended in PO4 buffer in a 10ml glass LSL tube placed in a 37oC orbital 
incubator cabinet, and allowed to reach operating temperature over 5 minutes. 
Reactions were initiated by the addition of warmed microsomal protein to give a 
total reaction volume of 500 µl. Control samples were run alongside all samples, 
one containing no protein and one containing no drug. Amount of SN-38 detected in 
the protein-free sample (control) was subtracted from the amount detected in the 
incubations. Reactions were terminated after an appropriate time by the addition of 
500 ul of 50% ACN; 50% MeoH; 0.005% TFA, containing 40 nM camptothecin.  
 
3.3.4.1 Irinotecan concentration optimisation 
Incubations were performed with a microsomal protein concentration of 4 mg ml-1. 
Incubations were conducted for 30 minutes with agitation at 37oC. Increasing 
concentrations of irinotecan led to a linear increase in SN-38 production (Figure 28). 
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Figure 28 Graph showing SN-38 production at increasing concentrations of 
irinotecan incubated with 4mg ml-1 microsomal protein. 
 
3.3.4.2 Protein concentration optimisation 
Incubations were performed with an initial irinotecan concentration of 5 µM. 
Incubations were conducted for 30 minutes at 37oC. Increasing concentrations of 
microsomal protein led to a linear increase in SN-38 production (Figure 29). There 
was a linear relationship between SN-38 production (pmol mg-1 min-1) and protein 
concentration (Figure 30), suggesting that at 5µM irinotecan it is the availability of 
catalytic enzyme that is the rate-limiting step in SN-38 production. 
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Figure 29 Graph showing increasing SN-38 production with increasing protein 
concentration 
 
Figure 30 Graph showing linear production of SN-38 (pmol mg-1 min-1) with 
increasing protein concentration suggesting that protein availability is the 
rate-limiting step in SN-38 production when incubated with 5 µM irinotecan.  
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3.3.4.3 Microsomal incubations with co-factors 
Incubations were repeated with an initial irinotecan concentration of 5µM, 0.5mg ml-
1 microsomal protein with the addition of 1mM NADPH and/or 2mM UDPGA. These 
cofactors were necessary for the CYP3A4 mediated production of APC and the 
UGT1A1 mediated production of SN-38G respectively.  
A time course was run, with incubations of 0, 10, 20, 30, 60, 120, 180 and 240 
minutes. Reactions were terminated by the addition of an equal volume of 50% 
ACN; 50% MeoH; 0.005% TFA, containing 40 nM of camptothecin (final 
concentration 20 nM). In all cases, irinotecan consumption was <5%. 
SN-38 production was comparable for all incubation conditions, irrespective of co-
factors. This shows that at a concentration of 5 µM irinotecan, the interconversion of 
irinotecan to SN-38 was not affected by the CYP3A4 deactivation of irinotecan and 
UGT1A1 mediated formation of SN-38G, indicating that the relative capacity of CES 
pathway far exceeds that of the CYP3A4/UGT1A1 pathway (Figure 31).  
 
Figure 31 Graph showing SN-38 production in the presence of the cofactors 
UDPGA & NADPH at 5µM irinotecan. 
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The CYP3A4 mediated conversion of irinotecan to APC was dependent on the 
presence of NADPH, with no APC produced if this co-factor was not present (Figure 
32). The production of APC showed marked plateauing after 60 minutes, 
presumably because of NADPH exhaustion. The presence of UDPGA, allowing the 
glucuronidation of SN-38G, did not result in a detectable reduction in APC 
production, suggesting these pathways are not competitive at this concentration. 
 
 
Figure 32 Graph showing APC production with the addition of NADPH, a co-
factor necessary for the function of CYP3A4. The addition of UDPGA (a co-
factor necessary for the UGT1A1 mediated glucuronidation of SN-38) does not 
appear to lead to competition between these 2 pathways. Plateauing of this 
curve likely represents exhaustion of NADPH. 
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SN-38G production only occurred in the presence of UDPGA (Figure 33). 
Production was linear to 240 minutes, suggesting that the co-factor had not been 
exhausted by this time point. The presence of NADPH did not reduce the amount of 
SN-38G produced, suggesting that at a 5µM concentration of irinotecan the CES 
mediated production of SN-38 was saturated and the CYP3A4 mediated production 
of APC did not reduce the production of SN-38.  
 
 
Figure 33 Graph showing the production of SN-38G with the addition of 
UDPGA, a co-factor necessary for the UGT1A1 mediated glucuronidation of 
SN-38. NADPH in addition to UDPGA did not lead to competition between 
these 2 pathways. 
 
3.3.4.4 Physiologically relevant irinotecan concentration optimisation 
These experiments were then repeated at a much lower concentration of 500nM 
irinotecan. 500 nM was used as it was comparable with reported serum irinotecan 
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concentrations 1 hour after embolisation (See section 4.3.5.1) and thus represented 
a physiologically relevant concentration. 
A similar pattern of analyte production to the 5µM irinotecan incubations was seen, 
suggesting that at a physiologically relevant dose competition between pathways 
does not alter the production of the active metabolite SN-38 (Figure 34, 35 & 36). 
 
Figure 34 Graph showing SN-38 production irrespective of the addition of 
enzymatic cofactors with no interpathway competition at a physiologically 
relevant dose. SN-38 production is approximately 10-fold lower than the 5uM 
irinotecan incubation. 
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Figure 35 Graph showing APC production with the addition of NADPH, a co-
factor necessary for the function of CYP3A4. The addition of UDPGA does not 
lead to competition between these 2 pathways at this concentration. APC 
production is approximately 10-fold lower than for the 5uM irinotecan 
incubation. 
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Figure 36 Graph showing SN-38G productions with the addition of UDPGA. At 
this concentration, addition of NADPH and UDPGA does not appear to lead to 
competition between the 2 pathways. 
 
3.3.4.5 Quantification of SN-38G 
As SN-38G could not be purchased as an existing standard, an alternative 
approach to quantification was developed. 
A microsomal incubation was performed using 1mg ml-1 protein, 2mM UDPGA, 
5mM MgCl2, and 20µM SN-38. An LC-MS MRM assay was run using M/Z data from 
previously published data  (Chen et al., 2012). This confirmed the detection of a 
peak that was thought to represent SN-38G. This incubation was repeated for 0, 10, 
20, 30, 60, 120 and 180 minutes, both with and without UDPGA. 
The incubation containing UDPGA clearly demonstrated a linear increase in signal 
intensity for presumed SN-38G. This signal was absent when UDPGA was not 
added (Figure 37). 
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Figure 37 Graph showing increasing SN-38G signal as SN-38 is incubated with 
hepatic microsome and UDPGA. This signal is absent for incubations without 
UDPGA. 
 
3.3.4.6 β -glucuronidase mediated production of SN-38 
This incubation was then repeated, with the sample allowed to incubate for 660 
minutes to maximise conversion of SN-38 to SN-38G. Confirmation that this signal 
was SN-38G was achieved by the addition of 40 000 Fishmann units of β-
glucuronidase dissolved in 0.1M sodium acetate buffer. This incubation was then 
conducted for a further 440 minutes, and the loss of signal recorded (Figure 38). 
The reducing signal intensity corresponded to the back conversion of SN-38G to 
SN-38. 
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Figure 38 Graph showing the formation of SN-38G in human liver microsome 
incubated with UDPGA. The addition of β-glucuronidase results in a rapid loss 
of signal as SN-38G is back-converted to SN-38. 
 
In order to quantify the amount of SN-38G, a stoichometric method was used. A 
series of SN-38 standards were made, with concentrations ranging from 0 – 200 
nM. These standards were then incubated with 1mg ml-1 protein, 2mM UDPGA and 
5mM MgCl2 for 5 hours. There was a linear increase in SN-38G formation with 
increasing SN-38 concentration (Figure 39). 
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Figure 39 Graph showing SN-38G formation (AUC) increases with increasing 
concentrations of SN-38. 
 
The same QC standards were then analysed without protein or UDPGA. The 
difference in SN-38 measured between the incubated and non-incubated sample 
([SN-38]QC-[SN-38]incubation) was assumed to be the amount of SN-38G produced, 
and correlated with signal intensity. This standard curve was then used for all future 
estimations of SN-38G concentration (Figure 40). 
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Figure 40 Standard curve used for the quantification of SN-38G in future 
incubations. Using a stoichiometric approach, the difference in SN-38 
detected in the incubated and non-incubated samples was assumed to 
represent the amount of SN-38G produced. This was then plotted against 
signal intensity, and this relationship used to quantify all future 
measurements of SN-38G production. 
 
3.3.4.7 Summary of optimal assay conditions for analysis of human serum  
200µl of 50% ACN; 50% MeoH; 0.005% TFA containing 40 nM camptothecin as 
internal standard was added to 200 µl of serum to precipitate the plasma protein 
fraction. pH of the stop buffer was <3, converting all drug and metabolites into the 
active lactone form. Samples were vortex mixed for 15 seconds, then centrifuged at 
20 130 g at 3oC for 20 minutes. 300µl of supernatant was filtered through a pre-
wetted Millipore Multiscreen Solvinert 96 well filter plate and collected in a clean 96 
well plate. 100µL of the sample was transferred to a sealed 200µl Chromacol glass 
autosampler vial and 20 µL injected onto the column. Amount of drug and analyte 
detected was normalised to the amount of internal standard. All measurements 
were performed 3 times. 
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3.3.4.8 Summary of optimal microsomal drug incubation conditions 
Incubations consisted of 500nM irinotecan, 2mM UDPGA and 1mM NADPH in 500 
µl of PO4 buffer. Incubation mixtures were pre-warmed in a 10ml glass SDS tube 
suspended in a 37oC agitating water bath, and allowed to reach operating 
temperature over 5 minutes. Reactions were initiated by the addition of warmed 
microsomal protein (final concentration 0.5mg ml-1).  Reactions were terminated 
after 120 minutes by the addition of 500µl of 50% ACN; 50% MeOH; 0.005% TFA 
containing 40 nM camptothecin as internal standard. Control samples were run 
alongside all samples, one containing no protein and one containing no drug. 
Amount of analyte detected in the protein-free sample (control) was subtracted from 
the amount detected in the incubations.  Samples were vortex mixed for 15 
seconds, then centrifuged at 20 130 g at 3oC for 20 minutes. Samples were filtered 
as described above and injected onto the column. Amount of drug and analyte 
detected was normalised to the amount of internal standard. All reactions were 
completed three times.  
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3.4 Discussion 
This study shows the development of a novel one-step protein precipitation-
extraction LC-MS/MS assay for the quantitative detection of irinotecan, SN-38, APC 
and SN-38G in a variety of human biological matrices. The assay was fully validated 
to FDA standards. The assay is sensitive, specific, accurate, and reproducible, and 
was successfully used for the optimization of microsomal incubation conditions.  
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4 Metabolic profiling to identify predictive 
biomarkers for DEBIRI 
!  
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4.1 Introduction 
Transcatheter embolic therapy with irinotecan-eluting beads (DEBIRI) allows the 
targeted delivery of irinotecan to patients with CRLM. PARAGON Bead is a next 
generation investigational product where the manufacturer preloads the embolic 
bead with a standardized dose of irinotecan. Irinotecan is a water-soluble prodrug 
converted into the active agent SN-38 by carboxylesterases 1 & 2 (CES-1 & CES-2  
(Guichard et al., 1999). SN-38 directly targets the DNA repair enzyme 
topoisomerase I (Topo-1) promoting apoptotic cell death  (Hsiang et al., 1985) 
leading to tumour replacement with fibrosis. Patients who have a large fibrotic 
response to chemotherapy demonstrate better overall survival  (Rubbia-Brandt et 
al., 2007) (Blazer et al., 2008)  (Poultsides et al., 2012) and so it is vital that patients 
are treated with the most effective chemotherapeutic regimen possible. Irinotecan 
and SN-38 both undergo metabolic inactivation; irinotecan is deactivated by 
CYP3A4 to the metabolite APC, whilst SN-38 is conjugated to glucuronic acid by 
UDP-glucuronyl transferase 1A1 (UGT1A1) (Figure 41). A complex balance 
between the activities of multiple hepatic enzymes therefore determines the overall 
exposure to SN-38. There is wide interpatient variation in expression of these key 
enzymes. Levels of CES-2 show 15-fold variation in hepatic parenchyma  (Xu et al., 
2002) and 23-fold within colorectal cancer  (Sanghani et al., 2003), levels of 
CYP3A4 can be affected by environmental exposure  (Lau et al., 2011) and the 
promoter of UGT1A1 is subject to a common and functionally relevant 
polymorphism  (Iyer et al., 2002). Perhaps unsurprisingly there is large interpatient 
variability in the pharmacokinetics and metabolism of irinotecan  (Mathijssen et al., 
2004).  
This study assessed serum concentrations of irinotecan and its metabolites after 
administration of DEBIRI, as well as investigating the hepatic metabolism of 
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irinotecan. These metabolic factors were then correlated with response to treatment 
to identify potential clinically relevant predictive factors.  
!
Figure 41 Diagram summarizing the metabolism of irinotecan and co-factors 
necessary for metabolite production. Irinotecan is converted into the active 
metabolite SN-38 by carboxylesterase (CES-1 and CES-2). No co-factors are 
necessary for this step. Irinotecan is converted to its inactive metabolite APC 
by the enzyme CYP3A4. This step requires the cofactor NADPH. SN-38 is 
deactivated by glucoronidation mediated by UGT1A1, which requires the 
cofactor UDPGA. 
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4.2 Methods !
4.2.1 Patients 
This study was the translational arm of the PARAGON II trial, which assessed the 
feasibility and safety of a single treatment with neoadjuvant DEBIRI before resection 
of CRLM with an endpoint of pathological tumour response  (See section 2.2.5). All 
patients had resectable CRLM and had not previously been exposed to irinotecan. 
Tumours were embolised with a nominal dose of 200mg irinotecan using 
PARAGON Bead (Biocompatibles UK Limited) as previously described (See section 
2.3.2).  
 
4.2.2 Biosampling !
4.2.2.1 Peri-TACE serum sampling 
Blood samples were taken from patients treated with DEBIRI-TACE immediately 
pre-treatment, one and six hours after embolisation and again at the time of 
surgery. Samples were immediately placed on ice until centrifugation at 2000 g for 
10 minutes at 4°C. Serum was removed, placed in a Cryodorf vial and snap frozen 
in liquid nitrogen before storage at -80oC until analysis.  Time from sampling to snap 
freezing was consistently less than 30 minutes. 
 
4.2.2.2 Hepatic parenchymal sampling 
Immediately after the resected specimen had been removed from the patient, 
samples of normal hepatic parenchyma and colorectal liver metastasis were placed 
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in a Cryodorf vial and snap frozen in liquid nitrogen and stored at -80oC. Time from 
sample removal to snap freezing was consistently less than 5 minutes. 
 
4.2.3 Pathological response scoring 
Haematoxylin and eosin stained tumour specimens were reviewed by an 
experienced hepatobiliary pathologist and assessed according to UK Royal College 
of Pathologists Liver Resection Standard Dataset  (Wyatt et al., 2012) (See section 
2.2.5). The pathologist was blinded to patient outcome. Tumour response was 
graded using a validated system  (Blazer et al., 2008). Briefly, the amount of 
residual cancer was assessed semi quantitatively by estimating the proportion of 
residual cancer cells, necrotic tissue and fibrosis in relation to the total area of 
cancer (Figure 42). The location of the beads within tumour was not assessed. 
 
Figure 42 Representative photomicrographs of colorectal liver metastases 
treated with DEBIRI showing differing pathological responses (A) 30% 
tumour, 60% fibrosis, 10% necrosis and (B) 0% tumour, 60% fibrosis, 40% 
necrosis. The beads are clearly visible in the vasculature (black arrows), with 
areas of necrosis (star), fibrosis (arrow head) and viable tumour (white arrow). 
Magnification x 4. 
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4.2.4 Instrumentation, chromatographic conditions and assay validation 
An LC-MS/MS assay for the measurement of irinotecan and its metabolites was 
established and fully validated to FDA standards  (FDA, 2001) (See section 3). 
Samples were separated using an Ultimate 3000 HPLC stack (Dionex) with an 
Altima C18 (150 x 2.1mm, 5µm) column (Grace). Mass spectrometric detection was 
performed on a 4000 QTRAP system (ABSciex) operating in a positive electrospray 
ionization (ESI) mode.  
 
4.2.5 Serum drug concentrations 
Serum samples underwent protein precipitation as previously described (See 
section 3.3.4.7). Analyte concentrations were calculated by linear regression using 
the peak area ratios of the analyte/internal standard. All measurements were 
performed in triplicate. 
 
4.2.6 Microsomal preparations & drug incubation conditions 
Microsomal incubations were performed as previously described (See section 
3.3.4.8). In brief, incubation mixtures (500nM irinotecan, 2mM UDPGA and 1mM 
NADPH in 500 µl of phosphate buffer, pH 7) were pre-warmed for 5 minutes then 
initiated by the addition of warm microsomal protein (final concentration 0.5mg ml-1) 
and terminated after 120 minutes by the addition of 500µl of extraction buffer. 
Metabolite activity was linear under these conditions (See section 3.3.4). Control 
samples were run alongside all samples, one containing no protein and one 
containing no drug.  All incubations were run in triplicate. 
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4.2.7 Targeted and global proteomic quantification  !
4.2.7.1 Global proteomic analysis using iTRAQ (Isobaric Tag for Relative and 
Absolute Quantification) 
Snap frozen hepatic parenchyma was thawed then mechanically homogenised in 
dissolution buffer (0.5M TEAB (tetraethylammonium bromide)/0.1% SDS in H2O). 
Following centrifugation at 2000 g for 20 minutes at 4oC, the supernatant was 
removed and protein concentration determined by sequential Lowry assay  (Lowry 
et al., 1951).  
100 µg of protein was added to 20 µl of dissolution buffer (Applied Biosystems) and 
reduced with tris(2-carboxyethyl)phosphine at 60oC for 1 hour. Cysteine sulfhydryls 
were then blocked by the addition of methyl-methanethiosulfonate at room 
temperature for 10 minutes. Proteins were digested by incubating with 10µl trypsin 
(Promega Trypsin Gold reconstituted in MilliQ water as per manufacturers 
instructions) overnight at 37°C.  
iTRAQ reagents (AB Sciex) were reconstituted in isopropanol and added to the 
appropriate sample tube. Following incubation for 2 h at room temperature, protein 
digests were combined and pH adjusted to <3 by addition of concentrated 
phosphoric acid and immediately underwent strong cation exchange, followed by 
LC-MS/MS using an AB Sciex tripleTOF 5600 mass spectrometer (Applied 
Biosystems). The accumulated LC-MS/MS data was analysed using Protein Pilot 
(Applied Biosystems). A common reference pool generated from 10 matched 
human liver samples was used to allow comparison of relative quantification 
between iTRAQ channels. 
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4.2.7.2 Targeted proteomic analysis using Western immunoblotting !
4.2.7.2.1 SDS-PAGE gel production 
Microsomal samples were prepared (See section 3.3.2.2), mixed with 2 x Lammelli 
buffer and boiled at 100oC for 10 minutes. 12% SDS-PAGE gels were generated 
using standard laboratory protocol, and 40µg of protein in a final volume of 15µl 
added to each channel. A further channel containing a common reference pool 
generated from 10 matched microsomal samples was run on each gel to allow 
intergel comparison. Seeblue molecular weight markers (Sigma) were run to aid 
analysis of the molecular weight of protein samples. Gels were subjected to 
electrophoresis at 150 volts and unlimited ampage until the blue dye front was at 
the bottom of the gel.  
 
4.2.7.2.2 Western immunoblotting 
After electrophoresis, gels were washed in transfer buffer (1 x running buffer in 20% 
methanol) and proteins transferred to a Hybond nitrocellulose sheet (GE 
Lifescience) using a blotting sandwich in a transfer unit containing transfer buffer.  
After transfer, the nitrocellulose membrane was gently washed in water for 5 
minutes then transfer of proteins assessed using Ponceau S stain. As microsomal 
extracts have low levels of suitable loading proteins (e.g. actin), comparable gel 
loading for all Westerns was verified by visual inspection of the Ponceau stain.  
The membrane was rinsed in TST (0.01M Tris-HCL, pH8, 0.15M NaCl, 1% TWEEN 
20) to remove the stain then incubated for 1 hour at room temperature with constant 
agitation in 5% (w/v) milk solution consisting of Marvel milk powder in 1x TBST 
(20mM Tris-Cl pH 7.6, 150mM NaCl, 0.1% Tween 20) to block non-specific antibody 
binding sites. 
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4.2.7.2.3 Antibody incubation conditions 
Primary antibody conditions and concentrations were optimized by experimentation. 
Primary antibody against the protein of interest was added to fresh 1% milk solution 
at the appropriate dilution (table 24) and incubated with the membrane overnight at 
4°C under constant agitation. The membrane was washed 3 times for 5 minutes in 1 
x TBST, and then incubated in fresh 1% milk solution with the appropriate 
secondary antibody (IRDye 680 LT (Li-Cor) 1:20 000, apart from UGT1A1 where 
1:5 000 used) for 1 hour at room temperature, with constant agitation.  
Antibody Reference Manufacturer Concentration 
CES-1 Anti CES-1 Sigma-Aldrich 1: 5 000 
CES-2 Anti CES-2 Sigma-Aldrich 1:10 000 
UGT1A1 Anti-UGT1A1 AbCam 1: 1 000 
CYP3A4 Anti-human CYP3A4 BD Biosciences 1: 3 000 
Table 24 Primary antibodies used for Western blotting. Antibody 
concentration and incubation times were optimized by experimentation. 
 
4.2.7.2.4 Western blot visualisation and quantification 
Blots were visualized and quantified using the LI-COR Odyssey CLx system (LI-
COR Biosciences). For each channel, a ratio of sample:reference pool was 
calculated. All blots were performed at least 4 times, and a mean sample:reference 
value calculated. 
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4.2.8 UGT1A1 genotyping !
4.2.8.1 DNA extraction 
Genomic DNA was extracted from fresh frozen liver using a salt precipitation 
protocol (Gustincich et al., 1991). Approximately! 10 mg of fresh frozen hepatic 
parenchyma was finely chopped and placed in an Eppendorf tube with an equal 
volume of Trizol (Invitrogen). Tissue was mechanically homogenized using a 
Qiagen tissue ruptor. 200 µl of chloroform (Sigma) was added to the sample 
followed by centrifugation at 2000 g for 15 minutes at 4oC. The clear supernatant 
containing the DNA fraction was pipetted off and mixed with an equal volume of 
ethanol to precipitate out DNA. This mix was centrifuged again to create a DNA 
pellet that was washed twice in 0.1M sodium citrate/10% ethanol. After air-drying, 
the DNA pellet was resuspended in 50µl of Tris EDTA. DNA quality was quantified 
using a Nanodrop 8000 spectrophotometer (Thermoscientific).! By measuring the 
relative UV absorbance at wavelengths of 260nm (DNA) and 280nm (protein) it was 
possible to assess the DNA purity of each sample. A 260:280 ratio >1.8 was 
considered sufficient for further analysis.!Samples were air-dried then re-suspended 
in ddH2O to a final concentration of 20ng ml-1.   
!
4.2.8.2 Primer development 
Primers (Life Technologies) were designed using Primer BLAST (available at 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and underwent BLAST quality 
control prior to use (Forward-5'-CTTGGTGTATCGATTGGTTTTTGC-3', Reverse-5'- 
AGAGGTTCGCCCTCTCCTAC-3'). PCR samples were prepared (see table 25) to 
give a final primer concentration of 0.5 µM.  
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 Units 
10 x PCR Buffer 5 µL 
25mM MgCl2 2 µL 
dNTP Mix (25mM) 0.4 µL 
Primer Forward (10µM) 2.5 µL 
Primer Reverse (10µM) 2.5 µL 
dd H2O 35.35 µL 
Sample DNA (20ng µl-1) 2 µL 
Final Volume 49.75 µL 
 Table 25 Content of PCR incubation samples. The addition of 1.5 units of 
Taqman HotstartDNA polymerase (in a volume of 0.25 µL) gave a final 
incubation volume of 50 µL. 
 
4.2.8.3 PCR conditions 
The final reaction conditions included 10 µM forward and reverse primer and 1.5 
units of Taqman HotstartDNA polymerase (in a volume of 0.25 µL) (Applied 
Biosystems) in a final incubation volume of 50 µl.  Thermocycling was performed on 
a GSTORM GS4822 PCR thermocycler (Labtech) using the following conditions:  5 
minutes denaturation at 95°C followed by 35 cycles of 1 minute at 94°C, 1 minute at 
60°C and 1 minute at 72°C, and a final 7 minute extension step at 72°C.  
 
4.2.8.4  Analysis of PCR products 
PCR products were separated on a 3% agarose gel (NuSieve) with ethidium 
bromide staining. Invitrogen Plus DNA control ladder was used to aid identification 
of PCR products. Blank PCR incubation mix (without sample DNA) provided the 
control. The gel was resolved at 120 v for ~ 2.5 hours and visualized on an 
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ultraviolet light box. PCR products were further quantified using an Agilent 2100 
Bioanalyser. Each sample (1µl) was loaded onto an Agilent 16 well DNA chip, 
followed by 5µl of high sensitivity DNA marker to each sample channel. Blank PCR 
incubation mix was used as a control channel on each chip. All samples were 
analysed in duplicate. 
 
4.2.9 Statistical analysis 
Statistical analysis was performed using SPSS Statistics version 20 (IBM). All tests 
were bidirectional. Linear correlation between continuous variables was compared 
using Pearson coefficient of correlation. Mann-Whitney U-test was used to assess 
the relationship between continuous pharmacological variables (serum 
concentrations) and patient groups defined by median protein expression. p<0.05 
was considered to represent statistical significance. 
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4.3 Results !
4.3.1 Biosampling 
Complete sets of blood samples were obtained from eight patients who underwent 
neoadjuvant DEBIRI. Both tumour and normal parenchymal tissue were harvested 
from all eight patients at the time of surgery. In addition, another 2 patients provided 
tumour and parenchymal samples but had already received DEBIRI at the time 
recruitment started and so these did no undergo serum sampling (Table 26). 
 
 
  Serum sampling Tissue sampling 
Dose of 
DEBIRI-TACE 
(mg) 
Pre-
TACE 1 hr 6 hrs Pre-surgery 
Hepatic 
parenchyma Tumour 
Patient 1 80 X X X X   
Patient 2 64       
Patient 3 80       
Patient 4 150       
Patient 5 160       
Patient 6 90 X X X X   
Patient 7 175       
Patient 8 105       
Patient 9 130       
Patient 
10 
100       
Table 26 Biosampling record sheet for patients recruited into translational 
arm of PARAGON II study 
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4.3.2 Pathological response rates 
Pathological response was evaluated in all ten patients. Median residual tumour 
was 30% (range 10-50%), median necrosis 40% (range 40-60%) and median 
fibrosis 20% (range 10-40%) (Table 27). 
 
 
Tumour viability (%) Tumour necrosis (%) Tumour fibrosis (%) 
Patient 1 
40% 30% 30% 
Patient 2 
30% 30% 40% 
Patient 3 
40% 50% 10% 
Patient 4 
10% 50% 40% 
Patient 5 
20% 40% 40% 
Patient 6 
40% 20% 40% 
Patient 7 
40% 40% 20% 
Patient 8 
30% 50% 20% 
Patient 9 
30% 60% 10% 
Patient 10 
50% 40% 10% 
Table 27 Tumour pathological response rate after neoadjuvant treatment with 
DEBIRI-TACE. 
4.3.3 Targeted and global proteomic analysis !
4.3.3.1 iTRAQ quantification 
iTRAQ analysis of whole hepatic parenchyma demonstrated a wide variation in 
protein expression, with ≈ 3-fold change in CES-2, ≈7-fold change in CES-1, a ≈5-
fold change in CYP3A4 and ≈ 3-fold change in UGT1A1 (Table 28).  
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CES-2 
expression 
(AU) 
CES-1 
expression 
(AU) 
CYP3A4 
expression 
(AU) 
UGT1A1 
expression 
(AU) 
Patient 1 1.12 2.49 1.20 1.27 
Patient 2 ♯ 1.42 2.61 1.19 1.84 
Patient 3 ♯ 1.56 1.89 3.28 2.31 
Patient 4 1.38 1.61 1.61 1.84 
Patient 5 1.42 2.11 1.37 1.42 
Patient 6 2.83 0.41 0.75 1.05 
Patient 7 ♯ 1.09 1.77 1.91 0.85 
Patient 8 1.84 1.42 2.01 1.03 
Patient 9 1.28 2.97 2.15 1.32 
Patient 10 0.90 3.16 1.13 1.84 
Table 28 Parenchymal protein expression by iTRAQ. Numbers are relative 
expression compared to a common reference channel containing a pool of 10 
control human hepatic microsomes. 
♯=UGT1A1*28 6/7 heterozygotes 
!
4.3.3.2 Western blotting 
Western blotting of microsomal protein demonstrated a single band at the expected 
molecular weight for each target protein (See Figure 43). Wide variation in protein 
expression between patients was observed. CES-2 expression varied ≈ 6.7 fold, 
with much lower variation in expression of CES-1 (≈2 fold), UGT1A1 (≈1.9 fold) and 
CYP3A4 (≈1.7 fold) (Table 29).  
 
 
!
!
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!
!
Figure 43 Representative Western blots (A) and column charts showing 
densitometry data of 10 microsomal samples blotted for (B) CES-1, (C) CES-2, 
(D) CYP3A4 and (E) UGT1A1. Antibody conditions were optimized by 
experimentation. A combined reference pool of 10 control human hepatic 
microsomes was run on each gel to allow inter-gel comparison. Densitometry 
shows mean value from 4 blots (Bar = SD).  
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CES-2 
densitometry 
(AU) 
CES-1 
densitometry 
(AU) 
CYP3A4 
densitometry 
(AU) 
UGT1A1 
densitometry 
(AU) 
Patient 1 0.92±0.20 1.34±0.08 1.07±0.17 0.89±0.07 
Patient 2 ♯ 1.48±0.33 1.05±0.06 1.23±0.23 1.14±0.54 
Patient 3 ♯ 0.49±0.12 0.74±0.10 1.01±0.09 0.88±0.03 
Patient 4 1.18±0.24 0.83±0.11 0.92±0.23 0.95±0.04 
Patient 5 0.79±0.18 0.93±0.10 0.75±0.12 0.82±0.11 
Patient 6 2.93±0.82 0.68±0.15 0.80±0.06 0.77±0.06 
Patient 7 ♯ 0.76±0.11 0.75±0.11 0.96±0.14 0.82±0.12 
Patient 8 0.91±0.10 0.77±0.09 0.87±0.13 0.78±0.05 
Patient 9 0.81±0.10 1.01±0.05 1.18±0.29 1.00±0.33 
Patient 10 0.44±0.09 1.21±0.14 0.71±0.05 1.48±0.78 
Table 29 Microsomal protein expression (±SD) by Western immunoblotting 
(n=4 different blots). The value is densitometry result compared to common 
reference pool. 
♯=UGT1A1*28 6/7 heterozygotes 
 
4.3.3.3 Comparison of protein quantification between iTRAQ and Western 
immunoblotting 
Differences in protein expression between samples using both iTRAQ and Western 
immunoblotting were concordant for CES-1 (r2=0.62, p=0.007) and CES-2 (r2=0.75, 
p=0.002). For example patient 6 showed the highest CES-2 expression and lowest 
values for CES-1 by iTRAQ analysis, which was confirmed by Western blotting. 
Concordance was less marked for CYP3A4 (r2=0.08, p=0.48) or UGT1A1 (r2=0.25, 
p=0.146) (Figure 44) and may reflect lack of absolute specificity of the isoform 
specific antibody used for Western blotting. However, the high concordance in 
protein quantification between 2 discreet techniques clearly validates the 
quantification of CES-1 and CES-2 in protein samples. 
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4.3.4 UGT1A1 genotyping !
4.3.4.1 Agarose gel visualisation 
Wild type UGT1A1*28 (6/6) heterozygotes were predicted to give a PCR product 62 base 
pairs long. In the case of a TATA repeat, a wider band would be anticipated on the 
agarose gel as a *28 (6/7) (heterozygous) or *28 (7/7) (homozygous) would give a product 
2 or 4 base pairs larger than the wild type *28 (6/6).  Initial visual inspection suggested 
samples 3, 7 and 9 produced a broader product band than the other samples (Figure 45). 
 
Figure 45 Agarose gel stained with ethyl bromide to visualize products of 
UGT1A1*28 PCR. The control channel shows no PCR product. All patient samples 
show a product of approximately 60 base pairs in size. Lanes 3, 7 and 9 show a 
broader product band, suggesting possible 6/7 or 7/7 repeat. 
 
4.3.4.2 Agilent 1200 bioanalysis 
Further quantitative analysis was performed on an Agilent 2100 Bioanalyser. Visual 
inspection of the agarose gel suggested patients 3, 7 and 9 had a broader product band. 
These samples were therefore loaded in duplicate onto an Agilent DNA Bioanalysis chip. 
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Microcapillary gel analysis clearly demonstrated a broader band for patients 3, 7 and 9. 
This was confirmed on the in-chip repeats, and the same results were seen on the second 
chip (Figure 46). 
 
 
Figure 46 Microcapillary gel from Agilent Bioanalyser 2100 of showing products of 
UGT1A1*28 PCR. The gel shows a wider product band for patient samples 3,7 and 9 
suggesting a larger PCR product as would be expected in the presence of an SNP. 
These samples were repeated within the same DNA chip, and show a similar 
pattern. 
 
Electropherograms from the DNA chip showed a clear spike on the peak representing the 
PCR product in samples 3, 7 and 9. This spike was seen in the duplicate runs, as well as 
the second chip, but was not present in other samples. This spike represents the larger 
PCR product produced by the *28 (6/7) (heterozygous) TATA repeat SNP (Figure 47). 
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Seven patients were therefore wildtype (6/6) (70% of population), with three patients 
heterozygotes (7/6) (30% of population).  
 
Figure 47 Representative electropherograms for UGT1A1*28 PCR products.  (A) 
patient sample 1, (B) patient sample 3, (C) patient 7 and (D) patient 9. The left hand 
peak in each window is the lower DNA marker. The large peak is the 62 base pair 
PCR product. The clear upward deflection on the large peak seen in samples 3, 7 
and 9 represents the 64 base pair product produced by a TA repeat (UGT1A1*28 
(6/7).  This upward deflection was not seen in other samples (UGT1A1*28 (6/6).  
 
4.3.4.3 Effect of UGT1A1*28 SNP on protein expression 
The three patients found to be heterozygous carriers of the UGT1A1*28 6/7 mutation are 
denoted in table 28 & 29 with a # symbol. There was no difference in level of UGT1A1 
expression between patients who were 6/6 and 6/7 using Western blotting (p=0.83) or 
iTRAQ (p=0.76). 
 
4.3.5 Serum metabolic profiling !
4.3.5.1 Serum concentrations of drug and metabolites 
Serum drug concentrations varied widely (See table 30, Figure 48), with a median 
irinotecan concentration of 188.3 nM (range 80.2 - 352.7) at 1 hour and 83.3 nM (38.5-
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207.7) at 6 hours. SN-38 concentrations were much lower than irinotecan, with a median 
of 11.2 nM (6.9-31.2) at 1 hour and 6.2 nM (3.9-10.6) at 6 hours. SN-38G was detected at 
higher levels than SN-38, with 55.1 nM (1.6-168.6) at 1 hour and 21.2 (1.1-57.5) at 6 
hours. APC reached a median concentration of 84.5 nM (12.8-237.0) at 1 hour, with 31.7 
nM (12.5-178.9) at 6 hours. No drug or metabolites were detected in serum taken at the 
time of resection. Individual patient serum concentrations varied widely. 
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 Irinotecan 
(nM) 
SN-38 
(nM) 
APC 
(nM) 
SN-38G 
(nM) 
Patient 1 
1 hour NA NA NA NA 
6 hour NA NA NA NA 
Patient 2 ♯ 
1 hour 80.2 16.9 30.2 58.0 
6 hour 25.4 5.9 26.3 51.4 
Patient 3 ♯ 
1 hour 105.1 24.1 50.9 79.4 
6 hour 44.9 8.8 25.5 19.5 
Patient 4 
1 hour 277.5 17.3 88.0 168.6 
6 hour 99.3 7.1 32.1 57.5 
Patient 5 
1 hour 341.7 7.1 12.8 1.6 
6 hour 267.7 6.1 12.5 1.1 
Patient 6 
1 hour NA NA NA NA 
6 hour NA NA NA NA 
Patient 7 ♯ 
1 hour 352.7 13.2 207.7 64.4 
6 hour 169.9 4.0 178.9 26.4 
Patient 8 
1 hour 187.3 31.2 80.9 38.3 
6 hour 65.9 10.6 31.3 12.8 
Patient 9 
1 hour 189.3 10.3 166.2 52.1 
6 hour 68.4 4.3 59.1 22.9 
Patient 10 
1 hour 80.0 7.1 42.2 27.9 
6 hour 35.5 4.2 21.1 13.8 
Table 30 Mean serum drug concentrations 1- and 6-hours post-DEBIRI (n=3 
separate measurements). NA=patients were not sampled for serum as they had 
already received DEBIRI and were awaiting resection when recruitment started 
♯=UGT1A1*28 6/7 heterozygotes 
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Figure 48 Composite graphs showing serum concentrations of (A) 
irinotecan, (B) SN-38, (C) SN-38G and (D) APC for 8 patients at 0, 1 and 6 
hours post-DEBIRI. No drug or metabolite was detectable in any patients at 
30 days. 
 
 
199 
 
There was a clear correlation between dose of DEBIRI and 1 and 6-hour serum irinotecan 
concentrations (r2=0.89 p=0.0001 and r2=0.65 p=0.016 respectively, see Figure 49). There 
was no correlation between dose of administered DEBIRI and SN-38 at 1 and 6 hours 
(r2=0.15, p=0.72 and r2=0.36, p=0.39) 
 
Figure 49 Scatter plot showing correlation between dose of DEBIRI and serum 
concentrations of irinotecan at 1 and 6 hours. 
To correct for variations in delivered drug dose, ratios of SN-38 to irinotecan were 
calculated for each patient. In all eight patients the ratio of metabolites was comparable at 
1 and 6 hours (table 30, Figure 48). However, there was wide interpatient variation in 
these ratios, suggesting differences in the activation of irinotecan between patients.  
There was no clear relationship between serum concentration of irinotecan and SN-38 
(r2=<0.01, p=0.92) or APC (r2=0.07, p=0.29), or SN-38 and SN-38G (r2=0.27, p=0.51). 
There was no difference in the ratio of SN-38G:SN-38 between UGT1A1*28 6/6 and 6/7 
patients (p=0.79). 
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Figure 50 Column chart showing ratio of SN-38:irinotecan measured in serum 1 and 
6 hours after TACE showing similar ratios of drug and metabolite. Patients 1 and 6 
were not sampled for serum as they had already received TACE and were awaiting 
resection when recruitment started. 
4.3.5.2 Hepatic parenchymal protein expression and serum drug concentrations 
Patients were divided into 2 groups (high and low) based on median microsomal protein 
expression (quantified by Western blotting) to try and identify possible cut-offs. Patients 
with low CES-1 showed no difference in SN-38:irinotecan ratio to those with high CES -1 
(0.40 vs. 037, p=0.91) (Figure 51). Patients with high CES-2 had a non-significant 
increase in the ratio of SN-38:irinotecan (0.55 vs. 0.23, p=0.11) whilst patients with high 
CYP3A4 had a non-significant increase in APC:irinotecan ratio (0.58 vs. 0.33, p=0.2). 
Patients with high UGT1A1 expression had a non-significant trend towards an increased 
SN-38G:SN-38 ratio (6.78 vs. 2.35, p=0.05). 
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Figure 51 Box and whisker plots of serum drug and metabolite concentrations stratified by 
microsomal protein expression quantified by iTRAQ (High = > median, Low = < median). 
Dark horizontal line = median, red box = interquartile range, whiskers = minimum & 
maximum value. (A) Patients with low CES-1 showed no difference in SN-38:irinotecan ratio 
to those with high CES -1 (0.40 vs. 037, p=0.91). (B) Patients with high CES-2 had a non-
significant increase in the ratio of SN-38:irinotecan (0.55 vs. 0.23, p=0.11). (C) Patients with 
high UGT1A1 expression had a non-significant trend towards an increased SN-38G:SN-38 
ratio (6.78 vs. 2.35, p=0.05) whilst patients with high CYP3A4 (D) had a non-significant 
increase in APC:irinotecan ratio (0.58 vs. 0.33, p=0.2).  
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4.3.6 Microsomal metabolism of irinotecan !
4.3.6.1 Microsomal metabolite production 
Incubations were performed to compare the metabolic activity of each relevant 
pathway in the metabolism of irinotecan. Microsomal fractions were used as they 
are enzyme enriched, maximizing drug turnover. Microsomal incubations 
demonstrated wide variation in drug metabolism (Table 31, Figure 52). SN-38 
varied 4-fold from 0.52-2.19 pmol mg-1 min-1. APC was much lower, varying 2.4 fold 
from 0.1-0.24 pmol mg-1 min-1. UGT1A1 varied 2-fold, from 0.3-0.59 pmol mg-1 min-1. 
Relative amounts of SN-38G to SN-38 varied from 26.2-81.6%. For both APC and 
SN-38G, the amount of analyte on column for this level of drug was close to the 
nominal lower limit of quantification for the assay (See section 3.3.3.4). 
 SN-38 (pmol 
mg-1min-1) 
APC (pmol 
mg-1min-1) 
SN-38G (pmol 
mg-1min-1) 
Patient 1 1.13±0.24 0.14±0.02 0.46±0.04 
Patient 2 ♯ 1.12±0.18 0.21±0.02 0.59±0.04 
Patient 3 ♯ 0.60±0.14 0.23±0.02 0.34±0.01 
Patient 4 1.11±0.16 0.24±0.04 0.55±0.07 
Patient 5 0.89±0.13 0.16±0.01 0.33±0.02 
Patient 6 2.19±0.27 0.22±0.05 0.58±0.04 
Patient 7 ♯ 0.76±0.10 0.10±0.02 0.30±0.01 
Patient 8 0.91±0.09 0.19±0.04 0.37±0.02 
Patient 9 0.93±0.13 0.20±0.04 0.34±0.01 
Patient 10 0.52±0.10 0.14±0.02 0.42±0.03 
Table 31 Microsomal drug metabolism (±SD) (n=3 separate incubations) 
♯=UGT1A1*28 6/7 heterozygotes 
 
 
203 
 
Figure 52 Column chart showing amount of metabolite present after 
microsomal incubation of 500 nM irinotecan for 120 minutes. (Column = mean 
of 3 incubations, bars = SD). 
 
There was a positive correlation between the amount of SN-38 present in an 
incubation and the absolute amount of SN-38G (r2=0.67, p=0.03). There was also a 
clear negative association between the amount of SN-38 present and the relative 
proportion of SN-38 glucuronidated (r2=0.64, p=0.04) suggesting that the 
glucoronidation pathway has relatively low capacity (Figure 53).  
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Figure 53 Scatter plots showing relationship between microsomal SN-38 and 
absolute and relative SN-38G. As SN-38 increases, so does the presence of 
SN-38G. However, relative glucuronidation decreases with increasing SN-38 
suggesting a relatively low capacity pathway.   
4.3.6.2 Hepatic parenchymal expression and microsomal drug production 
The presence of SN-38 was clearly related to microsomal CES-2 expression 
(r2=0.95, p<0.001) (Figure 54). No correlation was found between APC and 
CYP3A4 expression (r2=0.05, p=0.53) or SN-38 and CES-1 expression (r2=0.08, 
p=0.45) using either WB or iTRAQ. There was no correlation between expression of 
UGT1A1 and amount of SN-38 (r2=0.25, p=0.15) suggesting that inactivation of SN-
38 by glucuronidation was unlikely to have an effect of the availability of SN-38 at 
physiologically relevant doses. There was a strong relationship between the 
glucuronidation of SN-38 to SN-38G and UGT1A1 expression (r2=0.75, p=0.01). 
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Figure 54 Scatter plots showing correlation between microsomal drug metabolism and 
microsomal protein expression quantified by Western blot. SN-38 was clearly related to 
microsomal CES-2 expression (r2=0.95, p<0.001). There was also a strong relationship 
between the glucuronidation of SN-38 to SN-38G and UGT1A1 expression (r2=0.75, p=0.01). 
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4.3.7 Correlation between metabolic profile and pathological tumour response  !
4.3.7.1 Serum concentration and pathological response 
Absolute serum concentration of SN-38 at 1 and 6 hours showed no relationship 
with proportion of viable tumour (r2=0.003, p=0.88), degree of necrosis (r2=0.22, 
p=0.24) or fibrosis (r2=0.07, p=0.54). The lack of correlation between pathological 
tumour response and serum absolute or relative levels of SN-38 suggests single 
time point assessment of serum metabolites is a poor predictor of local tumour 
destruction. 
!!
4.3.7.2 Protein expression and pathological response 
The association between parenchymal protein expression and pathological 
response was weak. However, microsomal expression of CES-2 and fibrosis 
showed a clear trend that approached statistical significance (r2=0.3948, p=0.052) 
(Figure 55).  
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Figure 55 Scatter plot showing relationship between hepatic parenchymal 
expression of CES-2 and tumour fibrosis after neoadjuvant DEBIRI-TACE. 
 
4.3.7.3 Microsomal production and pathological response 
A highly significant association between microsomal SN-38 and degree of tumour 
fibrosis was observed (r2=0.41, p=0.01), with a moderate correlation between 
microsomal SN-38 and degree of tumour necrosis (r2=0.40, p=0.07). There was no 
correlation between SN-38 and overall tumour viability (r2=0.001, p=0.48) (Figure 
56).
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Figure 56 Scatter plots showing correlation between microsomal SN-38 and 
validated pathological markers of tumour response (viable tumour, necrosis and 
replacement by fibrosis). 
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4.4 Discussion 
The purpose of the experiments described in this chapter were to assess the 
variation in expression of key enzymes involved in the disposition of irinotecan 
across a panel of 10 patients treated with neoadjuvant DEBIRI-TACE and to relate 
this variation to differences in metabolic profile. The dataset was then further 
analysed to investigate the relationship between this metabolic profile and clinical 
outcome. 
Targeted proteomic analysis using Western blot and iTRAQ showed wide variation 
between patients in the expression of key proteins involved in the metabolism of 
irinotecan. Previous studies have suggested a 15-fold variation in cytosolic 
expression of CES-2, with a 3 fold variation in microsomal expression  (Xu et al., 
2002) as well as two-fold variation in the hepatic expression of CYP3A4! (Wolbold et 
al., 2003). The current study demonstrated similar variations in expression of CES-
2. However, variation in expression of CYP3A4 assessed by Western blotting 
demonstrated a much smaller range. In contrast, quantification using iTRAQ 
demonstrated fold-change in keeping with previous reports. The discrepancy may 
be explained by the relative specificity of each approach. CYP3A4 shares >80% 
sequence homology with CYP3A43, CYP3A7 and CYP3A5  (Redlich et al., 2008).  
Similarly, UGT1A1 shares 73% amino acid sequence identity with other UGT1As  
(Yang et al., 2012). Conversely, sequence homology between CES-2 and CES-1 is 
only 46%  (Holmes et al., 2010). These similarities may explain the fact that 
quantification by Western blotting and iTRAQ do not precisely mirror each other. 
Existing evidence surrounding the relationship between UGT1A1 genotype and 
drug efficacy and toxicity is conflicting. The UGT1A1*28 6/7 polymorphism has been 
reported in around 39% of Europeans, with 13% having the 7/7 SNP!  (Liu et al., 
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2007). This study found comparable incidence in a relatively small cohort, with 30% 
carrying the 6/7 SNP. In this series, 6/7 heterozygotes demonstrated no difference 
in UGT1A1 protein expression quantified by either Western blot or iTRAQ. 
Unsurprisingly, there were no differences in serum concentration of SN-38G 
between 6/6 and 6/7 patients, nor were there any differences in microsomal drug 
metabolism. These findings suggest that for the dose of irinotecan delivered during 
DEBIRI-TACE the presence of a UGT1A1*28 SNP does not affect treatment 
efficacy. Systemic toxicity after the administration of irinotecan normally manifests 
as diarrhoea and neutropenia, presumably caused by the accumulation of SN-38 in 
the gut and bone marrow. The UGT1A1*28 SNP!has been implicated in higher rates 
of toxicity after systemic delivery  (Iyer et al., 1998). However, there were no 
instances of irinotecan toxicity in the PARAGON II trial (see section 2.3.2), with 
similar findings reported in previous cohort studies. It therefore seems unlikely that 
UGT1A1*28 SNP is associated with increased toxicity after DEBIRI-TACE, 
presumably because of the relatively low dose of irinotecan delivered during 
embolisation. However, further large prospective studies are required to definitively 
answer this question.  
Analysis of serum drug concentrations allowed broad assessment of systemic 
exposure to drug and metabolites after treatment. A correlation between the dose of 
irinotecan administered and exposure to both irinotecan and SN-38 has been 
suggested in previous pharmacokinetic studies (Rouits et al., 2008) and although 
the current study did not perform formal pharmacokinetic analysis, there was a clear 
correlation between dose of DEBIRI and serum concentration of irinotecan 1 and 6 
hours post-TACE. The lack of correlation between SN-38 concentration and 
delivered dose suggests significant differences in patient drug metabolism. Serum 
drug and metabolite concentrations did not show any relationship with degree of 
tumour fibrosis or hepatic parenchymal metabolism, suggesting that assessment of 
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drug activation by measurement of serum drug concentration at a single time point 
is a poor predictor of hepatic drug metabolism. However, when serum 
concentrations were divided into 2 groups based on parenchymal protein 
expression there was a non-significant trend towards increased serum 
concentration in patients expressing high levels of the relevant protein for each key 
metabolite, suggesting that it may be possible to approximate hepatic irinotecan 
metabolism by measuring peripheral levels of drug metabolites. More 
comprehensive serum sampling strategies would offer further insight. 
At a microsomal level, CES-2 expression showed a very strong correlation with 
amount of SN-38 confirming that this is the key hepatic enzyme in this activation 
step. Expression of CYP3A4 did not impact on microsomal activation of irinotecan, 
suggesting saturation of the CES-2 pathway at physiologically relevant doses. 
Increasing concentrations of SN-38 led to increasing concentrations of SN-38G. In 
each case the amount of SN-38G was consistently less than the amount of SN-38 
(26.2-81.6%). This contrasts with the serum drug concentrations where SN-38G 
was consistently 3-4 times higher than SN-38. The relative conversion of SN-38 to 
SN-38G (as defined by ratio of SN-38G:SN-38) showed a negative correlation with 
the concentration of SN-38, suggesting that within the microsomal model system 
this remains a low capacity system that cannot limitlessly increase glucuronidation 
as required. The ability of hepatic microsomes to activate irinotecan into SN-38 
clearly correlated with tumour replacement by fibrotic tissue, suggesting that local 
drug activation in surrounding hepatic parenchyma is the key step in the 
effectiveness of DEBIRI with CES-2 the key enzyme in this pathway. 
Assessing the relationship between drug metabolism and pathological response 
within the PARAGON trial is limited by a number of factors. Pathological response 
was assessed using a relatively crude scoring system. This system has been 
validated in large series of resected CRLM. In these large series, any potential 
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sampling or scoring errors would have minimal effect on overall results. By contrast, 
in a small series of 10 patients under- or over-assessing tumour response could 
lead to marked distortion in results. The pathological tumour response assessment 
did not assess location of beads within lesion, proximity of beads to tumour and 
embolisation pattern – for example, central vs. peripheral embolisation.  There also 
remains the possibility that inherent differences in tumour genotype and phenotype 
may vary response to DEBIRI. A global proteomic assessment of resected tumour 
is currently being undertaken using iTRAQ. However, this post hoc analysis is 
limited by selection bias. Tumour tissue that remains is likely to have a DEBIRI-
resistant phenotype, with sensitive tumour tissue likely to have been destroyed 
during embolisation.  
In conclusion, these data show that there is large inter-patient variability in the 
hepatic expression of key irinotecan metabolizing enzymes particularly CES-2 
which is responsible for the formation of the active component SN-38. These wide 
variations clearly correlate with the ability of hepatic microsomes to activate 
irinotecan, and suggest patients who are better able to activate irinotecan within 
normal tissue surrounding tumour achieve better rates of tumour response after 
locoregional DEBIRI. The data in this small pilot study provide preliminary evidence 
for the use of hepatic metabolic profiling as an approach to predict response to 
locally delivered irinotecan chemotherapy, and suggests a pharmacological 
rationale for whole lobe embolisation for CRLM. 
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5 Concluding Discussion !  
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Chemotherapy before surgery is an integral part of the treatment algorithm for 
patients with colorectal liver metastases. For patients with irresectable disease, 
chemotherapy offers the only opportunity to bring patients to potentially curative 
surgery. For patients with high-risk resectable disease, chemotherapy offers a test 
of tumour biology as well as treating occult disease reducing the risk of recurrence 
therefore improving long-term outcome.  
The safety of neoadjuvant systemic chemotherapy before surgery has been 
demonstrated in a number of studies (Wein et al., 2003; Taïeb et al., 2005; 
Gruenberger et al., 2008; Nordlinger et al., 2008). However, the safety of 
neoadjuvant DEBIRI has not previously been shown. The PARAGON II trial 
reported in this thesis clearly demonstrated the safety and feasibility of delivering 
locoregional neoadjuvant DEBIRI prior to surgical resection. As well as the low rates 
of peri-procedural morbidity, no patients demonstrated any manifestations of 
systemic irinotecan toxicity. Although systemic triplet chemotherapy has been 
shown to increase response rate and overall survival, its use has been limited by 
high rates of toxicity. A phase III study comparing FOLFIRI vs. FOLFOXIRI 
demonstrated a doubling in the number of toxicity-related treatment breaks in the 
FOLFOXIRI arm, as well as increases in neurotoxicity and neutropenia  (Falcone et 
al., 2007). The absence of chemotoxicity reported in the PARAGON II trial suggest 
that the addition of DEBIRI may allow the delivery of systemic FOLFOX with liver-
targeted irinotecan allowing synergistic activity to occur at the site of the greatest 
tumour burden without overlapping systemic toxicity.  
This trial also demonstrated no compromise in surgical safety for liver resection 
after treatment with DEBIRI, with low post-operative morbidity and no increase in 
post-operative mortality directly attributable to treatment. Irinotecan-induced CALI is 
clearly associated with post-operative mortality and the reassuringly low rates of 
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background liver injury reported in this series suggest that single treatment DEBIRI 
do not increase the incidence of liver injury. 
The pathological response rates reported after a single treatment are impressive, 
with 76% of lesions showing a major or complete pathological response. These 
results compare favourably with response rates seen after multiple cycles of 
systemic cytotoxic and targeted biological therapies reported by other groups (See 
table 32). However, it is important to recognize that patients selected for PARAGON 
II will by definition have relatively low-risk tumour biology. All patients had limited 
intrahepatic lesions and were deemed not to require neoadjuvant therapy by a 
specialist liver MDT. By contrast, most published series reporting pathological 
response rates include a mix of initially irresectable lesions, as well as oncologically 
high-risk patients in whom a course of preoperative therapy was deemed 
necessary. The response rates to DEBIRI may therefore represent a subgroup with 
high levels of chemo-susceptibility as well as the effectiveness of treatment. 
It has been suggested that larger lesions have inadequate vascular supply to 
maintain viable tumour and that some tumour necrosis and fibrosis may be 
explained by inadequate perfusion rather than the effect of chemotherapy! 
(Poultsides et al., 2012). The evidence supporting this hypothesis is conflicting, with 
Blazer et al suggesting that tumour size >3cm was an independent predictor of 
major/complete pathological response (Blazer et al., 2008). By contrast Rubbia-
Brandt et al (Rubbia-Brandt et al., 2007) found no correlation between size and 
response, although there were no complete responses in tumors ≥2 cm. 
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 FOLFOX  +  
Bevacizumab 
FOLFOX FOLFIRI + 
Bevacizumab 
FOLFIRI DEBIRI 
(PARAGON II) 
Number of patients 81 
 
50 
 
27 113 
 
40 
Median treatment 
time (Weeks) 
10 12 20 16 - 
Complete 8.6% 12.0% 11.1% 8.0% 17.0% 
Major 54.3% 32.0% 29.6% 25.7% 59.0% 
Minor 37.1% 56.0% 59.3% 66.3% 24.0% 
 
Table 32 Pathological response rates reported after neoadjuvant treatment 
with systemic chemotherapy  (Blazer et al., 2008). Lesions treated with a 
single treatment with DEBIRI-TACE have a superior complete and major 
pathological response rate to lesions exposed to multiple cycles of systemic 
therapy. 
 
The PARAGON II study reported a median lesion size of 21mm (range 4-150) and 
although there was a statistically significant difference in median lesion size 
between minor (18mm) and major response (40 mm), and major and complete 
(19mm), the fact that the major response group tended to have larger lesion size 
than the complete response group makes it unlikely that pathological response after 
DEBIRI-TACE can be explained by size alone. In this study, three patients with 
lesions greater than 2cm exhibited a complete pathological response and it may be 
that the targeted mechanism of delivery of DEBIRI-TACE allows it to better achieve 
high rates of pathological response in large lesions. 
The intra-operative identification of previously untreated lesions allows direct 
assessment of tumour response attributable to DEBIRI. The large amount of viable 
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tumour observed in lesions supplied by arterial flow proximal to the point of bead 
release and the absence of tumour in previously unidentified lesions targeted by 
lobar embolisation supports the hypothesis that tumour fibrosis and necrosis is 
directly attributable to treatment with DEBIRI, and provides an oncologic rationale 
for very proximal whole lobe embolisation. These results suggest that undetected 
micrometastatic lesions within a lobar embolisation zone could be as effectively 
treated as lesions that are identified preoperatively and more selectively embolised. 
This finding is important for the design of future trials with lobar treatment with 
irinotecan bead being effective at destroying occult micrometastases. 
Importantly, radiological assessment of tumour response 4 weeks after treatment 
did not reflect degree of tumour destruction or correlate with long-term outcome. 
Similar findings have been reported after treatment with other locoregional embolic 
therapies! ! (Kennedy et al., 2013). However, these findings are in contrast to 
previously reported series of DEBIRI. A large US led registry of heavily pretreated 
patients with colorectal liver metastases treated with DEBIRI reported a 3-month 
RECIST tumour response rate of 65% with 12% of patients showing complete 
response and 53% showing partial response (Martin et al., 2009), whilst an Italian 
phase II randomized study reported 69% of patients having complete or partial 
response after a median of 2 cycles of DEBIRI, compared to 20% in those treated 
with systemic FOLFIRI. This increased response rate clearly correlated with 
improved progression free survival (Fiorentini et al., 2012). One possible 
explanation of the apparently contradictory findings of these studies and the current 
study may be the time period between treatment and radiological assessment. 
Embolisation leads to tumour infarct, after which lesions become ischaemic and 
oedematous which may cause an apparent increase in size. Over time, this oedema 
and inflammation settles with characteristic tumour replacement by fibrotic tissue 
(Poultsides et al., 2012) followed by centripetal contraction leading to a reduction in 
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tumour volume (Ng et al., 2008). Early imaging may therefore capture the swollen 
oedematous phase of the tumour response that occurs prior to eventual fibrotic 
involution. These findings have clear clinical implications for the design of any future 
trials involving DEBIRI where early assessment of tumour response is used to guide 
management. Contemporary trials investigating the treatment of irresectable 
colorectal liver metastases have traditionally administered between 4 and 8 cycles 
of therapy followed by radiological assessment of response (Folprecht et al., 2010; 
Garufi et al., 2010). For systemic treatments, this assessment may take place within 
2 weeks of the final cycle of therapy.  The future role of DEBIRI is likely to be 
alongside systemic therapy for liver-dominant disease, and it is therefore important 
that any trial design involves early administration of DEBIRI followed by multiple 
cycles of systemic therapy to allow adequate time for tissue inflammation to settle 
and to allow a more accurate assessment of tumour response. 
Despite relatively short follow up after resection, median DFS was 379 days with a 
nominal 1-year DFS of 56%. Although this may appear high, meta-analysis has 
demonstrated that around 65% of patients undergoing hepatectomy for CRLM will 
develop disease recurrence within 2 years  (Jones et al., 2012). The targeted 
administration of DEBIRI within the PARAGON II protocol meant that tissue 
exposed to treatment was then resected. Occult disease within the future liver 
remnant was therefore not treated, and it is therefore unsurprising that rates of 
recurrence remain in keeping with those reported in chemonaïve patients. 
Multivariate analysis of PARAGON II patients identified only KRAS status as a 
prognostic marker for long-term outcome after resection. The prognostic importance 
of KRAS status in colorectal cancer is controversial and the data often contradictory  
(Umeda et al., 2012; Lee et al., 1996; Stremitzer et al., 2012). However, the 
RASCAL II multicentre study assessed over 3000 patients with all stages of 
colorectal cancer and demonstrated that those with a KRAS mutation had an 
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increased risk of recurrence and death (Andreyev et al., 2001)!whilst the MSKCC 
group recently reported a trend towards reduced overall and disease free survival 
for patients undergoing resection of KRAS mutant colorectal liver metastases  
(Kemeny et al.,  2012).  In the current study, KRAS mutation was independently 
associated with worse DFS. Pathological response showed no relationship with 
KRAS status, suggesting that KRAS has a prognostic but not predictive role in this 
cohort. However, 3 patients could not be KRAS typed because of lack of viable 
tumour after treatment and this remains a potential source of bias. No BRAF 
mutations were identified in this study. Previous series that have reported very low 
rates of BRAF resection in patients with colorectal liver metastases that come to 
resection (Andreou et al., 2012) compared to primary colorectal cancers (Vakiani et 
al., 2012), suggesting BRAF mutant tumours have more aggressive biology and 
once metastasised are unlikely to become resectable. Future treatment approaches 
are likely to rely heavily on the direct analysis of tumour biology to define the 
optimal treatment approach. Although concordance between primary and metastatic 
tumour is high for many recognized mutations (PI3KC, RAS, BRAF)  (Vakiani et al., 
2012), it seems likely that assessment of the metastatic lesion by direct sampling or 
circulating tumour cell analysis will be necessary to compensate for subtle changes 
in phenotype between primary and metastatic tumour  (Gerlinger et al., 2012).  
As will as the development of prognostic markers to identify patients most likely to 
benefit from surgical intervention, there is growing interest in predictive biomarkers 
to guide the optimal chemotherapeutic approach.!These markers will help to identify 
patients who will respond well to cytotoxic agents, offering the promise of a stratified 
treatment approach with increased treatment efficacy whilst minimizing 
unnecessary toxicity. Tumour expression of genes and proteins involved in the 
metabolism of chemotherapeutic agents have previously been investigated as 
predicting benefit from cytotoxic therapies  (Kornmann et al., 2003), with TOPO-1 
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suggested as a potential predictive marker for irinotecan  (Braun et al., 2008). There 
is now growing interest in drug metabolism in surrounding normal tissue as an 
important factor in defining tumour response.  
Irinotecan appears a possible target for such an approach, as conversion into the 
active metabolite SN-38 is required for the cytotoxic effect. Yu et al demonstrated 
low levels of CES-2 in colonic cancer compared to normal adjacent colon  (Yu et al., 
2005), and in vitro modelling has shown the conversion of irinotecan to SN-38 in 
hepatic tissue  (Rivory et al., 1996; Mathijssen et al., 2001) which contains high 
levels of CES-2 compared to tumour  (Guichard et al., 1999).  DEBIRI allows 
targeted delivery of irinotecan directly to liver tissue and tumour, where it achieves 
high local concentrations  (Taylor et al., 2007). It is therefore plausible that the high 
level of CES-2 in hepatic parenchyma lead to local drug activation that can then 
diffuse into tumour cells causing death. However, this relationship has never been 
directly assessed. This study is the first to investigate local activation of drug within 
normal tissue surrounding tumour as a predictor of response.  
Assessment of serum concentrations of irinotecan and SN-38 demonstrated much 
lower levels than previously reported after intravenous administration of comparable 
doses of drug (de Jonge et al., 2000; Rouits et al., 2004). De Jonge et al reported a 
peak irinotecan and SN-38 concentration of 7.6 µM and 130 nM 1.6 hours after the 
administration of 175-300 mg m-2 of irinotecan, compared to 188.3 nM and 10.2 nM 
in this study. The much lower levels of systemic irinotecan detected in PARAGON II 
likely reflect both the lower dose of drug administered as well as high rates of first-
pass metabolism seen after hepatic intra-arterial delivery. This low systemic 
exposure to irinotecan may provide an explanation for the absence of systemic 
toxicity seen after treatment with DEBIRI. Interestingly, the relative proportion of 
irinotecan converted to SN-38 in the current study is much higher than that reported 
after intravenous administration and suggests that intra-hepatic delivery results in 
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high levels of drug activation. Liver-directed delivery of irinotecan therefore seems a 
sensible approach to maximize the activation of irinotecan whilst limiting systemic 
exposure. Interestingly, wide interpatient variations in serum drug and metabolite 
concentration were observed after treatment suggesting inherent differences in 
patient drug metabolism. However, these did not correlate with pathological tumour 
response or with hepatic drug metabolism. One possible explanation may be that 
extra-hepatic drug metabolism (e.g. within the gut) alters serum concentrations. 
Alternatively, Tmax may vary between patients because of inherent differences in 
hepatic metabolic capacity. More formal drug pharmacokinetic modeling would go 
some way to answering this question. 
By contrast, the ability of hepatic microsomes to activate irinotecan into SN-38 
clearly correlated with tumour replacement by fibrotic tissue, suggesting that local 
CES-2 mediated drug activation in surrounding hepatic parenchyma is the key step 
in the effectiveness of DEBIRI. The hypothesis that fibrosis is the predominant 
chemotherapy-induced pathologic change in CRLM was first suggested by Rubbia-
Brandt et al  (Rubbia-Brandt et al., 2007) and it has since been shown that patients 
with a large fibrotic response have improved long term outcome  (Poultsides et al., 
2012). This finding suggests that proximal embolisation, with DEBIRI delivered to a 
wide area of normal parenchyma rather than tumour tissue, may be a more rational 
approach to maximise conversion of irinotecan to SN-38 and therefore tumour 
response.  
These results suggest that assessing patients’ hepatic metabolic profile may allow 
selection of those who are most likely to benefit from DEBIRI. Single serum drug 
concentrations appear to be a poor surrogate of hepatic metabolism, although there 
was a non-significant correlation between parenchymal protein expression and 
serum concentrations suggesting this area may warrant further research. Previous 
attempts to correlate systemic activation of irinotecan and CES-2 expression in 
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peripheral blood monocytes have been inconclusive  (Cecchin et al., 2005), whilst 
other proposed markers of hepatic CES-2 activity have produced conflicting results  
(Guemei et al., 2001; Shingyoji et al., 2004) . There is currently therefore no good 
surrogate for directly assessing hepatic CES-2 expression. Directly assessing 
hepatic parenchyma is straightforward for patients who are being selected for 
adjuvant therapy – normal parenchyma will be removed as part of routine liver 
resection. For patients who are treated with neoadjuvant or conversion intent this is 
more difficult. One option is liver biopsy, although this is not risk-free  (Silva et al., 
2008). However, any risk must be balanced against the potential benefits of 
effective chemotherapy and the avoidance of unnecessary toxicity. The ability to 
characterise individual drug metabolic profiles may be especially important in 
patients who have CALI, with both CYP3A and CES-2 pathways impaired in 
patients with parenchymal liver damage  (d'Esposito et al., 2010). Another rational 
approach may be to induce the expression of CES-2. CES-2 is under the direct 
control of the transcription factor NRF-2 (nuclear factor erythroid 2-related factor 2), 
and induction of NRF-2 by butylated hydroxyanisole can increase CES-2 expression  
(Zhang et al., 2012). Dietary factors such as flavonoids (found in green leafy 
vegetables) are known to induce NRF-2 in man, suggesting that alterations in diet 
may increase irinotecan activation  (Leonardo et al., 2011).  As the amount of drug 
that can be delivered by beads is directly limited by their loading capacity! (Lewis et 
al., 2006), the ability to maximize the local activation of drug remains an attractive 
approach to maximize local response. The fully validated bioassay developed as 
part of this thesis allows the assessment of irinotecan and its metabolites in a 
number of biological matrices, and this assay is now integral to preliminary animal 
modelling performed within our group which has demonstrated reduced hepatic 
irinotecan metabolism within NRF-2 knockout mice, with CES-1 and CES-2 under 
direct transcriptional control. This work has recently been awarded a large grant 
from North West Cancer Research. 
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Future work will be required to identify the precise role of DEBIRI-TACE in the 
treatment algorithm for stage IV colorectal cancer, with early evidence suggesting 
that combination treatment alongside systemic chemotherapy (so called 
FOLFOXDEBIRI) is safe with minimal increase in toxicity compared to FOLFOX 
alone  (Martin et al., 2012). A large multicenter, open-label, two-arm phase III study 
(PARAGON III) has now been developed to formally assess DEBIRI alongside 
systemic chemotherapy. The study aims to evaluate whether the addition of DEBIRI 
to current first line chemotherapy increases the number of patients with initially 
irresectable colorectal liver metastases converted to resection. The primary 
endpoint will be conversion to resection, with secondary endpoints to include 
surgical and chemotherapeutic safety, overall survival and progression free survival. 
Because of its known prognostic value, patients will be stratified prior to 
randomization based of KRAS status to ensure equal distribution. The experimental 
arm (Figure 57) will involve administration of 4 cycles of standard systemic 
chemotherapy (FOLFOX + Bevacizumab) with 2 lobar treatments with DEBIRI, 
whilst the control arm will involve 4 cycles of systemic chemotherapy alone. After 4 
cycles, patients will be re-imaged and discussed at a specialist liver MDT. Those 
who have become resectable will be offered surgery, whilst those who demonstrate 
no response will move to second-line systemic therapy. Patients demonstrating a 
partial response but who remain irresectable will be offered a further 4 cycles of 
therapy with 2 further DEBIRI treatments.  The study is powered to detect an 
increase in resectability from 28% to 42%. 490 patients will be recruited to give an 
80% power and 5% two-sided significance with a 20% anticipated drop out. 
Because of work developed as part of this thesis, embolisation will adopt a whole 
lobe administration strategy to maximize tumour response and treatment efficacy. 
DEBIRI will also be delivered early in the chemotherapeutic cycle to allow 
peritumoural oedema to resolve prior to radiologic assessment. PARAGON III will 
also involve a translational component that will validate hepatic metabolism of 
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irinotecan as a predictive marker of response using the LC-MS/MS assay 
developed in this thesis, as well as attempt to develop non-invasive methods of 
assessment of drug metabolism and response. 
In conclusion, the work presented in this thesis clearly demonstrates the feasibility, 
safety and efficacy of neoadjuvant DEBIRI for the treatment of colorectal liver 
metastases. It also provides clear evidence that proximal whole lobe 
chemoembolisation is an oncologically and pharmacologically rational approach. 
This proximal delivery not only results in destruction of occult micrometastases, but 
also maximizes the exposure of CES-2 rich normal hepatic parenchyma to 
irinotecan maximising the interconversion to SN-38 maximising treatment response.  
These findings have been used to guide the development of a large phase III 
clinical study, where continued translational work will take place to confirm these 
findings in a larger randomized patient cohort. 
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!
Figure 57 CONSORT diagram for PARAGON III phase III RCT of systemic chemotherapy 
+/- DEBIRI-TACE for irresectable liver limited metastatic colorectal cancer. Because of 
the known prognostic value of KRAS, patients will be stratified based on KRAS status to 
ensure equal distribution between both arms.
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Summary!
Plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38, 
were available from 10 patients following intra-arterial administration of irinotecan-loaded DC 
bead microspheres at doses of 36-143 mg (average 85 mg) irinotecan (target dose of 400 
mg irinotecan).  Pharmacokinetic analysis of the concentration-time data resulted in the 
following mean pharmacokinetic parameters; 
 
Cmax  
(ng/mL) 
Tmax 
(h) 
AUCt  
(ng.h/mL) 
AUC24 
(ng.h/mL) 
AUC 
(ng.h/mL) 
λz 
(1/h) 
t1/2 
(h) 
Irinotecan        
Mean 194 2a 1510 1520 1680 0.1502 4.6b 
SD 124  1050 1040 1200 0.1346  
        
SN-38        
Mean 16.7 1a 147 147 281 0.0559 12.4b 
SD 11.3  99 99 352 0.0238  
        
a 5.1 Value is the median 
b 5.2 Calculated as ln2/mean λz 
NB Mean values for AUC, λz and t1/2 must be treated with caution as data from the majority 
of the patients did not meet the acceptance criteria defined in Data Processing 
Intra-arterial  injection of irinotecan-loaded DC bead microspheres at a nominal dose level of 
400 mg irinotecan resulted in a mean maximum plasma concentration of 194 ng/mL 
irinotecan at a median time of 2 hours post-dose.  The mean maximum plasma 
concentration of the pharmacologically active metabolite, SN-38, was much lower, 16.7 
ng/mL at a median time of 1 hour post-dose.  Inter-individual variability was greater than 
50% for irinotecan (CV% = 63.8%) and for SN-38 (CV% = 67.8%).  The mean metabolite 
ratio (SN-38/irinotecan) was low, 0.10, but as SN-38 is more potent than irinotecan, the 
metabolite concentrations would be more effective than the irinotecan concentrations. 
The terminal half-life of irinotecan in was determined to be in the range 1.6-7.2 hours.  The 
equivalent data for SN-38 were 7.6-8.5 hours. 
Sample analysis!
Plasma concentrations of irinotecan and SN-38 were measured using an HPLC procedure 
previously validated at CentraLabS Clinical Research (CentraLabS Clinical Research report 
number BCP 0252/062564).  The bioanalytical method is described in the validation report. 
Sample measurements were generated in three successful analytical batches. 
QC samples prepared during the previous validation study (CentraLabS Clinical Research 
BCP0252) were used during this study. 
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The analytical equipment, instrumentation and reagents used in this study, and as recorded 
in the raw data, were equivalent to those used during the validation study.  Any changes had 
no impact on the conduct or validity of the study. 
 
Results!
Following treatment, maximum measured plasma concentrations of irinotecan generally 
occurred at 2 hours post-dose and in the range 0.08 – 2 hours whereas maximum measured 
plasma concentrations of the metabolite SN-38 generally occurred at 1 hour post-dose and 
in the range 1-2 hours.   
The lack of sample times between 6 and 24 hours post-dose resulted in a paucity of data for 
the determination of the terminal half-lives of irinotecan and SN-38.  In fact, it was not 
possible to determine accurately a terminal half-life for irinotecan in 7 of the 10 patients for 
this reason.  Nor was it possible to determine accurately a terminal half-life for SN-38 in 7 of 
the 10 patients.  As a further consequence of the paucity of sample times between 6 and 
24 hours post-dose, it was not possible to determine accurately AUC for the majority of the 
patients (7/10 for irinotecan; 8/10 for SN-38).  Therefore the values presented in the tables 
for mean AUC, λz and t1/2 are intended as guidelines only. 
Determination of the ratio of AUC24 SN-38 to AUC24 irinotecan (metabolite ratio, not adjusted 
for molecular weight) resulted in a mean value of 0.10 and indicated that formation of SN-38 
from irinotecan was limited.  
At the request of the Sponsor, pharmacokinetic parameters of irinotecan and SN-38 were 
calculated from plasma concentration-time data up to 6 hours post-dose only. Again, an 
accurate half-life could not be determined in the majority of the subjects. 
Discussion!
Intra-arterial injection of irinotecan-loaded DC bead microspheres at a nominal dose level of 
400 mg irinotecan resulted in a mean maximum plasma concentration of 194 ng/mL 
irinotecan at a median time of 2 hours post-dose.  The mean maximum plasma 
concentration of the pharmacologically active metabolite, SN-38, was much lower, 16.7 
ng/mL at a median time of 1 hour post-dose.  In general (7/10 patients), the maximum 
measured plasma concentrations of irinotecan and its metabolite SN-38, occurred at the 
same time.  In two patients the Tmax of SN-38 was earlier than that of irinotecan and in 1 
patient it was later.  It is possible that the apparent shorter Tmax for SN-38 was an artefact 
resulting from a lack of sample times between 1 and 2 hours post-dose. 
The mean metabolite ratio (SN-38/irinotecan) was low, 0.10, but as SN-38 is ca 1000-fold 
more potent than irinotecan, the metabolite concentrations would be ca 100-fold more 
effective than the irinotecan concentrations.  The low concentrations of SN-38 in plasma 
relative to irinotecan may have been a consequence of the greater volume of distribution of 
SN-38 as it is lipophilic compared to the water-soluble irinotecan. 
The terminal half-life of irinotecan was determined to be in the range 1.6 – 7.2 hours, which 
is similar to the reported range of 6-12 hours.  However, accurate data were available from 3 
patients only, due to the limited number of sample points in the terminal phase of the plasma 
irinotecan concentration-time curve.  In addition, two estimates of the terminal half-life were 
determined from data up to 6 hours post-dose only and therefore represented a different 
disposition  phase of the plasma concentration-time curve.  The terminal half-life of SN-38 
ranged from 7.6-8.5 hours (data from 2 patients only) in comparison to a reported range of 
10-20 hours. 
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Conclusion!
Intra-arterial  injection of irinotecan-loaded DC bead microspheres at a nominal dose level of 
400 mg irinotecan resulted in a mean maximum plasma concentration of 194 ng/mL 
irinotecan at a median time of 2 hours post-dose.  The mean maximum plasma 
concentration of the pharmacologically active metabolite, SN-38, was much lower, 16.7 
ng/mL at a median time of 1 hour post-dose.  The mean metabolite ratio (SN-38/irinotecan) 
was low, 0.10, but as SN-38 is ca 1000-fold more potent than irinotecan, the metabolite 
concentrations would be more effective than the irinotecan concentrations. 
The terminal half-life of irinotecan in 3 of the patients was determined to be in the range 
1.6-7.2 hours, which is similar to the reported range of 6-12 hours.  The equivalent data for 
SN-38 were 7.6-8.5 hours (2 patients) in comparison to a reported range of 10-20 hours. 
 
Plasma concentrations of irinotecan and its metabolite SN-38 in a patient (Subject 1) 
treated with irinotecan-loaded DC bead microspheres at a nominal dose level of 400 
mg irinotecan 
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